Archives

Colon on Fire? Novel Suppression of Ulcerative Colitis InFLAMmation

Learning Objectives

  After completing this application-based continuing education activity, pharmacists will be able to
1. Differentiate UC from Crohn’s disease
2. Describe currently available and novel UC medications under development in the United States
3. Outline the relationship between the types of treatment for UC, patient characteristics and disease severity
4. Identify patient education pearls to address inflammation and advance to remission
After completing this application-based continuing education activity, pharmacy technicians will be able to:
1. Differentiate UC from Crohn’s disease
 2. Describe currently available and novel UC medications under development in the United States
3. Outline the relationship between the types of treatment for UC, patient characteristics and disease severity
4. List symptoms that a patient with UC may share with a pharmacy technician

Woman holding her abdomen with a cartoon picture of the large intestine superimposed

Release Date:

Release Date:  May 15, 2023

Expiration Date: May 15, 2026

Course Fee

FREE

This CE was funded by an educational grant from Bristol Meyer Squibb

ACPE UANs

Pharmacist: 0009-0000-23-014-H01-P

Pharmacy Technician: 0009-0000-23-014-H01-T

Session Codes

Pharmacist:  23YC14-HTX49

Pharmacy Technician:  23YC14-XHT82

Accreditation Hours

2.0 hours of CE

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-014-H01-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

 

Disclosure of Discussions of Off-label and Investigational Drug Use

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Faculty

 


Pamela Sardo, PharmD, BS
Freelance Medical Writer
Sardo Solutions
Josephine, TX

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr. Sardo worked for Rhythm Pharma until March 2022.  We identified no potential financial or other conflicts of interest.

ABSTRACT

Ulcerative colitis is an idiopathic relapsing/remitting disease that is increasing in incidence and prevalence. It is characterized by inflammation, abdominal cramping, bloody diarrhea, fatigue, and bowel urgency among other symptoms. It often presents in teens and young adults with various degrees of severity and significantly impacts quality of life. Primary treatment objectives include achieving rapid resolution of symptoms, mucosal healing, clinical and endoscopic remission, and improving a patient’s quality of life. In moderate to severe disease, prescribers employ immunosuppressive medications, anti-TNF agents, IL 12/23 antagonists, adhesion molecule inhibitors, JAK inhibitors, and S1P receptor modulators. Two organizations have published joint recommendations regarding these pharmaceuticals’ place in therapy. As more data is published and investigational therapies are approved, the treatment approach will continue to evolve. Ulcerative colitis is incurable, so some patients may require surgery. Optimizing care with a multidisciplinary team, including pharmacy personnel, remains an opportunity in this complex condition.

CONTENT

Content

INTRODUCTION

Fiery inflammation in the bowel can be due to several conditions. In inflammatory bowel disease (IBD), gastrointestinal (GI) tract inflammation episodes are common. Crohn’s disease (CD) and ulcerative colitis (UC) are two IBDs differentiated by location and bowel involvement.1 That’s a point to remember: that IBD is an umbrella term that includes CD and UC. In 10% to 15% of patients, the features of CD and UC are so similar that it is impossible to differentiate between them and misdiagnosis may result.1,2 Besides the GI tract, both CD and UC also may be accompanied by symptoms outside the intestine, called extraintestinal symptoms.

 

DIFFERENTIATING CD AND UC

CD results in patchy ulceration of any portion of the GI tract (see Figure 1) from the mouth to the anus. It frequently affects the terminal ileum and colon, and bleeding is uncommon. Typically, patients experience pain in the lower right abdomen.3 UC, this continuing education’s primary focus, involves inflammation of the colon mucosa. UC often affects the rectum, referred to as proctitis, and bleeding during bowel movements is common. Typically, patients experience pain in the lower left abdomen. It may extend into the left (sigmoid) part of the pelvis or beyond the sigmoid, or include the entire colon, referred to as pancolitis.4 In UC, inflammation leads to edema, ulcers, bleeding, and electrolyte losses.

Figure 1. The Gastrointestinal Tract

Cartoon image showing the entire gastrointestinal tract, from mouth to anus

UC is a chronic idiopathic relapsing/remitting condition (meaning it waxes and wanes) with interactions between the environment, immune system, gut microbiome, and a genetic predisposition to the disease suspected as causes.UC’s incidence and prevalence is increasing worldwide.6 From 1990 to 2017, its incidence increased from 3.7 million individuals to 6.8 million affected individuals worldwide.7 UC is incurable, so treatment goals aim to achieve rapid resolution of symptoms, mucosal healing, and clinical and endoscopic remission. An additional goal is to improve a patient’s quality of life (QoL).6.

 

Individuals with this complex condition have a high level of disability and high healthcare resource utilization. Beyond medical management, 15% to 20% of patients with UC will require surgery. Compared to adults without IBD, adults with IBD experienced $11,029 higher direct costs per patient per year according to one report.8 Documenting this diagnosis in the pharmacy’s profile can help pharmacists and technicians screen for potential problems more efficiently.

 

Differentiating the two forms of IBD drives treatment. Both CD and UC present as similar repetitive episodes of GI inflammation and create significant patient burden. In CD, inflammation or ulceration commonly occurs in the ileum and colon.4 Outside of the intestine, CD may affect the esophagus, duodenum, or stomach, and gallstones may occur. In UC, extraintestinal manifestations may appear most commonly as inflammatory arthropathies (joint disease) and bile duct inflammation and scarring, but may include bone, eye, and skin involvement.9,10 Although IBD’s incidence peaks at age 15 to 29 years, 10% to 15% of new diagnoses occur among adults aged 60 years or older.11 Both forms of IBD are more prevalent among non-Hispanic White people than among people in other racial/ethnic groups.12

 

PAUSE AND PONDER: What support can you provide to a patient who tells you that wherever they go, their first action is to scan for the closest bathroom?

 

UC’S PATHOPHYSIOLOGY AND ASSESSMENT

 

The normal colon is five or six feet long and three inches wide. Its layers of circular and longitudinal muscles and tissues contract to move food and liquid forward. It wraps around the outside of the small intestine, has segments, and looks somewhat flat. A seam runs vertically down the middle so the segments bulge on either side of the seam. As UC becomes chronic, the colon becomes more rigid and short, leading to a pipe-like appearance.9

 

The most important risk factor for UC is a family history of IBD in a first-degree relative.14 Patients with disease extension to the left side of the colon, or extensive colitis, are more likely to need medication, undergo colectomy (removal of a portion of the colon), and develop colorectal cancer.15  Risk factors for colorectal dysplasia (abnormal that are not cancerous but can sometimes lead to cancer) or cancer include disease duration and extent, active inflammation, presence of a stricture (inelastic narrowing of a section of the GI tract), polyps, and family history of colorectal cancer. The bile duct may also become diseased in 3% to 7% of patients with UC.15,16

 

UC’s pathophysiology involves defects in the epithelial barrier, defective immune response, the presence of leukocytes, and microflora imbalance in the colon.17,18 UC’s inflammation deteriorates the epithelium, and exposure to certain intestinal microbes worsens the inflammation.9 Other immune-related factors that affect UC’s pathophysiology and the body’s response include tumor necrosis factor-alpha (TNF-alpha), numerous interleukins, and elevated immune globulin levels.17

 

Two measures are recognized in UC. Gastroenterologists and researchers tend to use the erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP) components of the Truelove and Witts criteria. Researchers frequently measure ESR and CRP before and during treatments as outcome measures. The prescribing information for anti-TNFs, JAK inhibitors, and IL-12/23 antagonists also include ESR and CRP measures. Table 1 illustrates UC disease severity measured by assessment in the modified Truelove and Witts criteria.15

 

 Table 1. Modified Truelove and Witts Criteria15

Parameter Mild Moderate Severe
Bloody stools/day (n) <4 4-6 >6
Pulse (beats/minute) <90 ≤90 >90
Temperature (T) °C

(T°F )

<37.5

(<99.5)

37.5 – 37.8

(99.5 – 100.4)

>37.8

(>100.4)

Hemoglobin (g/dL) >11.5 11.5 – 10.5 <10.5
ESR (mm/hr)

[or CRP mg/l]

<20 (normal) 20 – 30 (<30) >30 (>30)

°C=degree Celsius; CRP = c-reactive protein; ESR = erythrocyte sedimentation rate; °F = degree Fahrenheit

 

In the clinical setting, the simpler Mayo score (see Table 2) is used more widely than Truelove and Witts criteria.19 It reflects stool frequency, rectal bleeding, a physician’s global assessment, and a measure of mucosal inflammation at endoscopy, with a maximum score of 12. Clinical response in UC is defined as19

  • a reduction of Mayo score by at least 3 points and a decrease of 30% from the baseline score, or
  • a decrease of at least 1 point on the rectal bleeding subscale or
  • a total rectal bleeding score of 0 or 1

 

Table 2. Mayo Score for Ulcerative Colitis15,20,19

  Points
Mayo Variables 0 1 2 3
Stool frequency Normal 1-2/day more than normal 3-4/day more than normal 5/day more than normal
Rectal bleeding None Streaks of blood with stool <50% of the time Obvious blood with stool most of the time Blood passed without stool
Mucosa (endoscopic subscore) Normal or inactive disease Mild disease (erythema, decreased vascular pattern, mild friability) Moderate disease (marked erythema, lack of vascular pattern, friability, erosions) Severe disease (spontaneous bleeding, ulcerations)
Physician’s global assessment Normal Mild disease Moderate disease Severe disease

Mayo score = sum of scores for each of the four variables (maximum score 12)

 

 

Beyond clinical response, clinical remission is a desired objective and is defined as a Mayo score of 2 or less and no individual subscore exceeding 1.19 Mucosal healing is defined as a mucosa subscore of 1 or less. Disease activity is a measure used to decide what treatments to prescribe. Mild disease activity is defined as scores of 3 to 5. Moderate and severe disease activity are defined as scores between 6 and 10 and 11 and 12, respectively.19

 

The clinician’s patient assessment must be global (all encompassing).21 During patient interviews, clinicians should inquire about extraintestinal symptoms, which may include joint, mood, ocular, oral, or skin changes. They should order laboratory evaluation for anemia and liver function abnormalities. Clinicians should explore QoL issues, such as impact on school, work, or personal relationships. Treatment plans should incorporate patients’ unmet needs and preferences. Exploring the need for social and emotional support, financial resources, and adequacy of patient education regarding their disease are important.21

 

Throughout treatment, it’s important to assess the patient’s clinical response and remission periodically. Clinicians should monitor cross-sectional imaging, specifically MRI, CT and ultrasound, and surrogate markers, such as fecal calprotectin (FCP; type of white blood cell that migrates to inflamed tissue) and CRP.15,22 A sigmoidoscopy or colonoscopy is recommended within three to six months of initiating treatment to determine the level of suppression of the inflammation, treatment response, or the need to modify the treatment.22

 

THE PATIENT’S JOURNEY

The journey through symptoms, diagnosis, and treatment to quell the fiery inflammation associated with UC can be long and difficult. In one study, one in four individuals with IBD reported GI symptoms to their primary care physician more than six months before receiving a diagnosis.23 Of these individuals, 10.4% reported symptoms five years before receiving a UC diagnosis. Delayed diagnosis often results in disease progression, worsening tissue, and mucosal damage, surgery, colectomy, or colitis-associated cancer.  Patients with a previous diagnosis of irritable bowel syndrome or depression were less likely to receive a timely specialist appointment.23

 

UC is vastly heterogeneous. Table 3 presents two cases with distinct disease journeys.

 

 

Table 3. Two Distinct Patient Journeys24,25

UC Patient Case 1   UC Patient Case 2
9-year-old girl diagnosed after ileocolonoscopy reveals diffuse moderate inflammation UC since age 18
Moderate clinical disease activity, Mayo score = 8 Symptoms included bleeding, severe pain and swelling in lower abdomen, gas, and nausea
Low hemoglobin, low vitamin D Lifestyle: Undergraduate, lifeguard, swim coach
Oral corticosteroids started followed by dose tapering dose and mesalamine started Daily regimen of oral medication, rectal suppositories, nightly enemas
At week 4, active disease remained Symptoms worsened so → ED
IFX started at 10 mg/kg at 0, 2, and 6 weeks Barely able to eat or drink, covered with rash and inflamed eyes
At 26 weeks with IFX, she remained in clinical remission Incontinence in street, bus, and post office
At 1 year, she remained in remission Acute diarrhea with each BM → became homebound
Follow-up flexible sigmoidoscopy demonstrated mucosal healing At age 29, married → then 10 weeks of hospitalization without remission
  Agreed to surgical colectomy → difficult recovery, diarrhea, and intestinal blockages
  Finally exercising, back to work, and monitoring the quantity, texture, and timing of food. Remained on pre-surgical medications.

BM = bowel movement; ED = emergency department; IFX = inFLIXimab

 

UC affects many distinct populations. In the pediatric population with UC, unlike in adults, the clinical condition can present atypically with a more severe, early onset and continuous inflammation of the rectum and colon.26,27,28 In these patients, clinicians should assess disease location and severity. One study indicated 62% of pediatric patients with UC from birth to age 5 years had extensive pancolitis, and 38% and 31% from ages 6 to 11 and from ages 12 to 18, respectively, had pancolitis.27   Children can also experience rectal sparing (a normal/unaffected rectum) and limited distal disease.26,28

 

To optimize management, enhance QoL, and minimize complications in all patients, continued patient engagement is important.29

 

GOALS OF UC MANAGEMENT

 

The UC treatment guidelines recommend goals of therapy to include29

  • induction and maintenance of clinical and endoscopic remission
  • maintaining steroid-free remission
  • improving QoL, and
  • preventing complications, hospitalizations and surgery.

Pursuing these goals can also contribute to minimizing cancer risk.21,30,31 Long-term mucosal healing may reduce the risk of dysplasia.31

 

The Treat-To-Target Approach                                                         

UC is considered relapsing/remitting because it presents as relapses of symptoms and then periods of symptomless response and remission. Beyond symptom remission, a treat-to-target (T2T) approach focuses on32,33

  • minimizing disease activity
  • reducing futures risks and
  • reducing future relapses or complications such as ileal strictures (narrowing), fistulas, functional impairment, or colon cancer.

 

In 2015, the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative recommended that UC treatment goals should address two targets: clinical and endoscopic outcomes.32 IBD experts recommend using measures of inflammation such as FCP.32  FCP detects GI inflammation sensitively and is used to monitor disease activity and predict relapse.

 

PAUSE AND PONDER: Which UC treatments do you see in your practice location most often?

 

UC’s treatment options are plentiful and evolving. Pharmacy team members can collaborate with multidisciplinary professionals regarding patient care for UC. (See SIDEBAR). Pharmacists’ drug therapy and disease management expertise can promote individualized treatment decisions for these complex patients.

 

 

SIDEBAR: Working with the Multidisciplinary Team

Team collaboration can increase patient and provider education, enhance quality of care, and reduce disease burden, and morbidity. Many pharmacists don’t know how to introduce themselves to or work with multidisciplinary teams. Sometimes, team members from other disciplines will call with questions or concerns, and the call opens the door for regular communication. Often, however, pharmacy staff will need to take the initiative and introduce themselves. Here are four tips to working better with the UC care team.

  • Ask patients if they are seeing a nutritionist, primary care provider, gastroenterologist, or behavioral health provider (for stress support). If UC is severe, inquire if they have a surgeon or know their radiologist. Record these providers’ names in the patient record and contact them when questions or concerns arise.
  • Make the patient your ally and be your patient’s ally. When you educate patients well and show them your capabilities, they will report back to their clinicians.
  • When you work with a patient who has UC, let the professional team members know. Sending a quick note to say that, for example, the patient’s adherence was poor and you discussed ways to improve it with the patient sheds light on possible non-response. It also makes clinicians aware that you have skills and you’re not afraid to use them!
  • Don’t be afraid to make team members aware of issues like cost or availability of less expensive options. Often, prescribers have no idea that patients experience sticker shock when they fill their prescriptions.

 

TREATMENT

Medication is a mainstay of treatment for patients with UC. Prescribers may combine, dose-escalate, reduce, or discontinue medications, depending on the patient’s disease severity.

 

Traditional Treatments

When a patient presents with mild to moderate UC, the expert consensus is to start treatment with an oral 5-aminosalicylate (5-ASA; sulfasalazine, mesalamine, and diazo-bonded 5-ASA [the prodrugs, balsalazide and olsalazine, which convert to mesalamine]34) with or without a rectal 5-ASA.34,35 In many cases, rectal dosing improves symptoms; using a suppository, enema, or rectal foam applies the medication exactly where needed. Sulfasalazine, balsalazide, and mesalamine are similarly effective and safe.34 Some patients will respond inadequately and may need to escalate therapy to systemic corticosteroids, immunomodulators (IMM), biologics, or other agents. If symptoms persist, it is important to rule out infection, optimize adherence, increase the oral dose, and add rectal 5-ASA if not yet prescribed.34,35

 

Comparative efficacy studies are helpful to clinicians. One technical review of multiple drugs in mild to moderate UC compared rectal 5-ASAs (5-ASA enemas 1 to 4 g/day or 5-ASA suppositories 1g/day) to rectal corticosteroids (hydrocortisone enema 100mg/day, prednisolone enema 25–30 mg/day, budesonide enema 2 mg/day, beclomethasone 3 mg/day or comparable foam) in 13 trials.36 In mild to moderate ulcerative proctosigmoiditis cases treated for two to eight weeks, rectal 5-ASAs were superior to rectal corticosteroids for induction of clinical remission.36

 

Table 4 lists the broad categories of medications for mild, moderate, or severe UC and dosing information.

 

Table 4. Medications for UC22,37-42

Category Substance Dosage
5 – ASA Mesalamine

 

 

Balsalazide

 

Olsalazine

 

Sulfasalazine

2 – 4.8 g/day (oral)

1 – 2 g/day (rectal)

 

6.75 g/day (rectal)

 

1 g/day (oral)

 

2 – 4 g/day

Corticosteroids Budesonide

 

Budesonide MMX

 

Prednisone

 

Hydrocortisone

 

Methylprednisolone

2 mg/day (rectal)

 

9 mg/day (oral)

 

0.75 – 1 mg/kg/day

 

100 mg IV 4 times/day

 

125 mg IV/day

Thiopurines

Immunosuppressives

Azathioprine

 

6-mercaptopurine

2 – 2.5 (max 3) mg/kg/day

 

1 – 1.5 mg/kg/day

Calcineurin inhibitors Cyclosporine

 

Tacrolimus

2 mg/kg/day IV

 

0.2 mg/kg/day

Anti-TNF agents Adalimumab

 

 

 

Golimumab

 

 

 

Infliximab

160 mg wk 0, 80 mg wk 2, 40 mg wk 4, then 40 mg every 2 wks; may ↑ to 40 mg/wk SUBQ

 

200 mg wk 0, 100 mg wk 2, 50 mg wk 4, then 50 mg every 4 wks; may ↑ to 100 mg if pt>80 kg SUBQ

 

5 mg/kg wk 0, 2, 6, then every 8 wks IV

Adhesion molecule inhibitors

(anti-integrin)

Vedolizumab 300 mg wk 0, 2, 6, then every 8 wks IV
Janus kinase inhibitor Tofacitinib

 

 

 

 

 

 

 

Upadacitinib

5 – 10 mg/day (oral)

First 8 wks: 10 mg twice/day

10 mg twice/day for 8 more wks if partial response

Then 5 mg twice/day

or 22 mg XR/day for 8 weeks; then evaluate

 

45 mg/day for 8 wks then 15 mg/day (oral)

Interleukin 12/23 antagonist Ustekinumab 250 mg to 55 kg IV

390 mg if >55 kg – 85 kg IV

520 mg if >85 kg IV

Then 90 mg SUBQ every 8 wks

Sphingosine 1-phosphate receptor modulator Ozanimod 0.23 mg days 1-4, 0.46 mg days 5-7, then

0.92 mg/day (oral)

G = grams; IV= intravenous; kg=kilogram; mg= milligrams; MMX = Multi-Matrix System technology drug release; SUBQ=subcutaneous; wk= week

 

Sulfasalazine

If sulfasalazine is prescribed, 4 g provides approximately 1.6 g of 5-ASA equivalence.34 Typical doses are 2 tablets 4 times a day.37,43 In some cases, prescribers may initiate therapy with a smaller dose, (e.g., 1 to 2 g daily) to reduce possible GI intolerance and slowly increase as tolerated. They may also try enteric-coated sulfsalazine.37,43 Sulfasalazine is commonly prescribed for individuals with UC and rheumatologic comorbidities.43 Periodic monitoring of complete blood counts (CBC) and liver function tests (LFT) is recommended.

 

Sulfasalazine may be poorly tolerated due to adverse effects such as headache, nausea, diarrhea, and rash.43 Additional adverse events with sulfasalazine include folate metabolism interference, male infertility, and rare cutaneous side effects such as Stevens-Johnson syndrome. Anemia, leukopenia, or thrombocytopenia are also possible. Pneumonitis and hepatitis have been reported.43  Sulfasalazine is contraindicated if a patient has a sulfa allergy. Sulfasalazine tablets are a yellow/orange color; individuals who take it may notice an orange tinge in urine, tears, and sweat that can stain clothing and contact lenses. Auxiliary labels and counseling should emphasize drinking plenty of fluids, taking the drug on an empty stomach, and avoiding antacids.

 

Mesalamine and Balsalazide

Low dose mesalamine may be prescribed initially at less than 2 grams per day(g/d). Some patients need 2 to 3 g/d. Higher doses of 3 g/d or more may be required to induce remission.36 Combining oral and rectal therapy may deliver a higher effective dose of 5-ASA to the involved area and lead to higher rates of induction and maintenance of remission. This approach may avoid escalation to corticosteroids or other agents.36

 

Mesalamine and balsalazide are associated with rare idiosyncratic worsening of colitis.22 Rare interstitial nephritis may also occur. The prescribing information recommends periodic renal function monitoring. Olsalazine is generally less well tolerated than either mesalamine or balsalazide. Headache, nausea, diarrhea, leukopenia and hepatitis are possible. 5-ASA treatments should be avoided in pregnancy.22

 

Steroids and Other Traditional Treatments

Corticosteroids, such as budesonide, are generally prescribed for a short duration or for induction of remission.34 Some experts suggest prescribing oral mesalamine, balsalazide or olsalazine over budesonide because hepatic first-pass metabolism lowers budesonide’s systemic activity.34,44 As the patient’s condition improves, withdrawing the steroids and reaching steroid-free remission (SFR) is important. Long-term corticosteroid use may lead to infection, diabetes mellitus, weight gain, insomnia, osteoporosis, or glaucoma.45 Mood changes, cataracts and delayed wound healing are possible.45

 

Thiopurines and Cyclosporine

Thiopurines, including azathioprine and 6-mercaptopurine, may improve inflammation in patients with UC. They inhibit the proliferation of lymphocytes and are used to maintain remission. Their dosing is weight-based and their onset of action can be slow, taking up to three months.22 They are often used in combination with biologics. Monitoring for drug interactions is necessary. Allopurinol interactions with thiopurines are especially important because allopurinol inhibits thiopurine metabolism.46 The dose of mercaptopurine or azathioprine may need to be reduced to one-third or one-quarter of the normal dose if allopurinol is also prescribed. Prescribers determine dose reductions based on therapeutic response and toxicity.47

 

Even though thiopurines and cyclosporine have been prescribed for many years, remaining aware of their side effects is important. Possible adverse events of thiopurines include nausea, vomiting, fever, leukopenia, thrombocytopenia, pancreatitis, and hepatotoxicity. Rare adverse events may include non-Hodgkin lymphoma. Individuals prescribed calcineurin inhibitors, such as cyclosporine, may experience hypertension, nephrotoxicity, hyperkalemia, infection, lymphoma, or diabetes mellitus.37

 

Additional therapies include biologics and newer small molecules (tofacitinib, ozanimod). Before discussing newer therapies, a short review of step-up and step-down approaches is reasonable. If a patient presents with moderate to severe ulcerative colitis, philosophies differ among gastroenterologists regarding beginning with a step-up versus a step-down approach.36,48

  • The step-up approach begins with the traditional therapies mentioned above and followed by biologics and IMM if symptoms persist, if remission is not achieved, and the patient is considered high-risk. Extensive inflammation and the need for repetitive use of corticosteroids are examples of high-risk status.
  • The step-down approach occurs when prescribers begin with a more intensive treatment with biologics and IMM and then step down to the medications mentioned above if patients improve.

 

Step Up or Step Down?

A 2021 study (N = 1891) examined UC’s clinical presentation in the five years before starting biologic therapy. The researchers analyzed patients’ experiences, comorbidities, morbidity, and treatment burden over time. Figure 2 summarizes participants’ health burden, disease progression, medication burden, and increased comorbidities. Across the study period, the need for treatment with oral corticosteroids, 5-ASA, and other non-biologic immunomodulators (IMM) increased progressively. Due to the increasing burden, the researchers supported early use of biologics (a step-down approach) rather than gradual step-up after failing conventional therapies for adult patients with moderate to severe UC.30 

Figure showing results from the trials mentioned

 

Figure 2. Treatment and Health Experience Beginning Five Years Before First Biologic30

5-ASA = 5-aminosalicylates; ED = emergency department; OC = oral corticosteroids; Pts = patients

 

 

Anti-TNF agents

 

Anti-TNF agents are commonly prescribed for moderate to severe UC due to their effectiveness, length of time on the market, and healthcare professional comfort prescribing them.44 The U.S. Food and Drug Administration (FDA) has approved many anti-TNFs, but has approved only adalimumab, golimumab, or inFLIXimab for treating UC. Usually, prescribers use anti-TNFs after 5-ASA and corticosteroids in patients with mild to moderate severity and the step-up approach to treatment. Prescribers may prescribe the step-down approach, using biologics earlier, in some cases.38 They often employ concomitant IMM to decrease immunogenicity seen with anti-TNFs.38,47

 

Because biologics like anti-TNFs are made with living cells, patients may develop an unintended immune response (immunogenicity) in the form of anti-drug antibodies; if they develop, these antibodies may render the anti-TNF medication less effective. The antibodies may bind to the anti-TNF, interfere with its mechanism of action, reduce the anti-TNF’s serum concentration, increase its clearance, and lead to loss of effectiveness. Antibodies may also occur upon restarting an anti-TNF if a patient starts and stops an anti-TNF over time. It is unknown why some people develop anti-drug antibodies and others do not. The presence of antibodies and reduced response often prompt prescribers to switch the anti-TNF to regain effectiveness, and doing so often works. The addition of an IMM can suppress the antibodies which may reduce the risk of switching therapies or avoiding an anti-TNF dose increase.47

 

Pharmacy team members should remain diligent about look-alike, and sound-alike names of the anti-TNF agents and should remember that doses of anti-TNF agents vary by indication.

 

SIDEBAR: TECH TALK about Look-alike, Sound-alike medications

Medications with names that look-alike and/or sound alike are classified as high-alert medications.

  • Know that inFLIXimab had been confused with riTUXximab, so the Institute for Safe Medication Practices recommends using TALL Man lettering.
  • Prevent medication errors between therapies for UC, such as adalimumab and golimumab, ustekinumab and upadacitinib, or vedolizumab and ustekinumab or adalimumab. Segregate the medications in different locations or consider stickers or other alert methods prior to medication dispensing.

 

 

An Anti-integrin

Integrins are adhesion receptors that mediate cell-to-cell and cell-to-extracellular adhesion. Vedolizumab is a humanized monoclonal antibody that binds to the α4β7 integrin, blocks the interaction of α4β7 integrin, and inhibits lymphocyte migration into inflamed GI tissue.49 With fewer lymphocytes in the GI tract, vedolizumab helps reduce inflammation and UC symptoms. Vedolizumab can be referred to as a B-anti-integrin and an adhesion molecule inhibitor. Patients with steroid-dependent disease have treatment options, including treatment with thiopurines, anti-TNF agents (may be combined with azathioprine or 6-mercaptopurine), or vedolizumab.38

 

Prescribers and patients may ask about outcomes in clinical trials. A vedolizumab study enrolled patients with an inadequate response or intolerance to IMM therapy (i.e., azathioprine or 6-mercaptopurine) and/or an inadequate response, loss of response, or intolerance to an anti-TNF.49 Participants received IV vedolizumab 300 mg or placebo at week 0 and week 2. Concomitant stable dosages of 5-ASA, corticosteroids (prednisone dose of 30 mg/day or less or equivalent), and IMM (azathioprine or 6-mercaptopurine) were permitted through week 6. The percentage of patients achieving a clinical response at week 6 was 47%. The researchers also measured remission and found 17% of participants achieved remission at week 6. Those with a clinical response at week 6, or receiving open-label vedolizumab, were invited to enter a 52-week study with every 8-week dosing. At week 52, 42% of participants achieved clinical remission.49

 

JAK inhibitors

 

Tofacitinib and upadacitinib are referred to as small molecules because their molecular structure is smaller and simpler than the biologics’, which are large three-dimensional structures. The JAK inhibitors are dosed orally and require a loading dose. JAK inhibitors are indicated for adults with moderately to severely active UC who responded inadequately or couldn’t tolerate one or more anti-TNF agents.39 Many individuals are willing to visit an infusion suite for treatment; however, younger patients and those with very busy lifestyles or heavy travel schedules may prefer the small molecule oral drugs for their convenience.

 

When prescribing JAK inhibitors, pretreatment screening should include assessment for hepatitis B and tuberculosis. When patients start biologics or JAK inhibitors, their immune response may decrease, increasing risk of certain infections, such as hepatitis B or tuberculosis. If patients have active hepatitis B or tuberculosis, they need treatment to eradicate those infections before beginning biologics or JAK inhibitors. A risk of bacterial, viral, and herpes zoster infections exists, so prescribers must assess vaccination status before treatment. CBC and lipid panel monitoring is recommended. Prescribing tofacitinib in combination with biologics for UC or with potent IMM, such as azathioprine and cyclosporine, is not recommended.40

 

 

IL-12/23 antagonist

Interleukin 12 (IL-12) and IL-23 are proteins that can cause inflammation. Ustekinumab is a human monoclonal antibody against the shared p40 subunit of IL-12 and IL-23 cytokines. Ustekinumab disrupts inflammation by blocking IL-12/23.41 The FDA has approved this biologic for adults with various forms of psoriasis, CD, and UC. (It is also approved for children 6 and older for various forms of psoriasis.) In UC in adults, it is typically administered as an IV induction dose, followed by subcutaneous maintenance dosing every eight or 12 weeks. Clinicians should screen for hepatitis B and tuberculosis and monitor CBC every six months.41 To minimize the risk of medication errors, pharmacy staff should double-check the prescribed route (IV or subcutaneous). They should also be alert for look-alike, sound-alike issues, to prevent prescription transcribing errors or other confusion between ustekinumab and the JAK inhibitor upadacitinib.

 

Research has documented outcomes for this monoclonal antibody, too. A ustekinumab clinical trial assessed efficacy and safety in adults with UC; the primary endpoint was clinical remission at week 8.41 The researchers randomized participants to a single IV dose of ustekinumab of approximately 6 mg/kg, 130 mg (a lower dose than recommended), or placebo at week 0. Enrollment required previous inadequate response to corticosteroids, IMM, or at least one biologic. At week 8, 19% of participants successfully reached clinical remission.41

 

S1P Modulator

Ozanimod is an oral sphingosine 1-phosphate receptor (S1P) modulator indicated for the treatment of moderately to severely active UC in adults.42 It is also approved for relapsing forms of multiple sclerosis, and the pharmacy team may field questions about this medication’s various indications. Ozanimod binds with high affinity to S1P receptors 1 and 5. It blocks lymphocyte trafficking from lymph nodes, reducing the number of lymphocytes in peripheral blood. Ozanimod may transiently decrease heart rate and cause atrioventricular conduction delays, so a low-dose starter titration pack is available. Prescribers should escalate the dosing slowly to avoid rare but significant bradycardia. Progressive multifocal leukoencephalopathy, a disabling, sometimes deadly adverse event, is rare but possible. Pharmacy teams should counsel patients regarding the need for effective contraception to prevent pregnancy; patients should use contraceptives for three months after discontinuing ozanimod.42

 

An ozanimod clinical trial assessed efficacy and safety using a primary study endpoint of clinical remission at week 10.42 It enrolled adults with moderately to severely active UC if they had an inadequate response, or were intolerant, to specific other treatments. The treatments included oral 5-ASA, corticosteroids, IMM (e.g., 6-mercaptopurine and azathioprine), or a biologic (e.g., anti-TNF and/or vedolizumab). The proportion of patients reaching clinical remission at week 10 was 18% with an ozanimod dose of  0.92 mg once daily. Those achieving a clinical response were invited to be re-randomized to a 52-week study extension. The primary endpoint was the proportion of patients in clinical remission at week 52. The proportion of patients with an ozanimod dose of 0.92 mg once daily with clinical remission at week 52 was 37%.42

 

MEDICATIONS IN DEVELOPMENT

Etrasimod is a once-daily, oral S1P receptor modulator in development for the treatment of UC. Results from the phase 2 OASIS trial and open-label extension study revealed patients with moderately to severely active UC who received etrasimod showed improvements in clinical remission and symptom relief beginning as early as week 2. In the phase 3 ELEVATE UC 52 study, 27% of patients in the etrasimod group achieved clinical remission compared with 7% of patients in the placebo group at 12 weeks.50 Use of etrasimod in UC is not FDA-approved and regulatory authorities have not yet evaluated its safety and efficacy.

 

Risankizumab-rzaa is an IL-23 inhibitor that is FDA-approved for psoriasis and Crohn’s disease. It is in development for treatment of individuals with UC. In the INSPIRE trial, 20.3% of participants with intolerance or inadequate response to conventional or advanced therapies (biologics, JAK inhibitors, and S1P receptor modulators) achieved clinical remission at week 12.51 The FDA has not approved risankizumab in UC or evaluated its safety and efficacy.

 

Considerations for Medications in Therapy

Decision-making regarding UC treatment requires consideration of many factors, including

  • disease and inflammation location, severity, and extent
  • comparative effectiveness and long-term safety of available treatments
  • treatment availability
  • product labeling
  • guideline recommendation
  • prior treatment successes or failures
  • cost, and
  • patient preferences

Since some prescribers may dose escalate to an off-label (higher) dose or off-label shorter dosing interval, pharmacy teams need to remain alert regarding insurance policies that may impact treatment decisions.

 

Safety Information

Each medication’s full prescribing information includes comprehensive safety and efficacy details. The information in this section is not all-inclusive. It’s critical to keep in mind that all UC treatments have limitations. Because most infusions have similar adverse events, Table 5 summarizes select safety information and limitations regarding newer agents used in UC.

 

 

Table 5. Newer Agents: Select Safety Information and Limitations 37,41,42,49,52

Limitations and Safety Considerations Anti-TNF agents Anti-IL-12/23

Agents

JAK Inhibitors Anti-integrin S1PR

modulator

Immuno-suppression
Infection

(herpes zoster)

(upper respiratory)

Venous thrombo-embolism        
Psoriasis      
Major CV adverse event      
Infusion/ injection site reaction  
Malignancy
Tuberculosis  
Worsen CHF        
Lymphoma

(if combine with thiopurines)

   
Lymphocyte abnormalities        
Anemia      
Elevated lipids        
Headache
Nausea  
Fatigue
Liver function test elevations    
Contra-indication if post-MI within 6 months, or unstable angina, stroke or TIA        
Contraindicated if severe untreated sleep apnea        
PML      

MI = myocardial infarction; PML = progressive multifocal leukoencephalopathy; TIA = transient ischemic attack

 

Identifying drug interactions is a key skill for pharmacists. Of note, JAK inhibitors can interact with CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and CYP2C19 inhibitors (e.g., fluconazole, omeprazole).40 Drug interactions may be a concern with the use of ozanimod and concurrent IMM, tyramine, antiarrhythmics, beta blockers, or calcium channel blockers.42

 

ACG and AGA Guidelines for the Management of Moderate-to-Severe UC

The American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) published comprehensive treatment guidelines and interventions for UC.31,44 Both guidelines cover achieving a response, induction of remission, and maintenance of remission. Select highlights presented below are not all-inclusive.

 

For remission induction, ACG recommends the following options31:

  • In moderately active UC, oral budesonide MMX
  • In moderately to severely active UC, oral corticosteroids
  • In moderately to severely active UC, anti-TNF therapy
  • When inFLIXimab is used as induction therapy for patients with moderately to severely active UC, it should include a thiopurine
  • In moderately to severely active UC, or if failed anti-TNF, vedolizumab
  • In moderately to severely active UC, tofacitinib 10 mg orally twice a day for 8 weeks
  • For induction of remission in moderately to severely active UC with previous failure of anti-TNF therapy, tofacitinib

 

For maintenance of remission, ACG recommends the following options31:

  • For previously moderately to severely active UC in remission due to corticosteroid induction, thiopurines
  • Continue anti-TNF therapy after anti-TNF induction in patients with previously moderately to severely active UC
  • Continue vedolizumab in previously moderately to severely active UC now in remission after vedolizumab induction
  • Continue tofacitinib in previously moderately to severely active UC now in remission after induction with tofacitinib

 

The AGA provides the following recommendations for response and remission44:

  • Current evidence supports use of inFLIXimab, adalimumab, golimumab, vedolizumab, and tofacitinib for remission induction and maintenance in moderate-severe UC
  • Thiopurine monotherapy should not be used for induction of remission but may be considered for remission maintenance
  • Meta-analysis suggests that inFLIXimab and vedolizumab may be preferred first-line therapy in biologic-naïve patients, rather than standard-dose adalimumab or golimumab
  • In patients with prior inFLIXimab exposure, particularly those with primary non-response to induction therapy, vedolizumab or tofacitinib may be preferred over adalimumab or golimumab
  • Combination of a biologic agent with an immunomodulator is more effective than monotherapy with either agent
  • In patients with moderate-severe disease activity, at high risk of colectomy, biologic agents with or without an IMM, or tofacitinib, should be used early rather than gradual step-up therapy after failure of 5-ASA
  • Patients in remission with biologic agents and/or IMM, or tofacitinib, after prior failure of 5-ASA, may discontinue 5-ASA

 

PAUSE AND PONDER: What patient support questions may uncover a patient’s adherence challenges?

 

Patient Education Pearls for Patient Counseling

 

Pharmacy teams have numerous opportunities to provide UC patient education. Because the condition appears differently in affected individuals, conversations should align with the individual patient’s situation. Supportive patient education pearls addressing inflammation and advancing opportunities to remission should be individualized from these topics53:

  • UC’s exact cause is unknown
  • UC affects people differs widely
  • UC is a chronic condition and symptoms wax and wane
  • Medications are available to control UC
  • The number of people with UC has been increasing
  • It can occur at any age and in any racial or ethnic group
  • Symptoms will occur in the intestine and may occur outside of the intestine
  • Ulcers in the intestine lining that bleed may lead to low red blood cell count (anemia)
  • Ask the doctor what tests are needed
  • Diet and nutrition plans differ for each patient
  • Managing stress is important
  • Have supportive friends and family
  • Locate restrooms when outside the home
  • Carry extra underclothes, toilet paper or moist wipes
  • Ask for school or work accommodations

 

SIDEBAR: OTC and Alternative Therapies for Patient Discussion34,35,44,54

 

Patients with UC may use these OTC products:

  • Patients with UC may eat less, thinking it will decrease diarrhea. However, they need proteins, water, vitamins, and minerals to promote healing. Patients need vitamin D and calcium for bones if reduce their dairy intake.
  • Bismuth subsalicylate (Pepto Bismol) is an antidiarrheal liquid, chewable tablet, and also swallowable tablet. It helps reduce inflammation in the intestinal lining. Remind patients that it darkens stool and the tongue. That darkening is not a medical concern.
  • Simethicone (Gas-X) is an anti-flatulent that helps form gas bubbles in the digestive tract, making them easier to pass and relieving gas pain.
  • Loperamide (Imodium) should be taken with caution. It slows digestion. Occasional use may be effective, but patients should consult healthcare providers if they contemplate ongoing use.
  • If mild disease persists, such as seen with a Mayo score of 1, the AGA guidelines and some advocacy web sites mention curcumin (a phytochemical from turmeric) or suggest adding curcumin and probiotics for some individuals suffering with UC.
  • Patients with severe disease, frequent bleeding, anemia, or abnormal laboratory results may need folic acid. The usual folic acid dose is 1 mg/day. Asparagus, broccoli, and spinach are also foods that contain folate or folic acid.

Patients who have UC should avoid these OTC products:

  • Patients should consult their healthcare providers whether to avoid aspirin, nonsteroidal anti-flammatories (ibuprofen, naproxen), lactose, sugar substitutes, or preservatives.
  • Patients who take sulfasalazine or mesalamine should not take them with antacids.

 

Many institutions, hospitals and healthcare providers have created UC resources. Table 6 lists  examples of supportive options that can be shared with individuals with UC.

 

Table 6. Patient and Clinician Resources to Support Individuals with UC

Resource Contact
American College of Gastroenterology https://gi.org/topics/ulcerative-colitis/

·       Describes symptoms, tests, diagnosis, risks, surgery and treatments

Cleveland Clinic: Butts and Guts podcast https://my.clevelandclinic.org/podcasts/butts-and-guts

·       Covers a wide range of gastrointestinal issues including management and surgery

·       Use the search term “ulcerative colitis”

Crohn’s and Colitis Foundation (CCF)

 

Help Center (referrals, insurance info)

https://www.crohnscolitisfoundation.org/

info@crohnscolitisfoundation.org

1-888-MY-GUT-PAIN

(888-694-8872- extension 8)

Signs and Symptoms https://www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/living-with-ulcerative.pdf

Spanish Help Center
https://www.crohnscolitisfoundation.org/es/home

School Accommodation Suggestions

https://www.crohnscolitisfoundation.org/justlikeme/living-with-crohns-and-colitis/school/school-accommodations

Mayo Clinic https://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/symptoms-causes/syc-20353326

·       Includes a video and written materials on diagnosis, symptom management, and treatment

Downloadable Mobile Apps

·       Download from the App Store or Google Play

My IBD Care: tracks symptoms, flares, medical appointments, BMs, medications

Bathroom Scout: Identifies 1.3 million public toilets

MyPlate: Monitors calories, the nutrition content of food

MyColitis: Health tracking of bowel movements, medications, moods, symptoms, tests

 

CONCLUSION

UC is a debilitating chronic IBD that usually requires long-term treatment to control symptoms and prevent disease-related complications. Many treatments are available; however, the effectiveness, safety, and durability of response and remission vary, and careful assessment of these factors must drive a personalized approach to care. Pharmacy teams must recognize that every patient’s disease is different, and results in diverse manifestations. Pharmacists and pharmacy technicians are ideally positioned to collaborate with multidisciplinary teams to support strategies tailored to each patient to optimize care and to help patients maintain a positive outlook.

 

Many unanswered questions remain about UC. Researchers will continue to evaluate treatment advances and explore disease management opportunities while pharmacy teams encourage patients suffering from UC to have routine doctor visits, adhere to their medication regimen, and maintain a healthy lifestyle.

 

 

 

 

Pharmacist Post Test (for viewing only)

Learning Objectives
After completing this continuing education activity, pharmacists will be able to
1. Differentiate UC from Crohn’s disease
2. Describe currently available and novel UC medications under development in the United States
3. Outline the relationship between the types of treatment for UC, patient characteristics and disease severity
4. Identify patient education pearls to address inflammation and advance to remission

1. Which is true regarding the difference between Crohn’s and ulcerative colitis (UC)?
a. Crohn’s disease is limited to inflammation of the colon mucosa
b. Ulcerative colitis can appear anywhere between the mouth and anus
c. Ulcerative colitis involves inflammation of the colon mucosa

2. Which is the usual adalimumab starting dose for a newly diagnosed UC patient?
a. Adalimumab 160 mg at week 0, 80 mg at week 2, 40 mg at week 4
b. Adalimumab 20 mg at week 0, 40 mg at week 2, 50 mg at week 3
c. Adalimumab 200mg at week 0, 90 mg at week 2, 60 mg at week 4

3. Which statement reflects a novel characteristic of ozanimod?
a. Ozanimod is an IL 12/23 monoclonal antibody
b. Ozanimod is an oral S1P modulator
c. Ozanimod is a oral JAK inhibitor

4. When inducing remission, which statement(s) describe(s) ACG recommended UC treatment, patient characteristics, and disease severity?
a. In moderately to severely active UC or if failed anti-TNF, a 5-ASA is recommended
b. In moderately to severely active UC oral corticosteroids may be prescribed
c. In mild-to-moderate UC, lifestyle changes are usually sufficient to induce remission

5. Which are patient education pearls to discuss with a patient suffering with UC?
a. The number of people with UC has been decreasing
b. Intestinal ulcers that bleed will not lead to anemia
c. Many medication options are available to control UC

6. You receive a prescription or order for tofacitinib. Which of the following would be an appropriate dose for a patient who has UC?
a. 5 mg orally once a week
b. 5-10 mg orally daily
c. 10 mg IV every 8 weeks

7. Which statement contains safety information to be aware of with UC treatments?
a. Sulfasalazine carries a risk for venous thromboembolism, herpes zoster, and major cardiovascular adverse events
b. JAK inhibitors may interfere with folate metabolism, affect male fertility, cause rare cutaneous adverse effects
c. Ustekinumab may cause infections, infusion or injection site reactions and may increase the risk of malignancy

8. A 22-year-old college student with newly diagnosed UC is experiencing daily blood in the stool, cramping, and had bowel incontinence on the way to the parking lot after class. Multiple options are available to treat this patient. What are the goals of treatment?
a. To prescribe medication to obtain response in 1 week and remission in 8 days
b. To induce and maintain clinical and endoscopic remission and quality of life
c. To use oral medications only (and avoid infusions) because of her youth and lifestyle

9. A 17-year-old restaurant worker presents with pancolitis. She has no other significant past medical history. She was treated with adalimumab, but the condition is worse with daily blood in the stool, 5 BMs/day, and weight loss of 10 pounds in the past 2 months. She has been reading about UC and is interested in switching to an infusion. Which is a possible IV treatment option?
a. Prednisone
b. Vedolizumab
c. Balsalazide

10. A 30-year-old newly married patient with UC works as a flight attendant. She has pancolitis and was told she is anemic and today has a fever. She comes to the pharmacy before her doctor’s appointment asking which UC medications are oral. Which product names are options to provide this patient?
a. Methylprednisolone
b. Ustekinumab
c. Ozanimod

Pharmacy Technician Post Test (for viewing only)

Pharmacy Technician Learning Objectives
After completing this continuing education activity, the pharmacy technician will be able to
1. Differentiate UC from Crohn’s disease
2. Describe currently available and novel UC medications under development in the United States
3. Outline the relationship between the types of treatment for UC, patient characteristics and disease severity
4. List symptoms that a patient with UC may share with a pharmacy technician

1. Which is true regarding the difference between Crohn’s and ulcerative colitis (UC)?
a. Crohn’s disease is limited to inflammation of the colon mucosa
b. Ulcerative colitis can appear anywhere between the mouth and anus
c. Ulcerative colitis involves inflammation of the colon mucosa

2. Which is the usual adalimumab starting dose for a newly diagnosed UC patient?
a. Adalimumab 160 mg at week 0, 80 mg at week 2, 40 mg at week 4
b. Adalimumab 20 mg at week 0, 40 mg at week 2, 50 mg at week 3
c. Adalimumab 200mg at week 0, 90 mg at week 2, 60 mg at week 4

3. Which statement reflects a novel characteristic of ozanimod?
a. Ozanimod is an IL 12/23 therapeutic
b. Ozanimod is an oral S1P modulator
c. Ozanimod is an oral JAK inhibitor

4. A patient who visits the pharmacy often for medication related to his UC brings a few OTC products to the register. Which of the following might be a problem?
a. Simethicone
b. Naproxen
c. Curcumin

5. Which symptoms might a new patient suffering with UC reveal to a pharmacy technician?
a. cold sores, stomach ulcers, 1 BM/day, miss 1 day of work/year
b. bloody stools, 6 BMs/day, mood changes, had to quit work
c. 1 BM/day, cold sore, dental pain, perfect work attendance

6. You receive a prescription or order for tofacitinib. Which of the following would be an appropriate dose for a patient who has UC?
a. 5 mg orally once a week
b. 5-10 mg orally daily
c. 10 mg IV every 8 weeks

7. Which statement contains safety information to be aware of with UC treatments?
a. Sulfasalazine carries a risk for venous thromboembolism, herpes zoster, and major cardiovascular adverse events
b. JAK inhibitors may interfere with folate metabolism, affect male fertility, cause rare cutaneous adverse effects
c. Ustekinumab may cause infections, infusion or injection site reactions and may increase the risk of malignancy

8. A 22-year-old college student with newly diagnosed UC is experiencing daily blood in the stool, cramping, and had bowel incontinence on the way to the parking lot after class. Multiple options are available to treat this patient. What are the goals of treatment?
a. To prescribe medication to obtain response in 1 week and remission in 8 days
b. To induce and maintain clinical and endoscopic remission and quality of life
c. To use oral medications only (and avoid infusions) because of her youth and lifestyle

9. A 17-year-old restaurant worker presents with pancolitis. She has no other significant past medical history. She was treated with adalimumab, but the condition is worse with daily blood in the stool, 5 BMs/day, and weight loss of 10 pounds in the past 2 months. She has been reading about UC and is interested in switching to an infusion. Which is a possible IV treatment option?
a. Prednisone
b. Vedolizumab
c. Balsalazide

10. A 30-year-old newly married patient with UC works as a flight attendant. She has pancolitis and was told she is anemic and today has a fever. She comes to the pharmacy before her doctor’s appointment asking which UC medications are oral. Which product names are options to provide this patient?
a. Methylprednisolone
b. Ustekinumab
c. Ozanimod

References

Full List of References

REFERENCES

  1. Yu YR, Rodriguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26(6):349-355. doi: 10.1053/j.sempedsurg.2017.10.003
  2. Guindi M, Riddell RH. Indeterminate colitis. J Clin Pathol. 2004;57(12):1233-1244. doi: 10.1136/jcp.2003.015214
  3. Joo M, Odze RD. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy. Am J Surg Pathol. 2010;34(5):689-696. doi: 10.1097/PAS.0b013e3181db84cd
  4. Maaser C, Sturm A, Vavricka SR, et al. European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR] ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144-164. doi:10.1093/ecco-jcc/jjy113
  5. Kobayashi T, Siegmund B, Le Berre C et al. Ulcerative colitis. Nat Rev Dis Prim. 2020;6:74. doi: 10.1038/s41572-020-0205-x
  6. Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond). 2021;21(2):135-139. doi: 10.7861/clinmed.2021-0080
  7. Alatab S, Sepanlou SG, Ikuta K, et al.; GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30. doi: https://doi.org/10.1016/S2468-1253(19)30333-4
  8. Pilon D, Zhijie D, Muser E, et al. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. CurrMed Res Opin. 2020;36(8):1285-129. doi: 10.1080/03007995.2020.1771293
  9. Sturm A, Maaser C, Calabrese E, et al. European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR] ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13(3):273-284. doi: 10.1093/ecco-jcc/jjy114
  10. Trivedi PJ, Adams DH. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. J Crohns Colitis. 2018;12(suppl_2):S641-S652. doi: 10.1093/ecco-jcc/jjx145
  11. Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohn’s Colitis. 2015;9:507–15. doi: https://doi.org/10.1093/ecco-jcc/jjv059
  12. Xu F, Dahlhamer JM, Zammitti EP, Wheaton AG, Croft JB. Health-risk behaviors and chronic conditions among adults with inflammatory bowel disease—United States, 2015 and 2016. MMWR Morb Mortal Wkly Rep. 2018;67:190-5. doi: https://doi.org/10.15585/mmwr.mm6706a4
  13. Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65(12):100851. doi: 10.1016/j.disamonth.2019.02.004)
  14. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. doi: 10.1016/S0140-6736(16)32126-2
  15. Lamb CA, Kennedy NA, Raine T et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106. doi: 10.1136/gutjnl-2019-318484
  16. Shah SC, Itzkowitz SH. Reappraising risk factors for inflammatory bowel disease-associated neoplasia: implications for colonoscopic surveillance in IBD. J Crohn’s Colitis. 2020;14:1172-1177. doi: 10.1093/ecco-jcc/jjaa040
  17. Terry R, Chintanaboina J, Patel D, et al. Expression of WIF-1 in inflammatory bowel disease. Histol Histopathol. 2019;34(2):149-157
  18. Yamamoto-Furusho JK, Fonseca-Camarillo G, Furuzawa-Carballeda J, et al. Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. J Inflamm (Lond).2018;15:13. doi: 10.1186/s12950-018-0189-4.
  19. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis2008;14:1660–1666. doi:10.1002/ibd.20520
  20. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629. doi: 10.1056/NEJM198712243172603
  21. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501-523; doi: 10.1038/ajg.2009.727
  22. Dipentum. Prescribing information. Viatris Inc.; June 2021. Accessed April 12, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019715s029lbl.pdf
  23. Blackwell J, Saxena S, Jayasooriya N, et al. Prevalence and Duration of Gastrointestinal Symptoms Before Diagnosis of Inflammatory Bowel Disease and Predictors of Timely Specialist Review: A Population-Based Study. J Crohns Colitis. 2021;15(2): 203-211. doi:https://doi.org/10.1093/ecco-jcc/jjaa146
  24. Colman RJ, Dhaliwal J, Rosen MJ. Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. Front Pediatr. 2021;9:634739. doi: 10.3389/fped.2021
  25. Finkelstein A. You Will Have a New Life. Ann Fam Med. 2018;16(2):166-167. doi: 10.1370/afm.2181
  26. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis.2011;17:1314–1321. doi:10.1002/ibd.21493
  27. Aloi M, Lionetti P, Barabino A, et al. Phenotype and Disease Course of Early-onset Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2014;20(4):597-605.
  28. Levine A, de Bie CI, Turner D, et al. Atypical disease phenotypes in pediatric ulcerative colitis: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis.2013;19:370-377. doi:10.1002/ibd.23013
  29. Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis. 2021;53(7):803-808. doi: 10.1016/j.dld.2021.03.002
  30. Wang Y, Makadia R, Knoll C, Hardin J, Voss EA, Fife D, Davis K, Sloan S. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterol. 2021;21(1):121. doi: 10.1186/s12876-021-01708-6.
  31. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. J Am Coll Gastroenterol.2019;114:384–413. doi: 10.14309/ajg.0000000000000152
  32. Peyrin-Biroulet L, Sandborn W, Sands B, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol2015;110:1324-1338. doi: 10.1038/ajg.2015.233
  33. Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14(2):254-266. doi:10.1093/ecco-jcc/jjz131
  34. Ko C, Singh S, Feuerstein J, et al. American Gastroenterological Institute Guideline on the management of mild-moderate ulcerative colitis. Gastroenterology. 2019;156(3):748-764. doi: 10.1053/j.gastro.2018.12.009
  35. Diaz G. Mild-to-moderate ulcerative colitis. GrepMed. Updated July 31,2020. Accessed April 9, 2023. https://www.grepmed.com/images/9608/moderate-algorithm-management-colitis-treatment-
  36. Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2019;156(3):769-808.e29. doi: 10.1053/j.gastro.2018.12.008
  37. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553-63. doi: 10.1016/j.mayocp.2014.07.002
  38. Burri E, Maillard M, H, Schoepfer A, M, et al. Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update. Digestion. 2020;101(suppl 1):2-15. doi: 10.1159/000504092
  39. Rinvoq. Prescribing information. Abbvie Inc; April 2023. Accessed April 11, 2023. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf
  40. Xeljanz. Prescribing information. Pfizer Labs; January 2022. Accessed April 11, 2023. https://labeling.pfizer.com/ShowLabeling.aspx?id=959
  41. Stelara. Prescribing information. Janssen; July 2022. Accessed April 10, 2023. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf
  42. Zeposia. Prescribing information. Bristol-Myers Squibb; November 2022. Accessed April 10, 2023. https://packageinserts.bms.com/pi/pi_zeposia.pdf
  43. Azulfidine. Prescribing information. Pfizer Labs: October 2022. Accessed April 11, 2023. https://labeling.pfizer.com/ShowLabeling.aspx?id=524
  44. Feuerstein JD, Isaacs K, Schneider Y, et al. American Gastroenterological Association Institute clinical guideline on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450-1461. doi: 10.1053/j.gastro.2020.01.006
  45. Rubin WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255-260. doi: 10.1053/gast.2001.26279
  46. Zyloprim. Prescribing information. Casper Pharma. December 2018. Accessed April 9, 2023 https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016084s044lbl.pdf
  47. Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D'Haens GR. Suppression of anti-drug antibodies to inFLIXimab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(8):1128-1134. doi:10.1111/apt.13994
  48. Kim M, Kim E, Kang B, Choe Y. Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy. Yonsei Med J. 2021;62(7):608-614. doi: 10.3349/ymj.2021.62.7.608
  49. Entyvio. Prescribing information. Takeda Pharmaceuticals USA, Inc.; June 2022. Accessed April 10, 2023. https://content.takeda.com/?contenttype=PI&product=ENTY&languag e=ENG&country=USA&documentnumber=1

  50. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2
  51. Rizankizumab (SKYRIZI®) achieves primary and all secondary endpoints in phase 3 induction study in patients with ulcerative colitis. Abbvie. News Center. March 23, 2023. Accessed April 10, 2023. https://news.abbvie.com/news/press-releases/risankizumab-skyrizi-achieves-primary-and-all-secondary-endpoints-in-phase-3-induction-study-in-patients-with-ulcerative-colitis.htm
  52. Remicade. Prescribing information. Janssen Biotech, Inc. October 2021. Accessed April 8, 2023
  53. Living with Ulcerative Colitis. Crohn’s and Colitis Foundation. December 2018. Accessed April 11, 2023. https://issuu.com/ccfa1/docs/living-with-ulcerative-colitis-brochure-final?fr=sN2ZhYjM3MDAxNzI
  54. Patrick E. Over the counter medication for ulcerative colitis. Ulcer Talk. April 10, 2023. Accessed April 15, 2023https://www.ulcertalk.com/over-the-counter-medication-for-ulcerative-colitis/

 

 

 

Patient Safety: Your Personal Medication Error Rate: Checkpoints and Reality Checks

Learning Objectives

 

After completing this application-based continuing education activity, pharmacists and pharmacy technicians will be able to

  • Differentiate systemic approaches to medication errors and individual (personal) responsibilities for medication errors
  • Outline various causes for medications errors that can be traced back to individuals
  • Discuss how unique work habits influence the propensity to make errors
  • Apply methods to reduce an individual’s medication error rate

Cartoon character holding up traffic sign that says 'oops!'

Release Date:

Release Date:  May 1, 2023

Expiration Date: May 1, 2026

Course Fee

Pharmacists: $7

Pharmacy Technicians: $4

There is no grant funding for this CE activity

ACPE UANs

Pharmacist: 0009-0000-23-016-H05-P

Pharmacy Technician: 0009-0000-23-016-H05-T

Session Codes

Pharmacist:  23YC16-XVK33

Pharmacy Technician:  23YC16-TXP82

Accreditation Hours

2.0 hours of CE

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-016-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

 

Disclosure of Discussions of Off-label and Investigational Drug Use

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Faculty

Amanda Choi, PharmD
Pharmacist
Backus Hospital
Norwich, CT

Carren Jepchumba, PharmD
Pharmacy Manager
Kroger Health
Indianapolis, IN

Jeannette Wick, RPh, MBA, FASCP
Dir. Office of Pharmacy Professional Development
UConn School of Pharmacy
Storrs, CT


 

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Drs. Choi and Jepchumba and Ms. Wick have no relationships with ineligible companies and therefore have nothing to disclose.

 

ABSTRACT

Pharmacists and pharmacy technicians must be careful not to make
errors, but errors slip through from time to time. Organizations (healthcare systems,
hospitals, and pharmacies) often use systems-based approaches to error
prevention. Pharmacy employees need to know about systems-based approaches,
but they also need to know about approaches they can use themselves to reduce
their own chances of error. This activity describes factors that increase the
likelihood of error and methods that are proven to help individuals focus. We
discuss–and strongly recommend–knowing your limit, tracking and recording errors,
collaborating with coworkers, employing tools that increase accuracy, and
stopping the workflow when things “feel” wrong.

CONTENT

Content

INTRODUCTION

Pharmacists and pharmacy technicians strive to provide safe, high-quality care to people when they are unwell, but sometimes we make errors. No one likes to make an error, and in our field, errors can have devastating consequences: preventable illness and injury, unnecessary hospitalizations, disability, and sometimes even death. Experts who have extrapolated data indicate that medical errors now account for 9.5% of all deaths in the United States, which if true, would make medical mistakes the third leading cause of death after heart disease and cancer.1

Addressing issues systemically has become commonplace in healthcare systems. Most of us know that the first step in resolving medication errors is being able to identify where errors occur and factors that contribute to their occurrence. Tracking in this way allows us to integrate preventive measures into our systems and habits to reduce future occurrence. It’s also important to create safe workplace environments so individuals involved in errors are not afraid to address future errors.2

But external factors aren’t the sole cause of medication errors. Psychosocial and cognitive factors can seriously impact the rates at which errors occur. Individuals who identify their own habits or knowledge gaps that might contribute to errors can take the next step: working on improving.

Definitions of “Medication Error”

To identify and prevent medication errors properly, having a clear, unambiguous definition would be ideal. Unfortunately, everyone seems to use similar—but different—definitions. Each person has a role and individual actions impact the team’s overall performance. Let’s compare a few definitions:

 

An error is a failure to complete a planned action as intended or the use of an incorrect plan of action to achieve a specific endpoint. Bad judgment, ignorance, or inattention might cause this type of error. A pharmacy situation might be when a technician fails to remove expired, very expensive medication and order new stock. When a new patient is admitted to the hospital and needs the medication immediately, the pharmacist hurries to process the order. Assuming that all medication in stock is in-date, the pharmacist approves an intravenous (IV) bag. At final verification, the pharmacist finally notices the medication’s expiration date. With no in-date stock, the pharmacist cannot send the IV. This mistake disrupts patient care. The pharmacy technician failed to keep the inventory in-date and the pharmacist assumed, failed to pay attention, and didn’t double check before proceeding.

 

An error is the enactment of a misconception due to incorrect information or part of a statement that is incorrect. An example in pharmacy might be when a doctor sends a new prescription with a higher-than-expected quantity, fails to update the prescription signatura (sig) or instructions, but tells the patient to take a higher dose. The puzzled pharmacist proceeds to process it. The insurance rejects the claim highlighting the calculated days-supply did not match the quantity indicated. While the pharmacist works on the prescription, the patient comes to the pharmacy to pick up her prescription. The pharmacist cannot contact the doctor who wrote the prescription and the doctor’s colleagues cannot confirm the prescription because they are unsure. The pharmacist decides to dispense a lower quantity per the old instructions so that the insurance will approve it. With the prescription now approved, the pharmacist dispenses the prescription but because the patient follows the doctor’s verbal directions, she runs out sooner than indicated on the prescription. She returns a few days later demanding more. The patient must now contact the insurance, the doctor, and the pharmacist to obtain the prescription that she needs. This could have been avoided if the doctor had noted that the patient would be taking the same drug at an increased dose.

 

An error is the departure from what is ethically acceptable or an incorrect result produced by automation. As healthcare systems increase their use of electronic health records, this problem is  increasing. Most systems are programmed to increase efficiency with the autofill function—meaning the computer will fill a field automatically based on the most common entry—which can increase avoidable errors. Too often, healthcare personnel blindly accept the computer-generated entry or calculations. This can result in a patient being given too much or too little drug and disrupt the quality of care.

 

In summary, medication errors occur in many ways (see Table 1). When a medication error occurs, it reduces the chances of achieving a desired outcome and the margin of safety associated with that outcome. Some medication errors result in adverse drug reactions but many do not. This is because not all adverse events cause adverse drug reactions.3 Many of us have made errors that serendipitously improved something. For example, a person making carrot soup may misread the words “1 garlic clove” and “1 teaspoon of cloves.” The soup will be different—and possibly better—than if the cook used garlic cloves. In medicine, however, errors are rarely “Happy Accidents” and we need to make every effort to reduce and eliminate them.

 

Table 1. Definition of Medication Errors

  • A misconception resulting from incorrect information
  • A wrong action attributable to bad judgment or ignorance or inattention
  • Departure from what is ethically acceptable
  • Inadvertent incorrectness
  • Part of a statement that is not correct
  • The occurrence of an incorrect result produced by a computer
  • Unintentional failures to act or plan (when it’s intentional, it’s a violation, not an error)

Source: Reference 3

Systemic Failures: Avoiding Blame

Many healthcare systems and providers now stress approaches that analyze errors as systemic failures. Systems, by nature, are interrelated units that work together toward the same goal. Most medication errors occur as a result of multiple, compounding events—or collapse of a faulty system—rather than an individual’s isolated act.4,5 It’s amazing how many times a serious error occurs because employees missed the opportunity to catch and rectify an error at multiple points in the patient’s care. Using a systems approach4,6

  • avoids assigning blame
  • explores relationships between various parts of the system, and
  • recognizes that cause and effect may be separated by space or time.

 

Many experts describe systemic failure using a Swiss cheese analogy. The holes in Swiss cheese represent the faults within a system. If an error passes through one of the holes in one slice of Swiss cheese, one would hope that the holes of the next slice of cheese won’t align, blocking the error. If the holes of the Swiss cheese slices all align, that medication error would slip through and reach the patient. Recognizing the placement of each slice—or the placement of each healthcare professional and that professional’s responsibility to be vigilant—can decrease the likeliness that a medication error will occur and it’s also key in identifying systemic failures.7,8

 

This Swiss cheese analogy can be applied to community pharmacy, where pharmacy staff establish multiple checkpoints during the filling process to ensure prescriptions are filled correctly (reviewing, scanning barcodes, tablet appearance, etc.). However, many patient safety cultures tend to look for explanatory causes for trouble and encourage blaming, criticizing, or silencing healthcare providers who make errors.4 For this reason, some experts refer to the individual who makes an error as the “second victim.” Lack of support from colleagues and supervisors can greatly affect involved health care providers’ ability to cope, leading to greater distress or protracted recovery.9

 

Fears of blame and punishment can deter individuals from reporting their errors, which can prevent creation of a culture of safety. Admitting one’s mistakes allows open discussion with peers and performance improvement experts can prevent further patient harm if they identify and fix the systemic “hole” causing the mistake.2,4 Let’s look at systems-based approaches first, and then examine why individual approaches are also critical.

 

QUALITY AND PERFORMANCE IMPROVEMENT APPROACHES

Various workplaces take different approaches to errors, but risk managers have proven certain approaches are more successful than others (see Table 2). The two most common approaches to analyzing medication errors are tracking and trending. Almost every workplace, whether it’s a healthcare facility or some other kind of business—requires employees to complete incident reports if they make an error. A responsible individual (usually someone designated as a quality or performance improvement specialist or a risk manager, although individuals may be interested in looking at their own errors) should look at incident reports over time to determine

  • What type of error or errors are most common
  • If a particular drug or product is involved in multiple incidents and why
  • The time of day or workload volume when the error occurred
  • The individual or individuals involved

 

This amounts to a type of detective work, in which the responsible party investigates medication errors individually and collectively to track and trend predisposing factors. If the data indicates that certain factors are trending (occurring more than once), the workplace can take action to prevent the error from happening again.10 Sometimes the action is as simple as heightening employees’ awareness that errors have occurred. Other times, the workplace might place a sign on a shelf indicating that a product is a look-alike or sound-alike product, mark bottles with bright colors to differentiate them, use TALL man lettering (see SIDEBAR), or conduct training so staff is better educated.

 

SIDEBAR; What is TALL man Lettering?

TALL man lettering is the practice of writing part of a drug's name in upper case letters to help distinguish sound-alike, look-alike drugs from one another. The goal is to differentiate drug names visually and avoid medication errors. The Office of Generic Drugs of the U.S. Food and Drug Administration (FDA) encourages manufacturers to use TALL man lettering labels. Many hospitals, clinics, and health care systems use TALL man lettering in their computerized order entry, automated dispensing machines, medication admission records, prescription labels, and drug product labels. Does your system use TALL man lettering? If not, should it?

 

The Institute for Safe Medication Practices creates a list of TALL man lettering for drug names. Most—but not all—of the drugs on the list are generic products. Find the list here: https://www.ismp.org/recommendations/tall-man-letters-list.

 

Here’s a snapshot from the center of the list:

 

Drug Name with TALL Man Letters Confused with
hydrALAZINE hydrOXYzine – HYDROmorphone
HYDROmorphone hydrOXYzine – hydrALAZINE
hydrOXYzine hydrALAZINEHYDROmorphone
medroxyPROGESTERone methylPREDNISolone – methylTESTOSTERone
methylPREDNISolone medroxyPROGESTERone – methylTESTOSTERone
methylTESTOSTERone medroxyPROGESTERone – methylPREDNISolone
mitoXANTRONE Not specified
niCARdipine NIFEdipine
NIFEdipine niCARdipine
prednisoLONE predniSONE
predniSONE prednisoLONE
risperiDONE rOPINIRole
rOPINIRole risperiDONE

 

Source: Reference 11

Table 2. Common Approaches to Medication Error-Related Performance Improvement

Term Definition
Tracking ·       The ability to assess performance; following the course or trail of someone or something, usually to find them or note their location. In pharmacy, this could include:
  • Product identification and verification, detection of and response to suspicion of illegitimate products
  • Record keeping located in pharmacies, distributers, and providers’ records
  • Patient data sharing to assist with medication reconciliation
  • Recording all variances on unusual incident reports
Trending ·       Monitoring the general direction in which something is developing or changing. In pharmacy, monitoring has led to expansion of the pharmacists’ role. Examples include vaccination administration, collaborative practice agreements in certain states, tobacco cessation programs, and point-of-care testing.

·       A method of estimating future costs of health services by reviewing past trends in cost and utilization of those services.

Root cause analysis ·       A full investigation of the causes of unexpected events followed by identification and implementation of appropriate and effective strategies to prevent similar occurrence in the future.

·       Asking “Why?” until it cannot be answered, often employing a “fishbone diagram” that looks at potential issues with materials, machines, methods, environment, measurements, and people.

·       It helps pharmacies take a process-driven, system-based approach to address errors.

Workplace re-engineering ·       Planned elimination, addition, or distribution of functions or duties in the workplace focused on innovative strategies to develop leaders, engage employees, and foster healthy workplace culture.

·       Is often influenced by excessive or insufficient labor, poor patient outcomes, or political or economic changes.

Disaster drill or mock code ·       An exercise or demonstration that tests the readiness and capacity of a hospital, a community, or other systems to respond to a possible public health emergency or other disaster.

Source: References 12, 13, 14, 15, 16, 19

 

In the event a serious error occurs, workplaces need to go beyond simple steps. One such step is to conduct a root cause analysis (RCA). RCA starts by reviewing what and how an event occurred, and expands the investigation to identify why it happened. Many organizations explain to their employees that RCA is the art of asking “Why” until no more questions beginning with “Why” are possible. Armed with that information, the RCA team can develop workable corrective measures that prevent future events of the type observed. RCA is not flawless, but it ensures that teams of people look at very serious errors and develop approaches that could prevent them in the future.20

 

Finally, errors are more likely to occur when unusual, unexpected, or unanticipated situations arise. For this reason, many organizations run disaster drills and observe them closely. In this way, they can identify areas where their systems are weak and implement corrective measures.21

 

Successful Programs

To create the best possible error prevention program, organizations can look at what has been proven to work. It’s clear that behavior-based programs create better outcomes than technology or any other approach.4 A leading researcher in pharmacy error identified six elements common to the most effective behavior-based programs (See Figure 1).4

 

Figure discussing six elements of performance improvement programs

Efforts that address the system and the individual jointly and individually are prudent. Consider a systemic safety measure: the widespread use of technology that is “smart.” Relying on technology and assuming it never fails may make some individuals become complacent and less vigilant until it is too late.4 Examples in community pharmacy are automated inventory systems and bar-code scanners. A person who enters data into a system—this would be an employee in the inventory management section in most pharmacies or healthcare systems—has a slight chance of entering an incorrect drug name. If no one catches the error, the last chance to prevent an error rests with the pharmacist who verifies that the tablet matches the description in the system before it is dispensed to the patient. The final check—a step that cannot and must not be automated—is an individual responsibility. Taking the extra seconds to verify the drug (while remembering that sometimes technology fails) can save a patient’s life from what could have been a deadly mistake.4

 

Many psychosocial factors also influence work performance. Work-as-imagined (work that is anticipated and described in official policies and procedures compiled by administrators or policy makers) and work-as-done (the way that employees actually accomplish work) are often quite different.22 Factors associated with the process of filling prescriptions are shown in Table 3.

 

 

Table 3. Psychosocial Factors that Influence Work Performance

  • Anxiety or depression
  • Changing workload
  • Competing tasks
  • Determination to “get the job done” despite barriers
  • Distraction or interruption
  • Hurrying
  • Insufficient decision support
  • Insufficient staffing
  • Knowledge gaps
  • Lack of experience
  • Lack of non-technical skills training (examples include communication, decision-making, reasoning, team work, time management)
  • Machinery or hardware that is difficult to operate
  • Perception that an error could lead to criminal charges
  • Rapidly changing or evolving roles
  • Use of “work-arounds” (shortcuts or approaches that differ from procedure) to overcome barriers
  • Vague or incomplete policy or procedure

 

Source: References 6, 22, 23, 24

 

The physical environment (inadequate illumination, environmental distractions, and noise), interruptions in workflow, facility design, technology, poorly designed labels, interpersonal relationships (e.g., number of interfaces with people and the level of stress and conflict caused by those interactions), and workload can adversely affect accuracy. 25,26,27

 

Many pharmacy employees associate high workload with increased error rates. They are often surprised to learn that low-workload conditions are more closely linked with errors than high-workload conditions. Consider a study conducted in 2000 that involved pharmacists, pharmacy technicians, and 21,672 prescriptions. Pharmacy employees made more process errors under low-workload conditions (11.2%) than under high-workload conditions (6.1%) and during periods when the workload trended downward in volume (at the start of a shift or after a break).28,29 In general, pharmacists were more vulnerable to mistakes when processing fewer than 15 prescriptions per hour than when processing more than 25 prescriptions per hour. (Author aside: We include these numbers because the study reported them, not as a hard and fast rule. We acknowledge that everyone has unique working habits, and some people can feel burned out processing fewer prescriptions than others.) A little bit of task tension (from perceived workload) seemed to result in fewer errors while filling prescriptions. However, there may be limits to the increases in task tension that would provide desirable results—too much stress and tension can become a problem. Overall, low levels of objective workload and subjective task tension were associated with more errors.26,30

 

Personal qualities can also play a role. Impulsivity, task frustration, fatigue, perceptual ability, concern for doing well, a lack of physical hardiness, and magnitude of personal effort expended can cause more errors to progress through the verification process unnoticed. Individuals should examine their task-related anxiety and overall job-related depression (a strong predictor of overall job stress often manifesting as constant complaining at work, impatience with coworkers, the need for “mental health days,” difficulty getting up on workdays, or physical illnesses) and address them if possible. Supervisors should examine employees’ task-related anxiety and overall job-related depression to help individuals cope; if not, anxiety and depression will affect job satisfaction and performance.4,22

 

Workplace support is also an important factor and the study mentioned earlier also demonstrated its importance. Pharmacists who had supervisors who they perceived as helping them set task goals and gain appropriate autonomy made fewer errors. Pharmacists who had supervisors who were overly autocratic (meaning domineering or overly involved in supervision) experienced tension that interfered with dispensing prescriptions accurately. Pharmacists who believed the number of breaks they receive was adequate to meet their needs made fewer process errors. 26 Later studies also confirm that poor leadership and insufficient support can adversely influence accuracy.22

 

ERRORS: WHAT WE KNOW

 

Errors are inevitable, but we must be able to recognize when we are prone to making errors to be able to limit them. Everyone has periods of increased errors—for instance during dramatic shifts in workload. Entering the pharmacy during peak hours can be stressful and predispose some individuals more than others to make errors they wouldn’t usually make. When we are flustered, our sense of logic escapes us momentarily.4,26

 

Some individuals make more frequent or predictable errors than others because of different cognitive styles. A classic study found that pharmacists whose cognitive styles include attention to details made fewer errors. It also found that about 12% of pharmacists have difficulty attending to details, and that 12% of pharmacists made 33% of errors.26 By using high-intensity task lights, exaggerated product label names (labels that are large and multicolored), NDC numbers, and specially designed devices for holding prescriptions at eye level during data entry, pharmacy staff who had difficulty being attentive to details made fewer errors.26 An 1999 incident monitoring study found poor communication and failure to check medical records when questions arose also contributed to errors.31 A more recent PRIORITIZE study conducted between September 2013 and November 2014 involving 500 North West London primary care clinicians noted the top three problems relating to medication errors in primary care were incomplete medication reconciliation during transitions of care, inadequate patient education about medication use, and poor discharge instructions.32 Clearly, healthcare providers have some communication problems.

 

A patient case in Pennsylvania illustrates the alarming consequences of poor communication between healthcare providers and fewer medication reconciliations. The patient was first hospitalized for uncontrolled blood pressure and acute kidney injury. At the time of discharge, one of her prescription medications was Norvasc® (a high blood pressure medication). The patient experienced worsening fatigue, slow movements, personality changes, and a ‘stoic’ facial expression with suboptimal blood pressure control. Soon after, she was hospitalized the second time for chest pain and underwent angioplasty. Several weeks later, she was diagnosed with anxiety and depression and was prescribed prescription medications for these conditions. The patient was admitted a third time to the emergency room after a fall with light-headedness and poor ambulation. It was only at the third visit when the medication reconciliation team realized her outpatient pharmacy accidentally dispensed Navane® (generic name as thiothixene, an antipsychotic) instead of Norvasc®. When thiothixene was discontinued, her clinical status improved. This preventable medication error occurred because the pharmacy staff and physician deemed the written prescription legible, when in actuality, it was not.8

 

Typically, people make mistakes or slips most frequently when new to the profession and lacking experience. A long period during which mistakes are rare follows. Eventually everyone develops unique work habits, and error rates tend to increase again, usually as bad habits develop.29,33

 

Finally, humans work on autopilot around 80% of the time. This means that 80% of the time, we don’t fully register what we are doing in our brain; we don’t engage with the task at hand and instead just go through the motions. Pharmacists also have an “inner pharmacist” who should kick in and take them out of autopilot mode when issues out of the ordinary arise.30,34,35 Often, when faced with errors after-the-fact, we clearly recall the circumstances under which they occurred because we wake up from our autopilot. We’ll talk more about autopiloting below.

 

How People Work

Workload in the pharmacy has been traditionally measured as the number of prescriptions dispensed per hour or day, or the number of prescriptions dispensed per pharmacist. Experts predict that the typical pharmacist’s workload has and will increase for two reasons:

  • An increase in demand from an aging population and
  • The addition of pharmacist-provided services (examples include medication therapy management, helping women select oral contraceptives in some states, and immunizations).

 

Instead of only focusing on the numbers, pharmacists, pharmacy technicians, and the organizations that employ them should focus on understanding the individual’s subjective experience of work demands. For pharmacists, verifying patient’s information, performing patient consultation and drug utilization reviews, and verifying prescriptions for accuracy can be demanding to the point that high workload negatively impacts performance. For technicians, similar factors—performing repetitive and mundane tasks, expanding roles, and high-risk assignments—may increase stress or create situations in which they must multi-task. Understanding that work is a process and not a series of discrete events can help maintain the “big picture.”30 That big picture is that pharmacists and pharmacy technicians must promote patient safety; dispensing to keep up with the pharmacy queue—the people who are in line or who have called in—is not prudent.36

 

Over the course of the day, filling many prescriptions is bound to cause a person go on autopilot—which is understandable. Humans are creatures of habit and routine. All humans work on autopilot around 80% of the time.4,34,35 Autopiloting occurs when the brain recognizes a situation and rapidly selects appropriate responses using familiar, predictable behavior context. The brain does this to preserve energy. Essentially, we perform most tasks reasonably well without thinking much about them. Many readers will sigh with recognition when they read this example: many people have left home on a non-work day to go someplace that’s in the general direction of work. They may be surprised to find themselves in their workplace’s parking lot. That’s autopilot. In the retail setting, pharmacy technicians and pharmacists autopilot the most when they are dealing with insurance coding and billing to third-party insurers. Autopiloting is usually safe.37

 

Our autopiloting should stop when we encounter stressful situations that are unfamiliar because our brains don’t know how to react appropriately in unfamiliar situations. In stressful situations, we tend to misapply familiar rules and knowledge. Intense emotion blocks out our sense of logic. In these situations, we have to remember to exercise mindfulness—taking a little bit of time away from the regular work stream to assess the situation calmly and proceed with a plan of action.4

 

It’s also crucial for each worker to know his or her own tendency to make errors and do what is necessary to refocus.4 However, all pharmacy employees must recognize that some people’s propensities and capabilities are hardwired.33 They cannot change their abilities and will approach work the same compulsive way, regardless of training.

 

Using technology to help us work is effective, but technology has limitations.38 Technology makes us lazy and unfamiliar with manual processes that have been automated. It is common for individuals to become complacent because we believe a machine designed for a specific purpose will complete the task correctly for us. We tend to trust that technology will work well all the time. It doesn’t.39 For instance, refilling a carousel cassette with the wrong medication will not prevent the machine from filling the prescription. This error can go undetected unless the pharmacist performs a final check before dispensing to the patient. This emphasizes the importance of the pharmacist’s individual responsibility as mentioned earlier.4,39

 

Self-improvement

While all of us prefer not to make errors, expecting an error rate of zero is unreasonable.4 Errors will happen. As noted above, some people make more errors than others, and a landmark study found that 12% of pharmacists made 30% of reported errors.26 Certainly, we all work with others who seem to make a disproportionate share of the workplace’s errors, and those who seem to be remarkably accurate. Where do you fall on the spectrum?

 

Examining your own error rate requires insight. This term—insight—is used most often in psychiatry and is defined as the patient’s awareness and understanding of the origins and meaning of his or her attitudes, feelings, and behavior, and disturbing symptoms.40 It means understanding of oneself. It has a slightly different meaning in the context of medication errors. In problem solving, it means the sudden perception of the appropriate relationships between things that results in a solution.41,42

 

Some people, and especially those who are error-prone, have poor insight. It may result from fixation, over-reliance on experience and past circumstances, rushing to solve a problem, or using the same approach over and over and expecting different results. Let’s look at each of these individually.

 

Fixation error refers to the tendency for the brain’s perceptual field to narrow and shorten in a crisis.43,44 When this happens, we develop a sometimes stymieing compulsion to fixate on the problem we think we can solve, and ignore almost everything else. During periods of fixation, time becomes distorted; minutes often seem longer than usual. In addition, the fixated individual may not hear input from others. Even the most skilled and experienced professionals can develop a fixation in periods of high stress.43,44

 

An example is that of a stalled car stuck on a level crossing as a distant train barrels toward it. The driver starts and restarts the engine, when the best way to save his life is to exit the car and run. In pharmacy, fixation errors occur when the provider concentrates on a single aspect of a case or problem to the detriment of other more relevant aspects. To break out of a fixation, individuals must be able to recognize the demand for a new approach to the problem and to produce a solution that works. Individuals who tend to fixate need to learn to43,44

  • Ask themselves what is different about the current problem
  • Heighten awareness of the people around them and listen
  • Invite others into the problem solving team to identify alternatives

 

Over-reliance on experience and past circumstances often occurs during emergencies. In this case, the individual tends to rely on past experience (even if it doesn’t apply in the current situation), and have difficulty abandoning assumptions based on that experience. In short, the person applies incident-specific experience to a situation that is probably much broader in nature. An example would be investigating why a patient who has asthma is experiencing exacerbations. If the pharmacist assumes the problem is treatment nonadherence when the actual problem is that the inhaler is faulty or requires skills like visual acuity or manual dexterity that the patient does not possess, the assumption can be deadly. In addition, during emergencies, individuals may have trouble recalling information accurately (elevated cortisol levels tend to change cognition and thinking). Often, using a cognitive aid like a checklist, decision tree, or an algorithm can help clarify thinking and lead to faster—and better—solutions.45

 

It’s interesting that many pharmacy staff members say, “I was rushing,” when they analyze errors, but few studies looked at or identified rushing as a cause. Rushing to problem-solve can increase the likelihood of error. An older study found that physicians linked 10% of errors to rushing or fatigue.31 Experts in medication error science also indicate that rushing contributes to error.46 An older study in Canada looked at a pilot program that transferred order entry responsibilities from pharmacists to pharmacy technicians. At the end of the study, the error rate had increased from 2.5% to 6%. Analysis indicated that technicians were rushing to enter orders, and re-training technicians to slow down and be mindful reduced the error rate to below the baseline level.47 Often, technicians may try to fill more quickly, or pharmacists rush the final verification step of dispensing as the customer line lengthens, and errors occur.

 

One area of growing interest is interruptions and interruption management.48,49 Interruptions have been shown to increase the medication error rate, and some studies suggest a technique called interruption management. They suggest using a “do not interrupt” sign or even a piece of clothing that warns people to stay away until the healthcare professional completes the task. They also recommend using a checklist for multistep processes. At this time, it’s unclear if these interventions help.48,49

 

Finally, many of us have fallen victim to a common dilemma: using the same approach over and over and expecting different results.4 Healthcare practitioners as a rule, do many tasks—even complicated ones—from memory rather than from following a checklist. Over time, and especially when we see our error rates beginning to climb upward, it’s important to look at our own work and consider ways in which we need to adjust or change (see Table 4). We cannot rely on what we did before. Over time, people change, workplaces change, and many of the problem’s underlying elements change.4 As we analyze errors, we must include what we’ve learned in the past, but be open to fresh approaches and ideas.

 

Table 4. Improving Your Own Accuracy

Do this…. And then do this…
Periodically review your errors and near-misses. Analyze errors to determine if you see a trend like confusing look-alike, sound-alike or spell-alike drugs.

Determine if you can take steps to reduce the likelihood of a similar error happening again.

Develop and use checklists if errors occur in multi-step processes.

Schedule visual and hearing exams more frequently as you age. Wear appropriate glasses or hearing aids at work.

Ask your employer for assistive devices (supplemental lighting, a magnifier, or a phone amplifier), or secure these yourself.

Solicit feedback from peers and supervisors about ways to reduce your own and others’ errors. Maintain a quiet, composed demeanor in the workplace.
Address workplace distractions as soon as you become aware of them. Reduce noise and clutter, improve lighting.
Understand technology’s limitations. Maintain your skills so that if technology fails, you can revert to the pre-technology work method.
Value relationships with coworkers and promote good organizational dynamics. Resolve disputes immediately, and retire grudges.

Provide feedback to coworkers constructively.

Address developing personal problems (alcohol abuse, marital discord) early.

 

Engage with your employer’s employee assistance program before your supervisor refers you.
Understand that some people make errors because they lack knowledge. Address your own knowledge gaps, and promote a culture of learning.
Avoid relying on “workplace re-engineering” or “work task design” to prevent errors; these may fail as the workplace composition and focus changes. Learn to engage and listen to your “inner pharmacist” or “inner technician” when something is out of the ordinary.

 

 

When we discuss medication errors, it’s critical to talk about data entry errors because they represent about 25% of all medication errors.25 The pharmacy has many repetitive tasks like data entry or filling prescriptions. Many of these tasks can be completed without conscious awareness. This ‘autopilot’ function contributes to data entry errors like misspellings or errors recorded on the patient’s profile. The vast majority of data entry errors are inconsequential, but some are dangerous.25

 

Many factors could impact the cognitive system directly. Pharmacists and pharmacy technicians can take some simple steps to increase accuracy in the pharmacy. Figure 2 suggests a few, but individuals will find the best solutions are those they develop themselves and tailor to their own habits and circumstances.

 

Figure discussing four error prevention techniques in the pharmacy

 

Reducing Workplace Turbulence

Workplace turbulence occurs when something causes discomfort or decreases workplace stability. Some things that cause workplace turbulence include poor temperature control (it’s either too hot or too cold), noise, clutter, uncertainty, or working with people who have different styles or personalities that are abrasive to you. These things affect accuracy and productivity. If workplace distractions are the problem, making small changes to decrease turbulence can make large differences.29,33

 

If the problems are environmental, ask the appropriate person to help resolve them. Establishing good relationships with the people who provide environmental support—people in building supervision, maintenance, and housekeeping—is imperative. They can often help adjust the ambient temperature or reduce clutter. Learning to work with instead of against or parallel to coworkers and supervisors can improve the environment.4 The key is telling your supervisor how you best hear constructive criticism and delivering constructive criticism to others in a positive way—and in the way they receive it best.

 

Finally, be aware of when you are fatigued or unable to perform at your peak and enlist coworkers' help by asking them to monitor your work.29,33

 

Poka-Yoke

Since the 1960s, many industries have adopted the principles of poka-yoke, also called “mistake-proofing,” to prevent errors.50 Poka-yoke is a systems approach, but unlike many systems approaches, the people closest to the work (not administrators or policy makers) propose the action. Defined broadly, poka-yoke refers to any behavior-shaping constraint in a process that prevents faulty behaviors by the worker. An industrial engineer at Toyota developed this concept, and it encourages workplaces to look at common mistakes and develop processes that make it impossible for workers to make the mistake in the future. Basically, it’s defensive workplace design. It depends on involving the people closest to the work to identify what to mistake-proof and develop ideas to prevent very specific mistakes. In pharmacies, four poka-yoke principles are used often, and can be applied in many more areas.50-52

 

First, workplace managers need to empower employees to pause or even stop the work process entirely if they believe that an error is in process.29 Employees need to be able to ask four questions respectfully:

  • Did we do everything?
  • Did we do everything right?
  • Does it look, sound and feel right?
  • Are these our usual work conditions?

 

Next, everyone in the pharmacy community from manufacturers to distributors to providers who work in direct patient care need to make it easier for people to do the right thing than the wrong thing. A short example can clarify this principle. Years ago at the National Cancer Institute, a collaborating company was developing a new monoclonal antibody (MAB). The MAB was lyophilized and came in a fairly large multidose vial. It needed to be reconstituted with 20 mL of a specific diluent. The manufacturer provided the MAB with a vial of the diluent that contained 30 mL. The astute reader will see the potential for error. In many cases, pharmacists and pharmacy technicians who worked in investigational drug preparation looked at the package, and simply transferred the diluent—all 30 mL of it—into the larger vial. The resultant solution was an incorrect dose. Can you see why? Diluting a 400 mg vial with 20 mL creates a 20 mg/mL solution. Using 30 mL creates a 13.33 mg/mL solution. After investigational drug employees identified and reported this error several times, and the NCI reported it to the manufacturer, the simple poka-yoke fix was implemented. Although it took quite some time to implement the change, eventually the manufacturer packaged the MAB with a vial of diluent that had the correct amount needed in it—20 mL.

 

People who work in pharmacy in any capacity can make it easier to do the right thing than the wrong thing in numerous ways. Let’s discuss four of them.

  • Putting items that will always be used together in that same container, and making sure that the items that are assembled are the correct sizes or doses or quantities, is kitting at work. It results in fewer missing parts, and it also speeds your process. Some experts estimate that it can cut errors by as much as 80%.53 The solution noted above is an example of kitting. Other examples of kitting are creating bowel evacuation kits for patients having colonoscopies, or assembling packages of items that are frequently prescribed together for specific procedures or treatments.
  • Keying simply means that a process can’t be started without a key or tool of some sort. The requirement to remove your ATM card before receiving cash is an application of this principle so people don’t leave their cards in the machine. An example in the pharmacy is a computer that requires the user to insert an ID card to start the system. This increases accuracy and prevents users from signing in early in the day, walking away from the computer, and allowing others to operate under an incorrect sign-in code. Another example of a type of keying is moving pseudoephedrine to behind the counter in the pharmacy. Adding that step—requiring customers to sign for pseudoephedrine and limiting quantities—ensures there is a check in the process. States that have implemented this step have decreased the amount of pseudoephedrine diverted to methamphetamine production significantly.
  • Interlocking uses simple mechanisms so that parts will only fit with other appropriate pieces. These are simple, low cost devices that prevent parts from being assembled incorrectly. An everyday example of poka-yoke for someone who always forgets or loses his keys is to place the keys in the shoes he will wear tomorrow. An example in pharmacy might be providing drugs meant to be administered intrathecally in a device that cannot attach to any intravenous equipment.
  • Tell-tales let you know when you have made an error. Barcoding is a type of telltale. When you scan a barcode and it doesn’t match the barcode on the actual order, it sends you an alert that you’ve made an error.

 

The last poke yoke principle we’ll cover is this: Make mistakes obvious to workers immediately and discretely so they can make on-the-spot corrections, and allow people to take corrective actions or stop the work flow before irreversible damage is done. This small kindness brings errors to the error-maker’s attention, and allows immediate learning.

 

CONCLUSION

Despite our best intentions, some errors escape the confines of the pharmacy. Randomly checking completed work that has apparently passed verification sometimes identifies problem areas. But, some errors are just that—unfortunate events that could not be anticipated and occurred due to a confluence of factors. Even though reaching a medication error rate of zero is improbable, we should still make efforts to acknowledge our professional responsibility in our own work habits. Creating solutions tailored to our habits and circumstances can help reduce error rates and encourage a focus on a workplace culture of patient safety—not the number of prescriptions filled—as the big picture in pharmacy.

 

 

Pharmacist Post Test (for viewing only)

LEARNING OBJECTIVES
After participating in this activity, pharmacists and pharmacy technicians will be able to:
1. Discuss the difference between systemic approaches to medication errors and individual (personal) responsibilities for medication errors
2. Outline various causes for medications errors that can be traced back to individuals
3. Discuss ways in which peoples’ unique work habits influence their propensity to make errors
4. Identify methods to reduce an individual’s medication error rate and apply them appropriately

1. Which of these can INCREASE the chance of making errors?
A. Labeling of common look-alike, sound-alike drugs on shelves
B. Working on autopilot to perform tasks that are very routine
C. Working during a dramatic increase or decrease in workload

2. Which is an example of individual responsibility for medication errors?
A. A hospital administration implements autofill functions in the computer software to improve efficiency
B. A pharmacist provides the final check of a prescription after the prescription bottle comes out of the carousel
C. A manufacturer packages an intramuscular injection and its diluent in proper quantities in the same box

3. Eloise is a pharmacist at your hospital pharmacy. She is a reliable employee and one of the most skilled and experienced members of the pharmacy team. She has good recollection, even in stressful situations, but she tends to fixate when dealing with emergencies. If this situation occurs, which of the following should she perform FIRST?
A. Isolate herself from the people around her so she can think
B. Try to rectify the problem based on her past experiences
C. Take a moment to ask herself what’s different about this problem

4. What have studies of errors in healthcare found to be TRUE?
A. Eventually everyone’s error rate increases after a period of time working in their profession.
B. Addressing the system and individual jointly and individually is useless for analyzing errors.
C. Technology creates better outcomes than behavior-based programs.

5. What was the cause of the medication error in the Pennsylvania patient case described in this CE activity?
A. Poor communication
B. Bad work habits
B. Autopiloting

6. Which one of these is an example of how can individuals can improve their personal medication error rates?
A. Using the same approach over and over for different situations for consistency
B. Pointing out other team members’ mistakes so others will not do the same thing
C. Applying what you know works well while being open to fresh approaches and ideas

7. Mike is a pharmacy technician who works in a community retail pharmacy. He prides himself on being a people-person and receiving good feedback from patients. Last month while chatting with customers, he accidentally reconstituted an antibiotic medication with too much diluent. The pharmacist dispensed it and the patient now has a resistant infection due to receiving suboptimal treatment. As the pharmacist filled out an incident report, he told ML to stop talking with the customers and focus on his work. Since then, ML has become quieter. Patients have noticed his change in demeanor and brought it up with the pharmacist. What do you think the pharmacist should do next?
A. Tell patients that nothing’s wrong with Mike. He’s just focusing on his work because he made an error when he was distracted previously.
B. Ask Mike if he has a moment to talk about last week’s incident, apologize, to him and ask how Mike would prefer to hear criticism in the future.
C. Disregard their concerns – Mike was a chatter box who needed to learn how to limit his talking sooner rather than later.

8. Which of the following statements describe how the workload in the pharmacy should be measured?
A. The number of prescriptions per hour or day
B. The individual’s subjective experience of work demands
C. The number of prescriptions per pharmacist

9. CJ is an experienced pharmacist. With a growing number of tasks, CJ has been struggling to stay afloat. On a busy afternoon, CJ administered multiple immunizations and answered dozens of phone calls. The wait time was longer and longer. CJ made a list of his remaining tasks. He decides to rush through prescriptions to clear the queue. Which of the following could contribute to increased risk of medication error and is within CJ’s control?
A. The growing list of tasks to be done as a pharmacist
B. A particularly busy work day or time of day at the pharmacy
C. Rushing without addressing ways to readjust to accommodate for new tasks

10. Which factors help reduce medication error?
A. Leaving conflicts in the workplace unresolved and unacknowledged
B. Avoiding personal problems until they become a problem at the work place
C. Creating a safe environment for individuals involved in the error

11. Which of the following is a cognitive factor that influences workplace performance?
A. Changing workload
B. Insufficient staffing
C. Attention to detail

12. Which is an example of a SYSTEMIC approach that would increase medication errors?
A. A pharmacist performs final verification of a prescription after final packaging
B. The pharmacy implements automated inventory systems, autofill, and bar code scanners
C. A technician carefully checks for expiration dates and disposes medication accordingly

13. Which of the following would INCREASE an individual’s medication error rate?
A. Relying on technology whenever possible and utilize more “smart technology”
B. Maintaining skills so that if technology fails, you can revert to manual work methods
C. Wearing appropriate glasses, secure assistive devices or hearing aids at work.

14. Which of the following will INCREASE medication errors that are traced back to individuals?
A. Employees routinely examine their task-related anxiety and job-related depression
B. The pharmacy has poor leadership and insufficient support for employees
C. Pharmacy employees believe the number of breaks they receive are adequate

Pharmacy Technician Post Test (for viewing only)

LEARNING OBJECTIVES
After participating in this activity, pharmacists and pharmacy technicians will be able to:
1. Discuss the difference between systemic approaches to medication errors and individual (personal) responsibilities for medication errors
2. Outline various causes for medications errors that can be traced back to individuals
3. Discuss ways in which peoples’ unique work habits influence their propensity to make errors
4. Identify methods to reduce an individual’s medication error rate and apply them appropriately

1. Which of these can INCREASE the chance of making errors?
A. Labeling of common look-alike, sound-alike drugs on shelves
B. Working on autopilot to perform tasks that are very routine
C. Working during a dramatic increase or decrease in workload

2. Which is an example of individual responsibility for medication errors?
A. A hospital administration implements autofill functions in the computer software to improve efficiency
B. A pharmacist provides the final check of a prescription after the prescription bottle comes out of the carousel
C. A manufacturer packages an intramuscular injection and its diluent in proper quantities in the same box

3. Eloise is a pharmacist at your hospital pharmacy. She is a reliable employee and one of the most skilled and experienced members of the pharmacy team. She has good recollection, even in stressful situations, but she tends to fixate when dealing with emergencies. If this situation occurs, which of the following should she perform FIRST?
A. Isolate herself from the people around her so she can think
B. Try to rectify the problem based on her past experiences
C. Take a moment to ask herself what’s different about this problem

4. What have studies of errors in healthcare found to be TRUE?
A. Eventually everyone’s error rate increases after a period of time working in their profession.
B. Addressing the system and individual jointly and individually is useless for analyzing errors.
C. Technology creates better outcomes than behavior-based programs.

5. What was the cause of the medication error in the Pennsylvania patient case described in this CE activity?
A. Poor communication
B. Bad work habits
B. Autopiloting

6. Which one of these is an example of how can individuals can improve their personal medication error rates?
A. Using the same approach over and over for different situations for consistency
B. Pointing out other team members’ mistakes so others will not do the same thing
C. Applying what you know works well while being open to fresh approaches and ideas

7. Mike is a pharmacy technician who works in a community retail pharmacy. He prides himself on being a people-person and receiving good feedback from patients. Last month while chatting with customers, he accidentally reconstituted an antibiotic medication with too much diluent. The pharmacist dispensed it and the patient now has a resistant infection due to receiving suboptimal treatment. As the pharmacist filled out an incident report, he told ML to stop talking with the customers and focus on his work. Since then, ML has become quieter. Patients have noticed his change in demeanor and brought it up with the pharmacist. What do you think the pharmacist should do next?
A. Tell patients that nothing’s wrong with Mike. He’s just focusing on his work because he made an error when he was distracted previously.
B. Ask Mike if he has a moment to talk about last week’s incident, apologize, to him and ask how Mike would prefer to hear criticism in the future.
C. Disregard their concerns – Mike was a chatter box who needed to learn how to limit his talking sooner rather than later.

8. Which of the following statements describe how the workload in the pharmacy should be measured?
A. The number of prescriptions per hour or day
B. The individual’s subjective experience of work demands
C. The number of prescriptions per pharmacist

9. CJ is an experienced pharmacist. With a growing number of tasks, CJ has been struggling to stay afloat. On a busy afternoon, CJ administered multiple immunizations and answered dozens of phone calls. The wait time was longer and longer. CJ made a list of his remaining tasks. He decides to rush through prescriptions to clear the queue. Which of the following could contribute to increased risk of medication error and is within CJ’s control?
A. The growing list of tasks to be done as a pharmacist
B. A particularly busy work day or time of day at the pharmacy
C. Rushing without addressing ways to readjust to accommodate for new tasks

10. Which factors help reduce medication error?
A. Leaving conflicts in the workplace unresolved and unacknowledged
B. Avoiding personal problems until they become a problem at the work place
C. Creating a safe environment for individuals involved in the error

11. Which of the following is a cognitive factor that influences workplace performance?
A. Changing workload
B. Insufficient staffing
C. Attention to detail

12. Which is an example of a SYSTEMIC approach that would increase medication errors?
A. A pharmacist performs final verification of a prescription after final packaging
B. The pharmacy implements automated inventory systems, autofill, and bar code scanners
C. A technician carefully checks for expiration dates and disposes medication accordingly

13. Which of the following would INCREASE an individual’s medication error rate?
A. Relying on technology whenever possible and utilize more “smart technology”
B. Maintaining skills so that if technology fails, you can revert to manual work methods
C. Wearing appropriate glasses, secure assistive devices or hearing aids at work.

14. Which of the following will INCREASE medication errors that are traced back to individuals?
A. Employees routinely examine their task-related anxiety and job-related depression
B. The pharmacy has poor leadership and insufficient support for employees
C. Pharmacy employees believe the number of breaks they receive are adequate

References

Full List of References

 

References

 

  1. Anderson JG, Abrahamson K. Your health care may kill you: medical errors. Building Capacity for Health Informatics in the Future. 234:13-17. DOI 10.3233/978-1-61499-742-9-13. Accessed December 27, 2022. http://ebooks.iospress.nl/publication/46132.
  2. Rogers EE, Griffin E, Carnie W, et al. A just culture approach to managing medication errors. Hosp Pharm. 2017;52(4):308-315.
  3. Aronson, J. (2019). Medication errors: definitions and classification. Accessed December 27, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723196/
  4. Grasha AF. Into the abyss: seven principles for identifying the causes of and preventing human erros in complex systems. Am J Health-Syst Pharm. 2000:57:544-564.
  5. Hodgson BB, Kizior RJ. Appendix L. In: Hodgson BB, Kizior RJ, Saunders Nursing Drug Handbook 2013. 1st edition. St. Louis, Missouri, Saunders/Elsevier; 2012:1290.
  6. Vosper H, Lim R, Knight C, et al. Considering human factors and developing systems- thinking behaviours to ensure patient safety. Clinical Pharmacist. 2018,10:2. Accessed December 27, 2022. https://dspace.lboro.ac.uk/dspace-jspui/bitstream/2134/28474/3/Hignett_Vosper%202018%20ACCEPTED%20%20pharmaceutical-journal.com.pdf
  7. Rosen RK. Medication errors: a 21st-century perspective. Proceedings (Bayl Univ. Med Cent). 2004;17(4):464-467;discussion 467-468.
  8. da Silva BA, Krishnamurthy M. The alarming reality of medication error: a patient case and review of Pennsylvania and National data. J Community Hosp Intern Med Perspect. 2016;6(4):31758.
  9. Quillivan RR, Burlison JD, Browne EK, et al. Patient safety culture and the second victim phenomenon: connecting culture to staff distress in nurses. Jt Comm J Qual Patient Saf. 2016:42(8):377-86.
  10. Rogers, Erin, et al. A Just Culture Approach to Managing Medication Errors. National Center for Biotechnology Information, April 2017. Accessed December 27, 2022. www.ncbi.nlm.nih.gov/pmc/articles/PMC5424837/
  11. Institute for Safe Medication Practices. Look-alike drug names with recommended tall man letters. Accessed December 27, 2022.Available at https://www.ismp.org/recommendations/tall-man-letters-list
  12. “Emergency Preparedness: 3 Steps to Prepare Your Pharmacy.” PBA Health, 12 Mar. 2018, Accessed December 27, 2022. Emergency Preparedness: 3 Steps to Prepare Your Pharmacy (pbahealth.com)
  13. Reorganization. Defined Term. Accessed December 27, 2022. https://definedterm.com/reorganization
  14. Root Cause Analysis Workbook for Community/Ambulatory Pharmacy. Institute For Safe Medication Practices. Accessed December 27, 2022. www.ismp.org/resources/root-cause-analysis-workbook-community-ambulatory
  15. Schwartz, Heidi. Re-Engineering the Workplace For Employee Wellness. January 26, 2015. Facility Executive Magazine. Accessed December 27, 2022. https://facilityexecutive.com/2015/01/employers-will-be-challenged-to-re-engineer-the-workplace-attract-and-retain-people/
  16. “Tracking.” Defined Term. Accessed December 27, 2022. https://definedterm.com/tracking

 

  1. Benedetto AR. Six Sigma: not for the faint of heart. Radiol Manage. 2003;25(2):40-53.
  2. Rodziewicz TL, Houseman B, Hipskind JE. Medical Error Reduction and Prevention. In: StatPearls. Treasure Island (FL): StatPearls Publishing; December 4, 2022.
  3. “Trending.” Defined Term. Accessed December 27, 2022. https://definedterm.com/trending
  4. Agency for Healthcare Research and Quality. Root cause analysis. Accessed December 27, 2022. https://psnet.ahrq.gov/primers/primer/10/root-cause-analysis
  5. “Lessons We Don't Learn: A Study of the Lessons of Disasters, Why We Repeat Them, and How We Can Learn Them.” January 15, 2015. HOMELAND SECURITY AFFAIRS. Accessed December 27, 2022. www.hsaj.org/articles/167
  6. Sutherland A, Ashcroft DM, Phipps DL. Exploring the human factors of prescribing errors in paediatric intensive care units. Arch Dis Child. 2019;104(6):588-595. doi:10.1136/archdischild-2018-315981
  7. Bhangu A, Bhangu S, Stevenson J, Bowley DM. Lessons for surgeons in the final moments of Air France Flight 447. World J Surg. 2013;37(6):1185-1192.
  8. Croft H, Nesbitt K, Rasiah R, Levett-Jones T, Gilligan C. Safe dispensing in community pharmacies: applying the software, hardware, environment and liveware (SHEL) model. Pharmaceutical J. 2017;9(7): DOI: 10.1211/CP.2017.20202919. Accessed December 27, 2022. https://www.pharmaceutical-journal.com/research/safe-dispensing-in-community-pharmacies-applying-the-software-hardware-environment-and-liveware-shell-model/20202919.article
  9. Grasha AF, Schell K. Psychosocial factors, workload, and human error in a simulated pharmacy dispensing task. Perceptual Motor Skills. 2001;92:53-71.
  10. Grasha AF. Understanding medication errors: a cognitive systems approach. Medscape. May 14, 2001. Accessed December 27, 2022. https://www.medscape.org/viewarticle/418538
  11. Grasha AF, Reilley S, Schell K, Tranum D, Filburn J. A cognitive systems perspective on human performance in the pharmacy: implications for accuracy, effectiveness, and job satisfaction. Cincinnati, Ohio: University of Cincinnati,2000, Cognitive Systems Lab Report 062100-R.
  12. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29-34.
  13. Barry R, Murcko AC, Brubaker CE. The Six Sigma Book for Healthcare. Ann Arbor, MI: Chicago Health Administration Press; 2002:19-43.
  14. Grasha AF. Misconceptions about pharmacy workload. Can Pharmaceut J. 2001;134(4):26-35.
  15. Bhasale AL, Miller GC, Reid SE, Britt HC. Analysing potential harm in Australian general practice: an incident-monitoring study. Med J Aust. 1999;170(6):287-288.
  16. Tudor CL, Papachristou N, Gallagher J, et al. Identifications of priorities for improvement of medication safety in primary care: a PRIORTIZE study. BMC Fam Pract. 2016;17(1):160.
  17. Bogner MS. Misadventures in Healthcare. Mahwah, NJ: Lawrence Erlbaum Associates; 2004:1-186
  18. Ashcraft MH. Human memory and cognition (2nd ed.). New York: Harper Collins, 1994.
  19. Anderson JR. Learning and memory: An integrated approach. New York: John Wiley & Sons, 1995.
  20. Chui MA, Mott DA. Community pharmacists’ subjective workload and perceived task performance: a human factors approach. J Am Pharm Assoc (2003). 2012;52(6):e153-e160.
  21. Vatansever D, Menon DK, Stamatakis EA. Default mode contributions to automated information processing. PNAS. 2017;114(48):12821-12826.
  22. Gouraud J, Delorme A, Berberian B. Autopilot, mind wandering, and the out of the loop performance problem. Front Neurosci. 2017;11:541.
  23. Casey S. Set Phasers on Stun: And Other True Tales of Design, Technology and Human Error. Santa Barbara, CA: Aegean; 1998.
  24. “Insight,” The Free Dictionary. Accessed December 27, 2022. https://medical-dictionary.thefreedictionary.com/insight
  25. Psychestudy. Insight Learning. Accessed December 27, 2022. https://www.psychestudy.com/behavioral/learning-memory/insight-learning
  26. How to Detect Insight Moments in Problem Solving Experiments. Accessed December 27, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854655/
  27. Fioratou E, Flin R, Glavin R. No simple fix for fixation errors: cognitive processes and their clinical applications. Anaesthesia. 2010;65(1):61-69.
  28. Leslie I. How mistakes can save lives: one man’s mission to revolutionise the NHS. June 4, 2014. Accessed December 27, 2022. https://www.newstatesman.com/2014/05/how-mistakes-can-save-lives
  29. Jenkins B. Cognitive aids: time for a change? Anaesthesia. 2014;69:655–668.
  30. Grasha AF. Tools for the reflective practitioner: Using self-monitoring, personal feedback and goal setting to reduce error. Health Notes Qual Assur. 2002;19-24.
  31. Tierney M, McLurg D, Macmillan C. Transferring medication order entry from pharmacists to pharmacy technicians. JCPH. 1999;52(4):240-243.
  32. Lapkin S, Levett-Jones T, Chenoweth L, Johnson M. The effectiveness of interventions designed to reduce medication administration errors: a synthesis of findings from systematic reviews. J Nurs Manag. 2016;24(7):845-858. doi:10.1111/jonm.12390
  33. Castro-Rodríguez C, De Lucas-Volle S, González-Roca I, Diaz-Redondo A, Mora-Capín A, Marañón R. Professionals' Perception of a Strategy to Avoid Interruptions During Medication Handling. J Patient Saf. 2023;19(1):29-35. doi:10.1097/PTS.0000000000001082
  34. Soliman-Junior, J., Tzortzopoulos, P., and Kagioglou, M. 2020. “Exploring Mistakeproofing in Healthcare Design.” In: Tommelein, I.D. and Daniel, E. (eds.). Proc. 28th Annual Conference of the International Group for Lean Construction (IGLC28), Berkeley, California, USA, doi.org/10.24928/2020/0034
  35. Van Scyoc K. Process safety improvement--quality and target zero. J Hazard Mater. 2008;159(1):42-48.
  36. Kumar S, Steinebach M. Eliminating US hospital medical errors. Int J Health Care Qual Assur. 2008;21(5):444-471.
  37. China Manufacturing Consultants. 6 Poka Yoke (mistake proofing) techniques that most factories overlook. Accessed December 22, 2022. http://www.cmc-consultants.com/blog/6-poka-yoke-mistake-proofing-techniques-that-most-factories-overlook

 

 

LAW: Getting Soft on “Hard” Drugs?

Learning Objectives

 

After completing this application-based continuing education activity, pharmacists and pharmacy technicians will be able to

·       DESCRIBE regulation of controlled substances and how it has changed over time
·        INDICATE how drugs are regulated internationally
·       CHARACTERIZE state and local actions that are loosening the regulation of controlled substances
·       DISCUSS the pros and cons of drug decriminalization

 

Picture of mushrooms on a blank white background

Release Date:

Release Date:  April 15, 2023

Expiration Date: April 15, 2026

Course Fee

Pharmacists: $7

Pharmacy Technicians: $4

There is no grant funding for this CE activity

ACPE UANs

Pharmacist: 0009-0000-23-015-H03-P

Pharmacy Technician: 0009-0000-23-015-H03-T

Session Codes

Pharmacist:  23YC15-XBC24

Pharmacy Technician:  23YC15-CBX42

Accreditation Hours

2.0 hours of CE

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-015-H03-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

 

Disclosure of Discussions of Off-label and Investigational Drug Use

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Faculty

Gerald Gianutsos, PhD, JD
Emeritus Associate Professor of Pharmacology
University of Connecticut School of Pharmacy
Storrs, CT


 

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

Dr. Gianutsos has no relationship with ineligible companies and therefore has nothing to disclose.

 

ABSTRACT

Early in the 20th Century, what are now called controlled substances were regularly available for retail purchase. Over the course of the last 100 years, the regulation of many drugs has become stricter and, since 1970, are subject to the restraints of the Controlled Substances Act. In 1996, some states began easing restrictions on the use and possession of marijuana. More recently, many municipalities and a few states (and some counties) have decriminalized the possession of an increasing number of controlled substances. This continuing education activity will review the national and international regulatory oversight of controlled substances and discuss the characteristics of some of the recent international, state, and local actions that have reduced penalties and continue the trend towards a more public health emphasis on drug control.

CONTENT

Content

INTRODUCTION

 

Congress, in order to reduce the black market in illegal drugs, should begin taking incremental steps toward making drugs less of a criminal justice responsibility and more of a public health responsibility.1

--Former Baltimore Mayor Kurt L. Schmoke

 

Has the time arrived for the incremental steps that Mayor Schmoke envisioned more than 30 years ago? One does not need to look any further than marijuana, which has been a tightly controlled substance in the U.S. for more than 85 years but is rapidly gaining acceptance as a medical product and a permissible intoxicant.2,3 It is likely that many pharmacists are supportive of this regulatory movement and may even have “experimented” with this Schedule I drug while in school. But what about something like cocaine? “That won’t happen,” you say? Then you should be aware that Oregon passed a law in 2020 that reduced the penalty for the unauthorized possession of less than two grams of cocaine to the payment of a small fine.4

 

Other states, municipalities, and countries have also begun taking steps towards loosening or eliminating penalties for prohibited recreational substances, in some cases including other drugs currently listed in Schedule I of the Controlled Substances Act (CSA). Is this the start of a new national trend leading to a relaxation of restrictions on previously controlled substance and perhaps even to someday permit retail sales? Will the future of drug control start to look more like the 1890s than the 1990s?

 

This continuing education activity will review national and international regulation of controlled substances and some changes that governments are enacting or considering to loosen their control. Do these events indicate that society’s view of controlled substances and use disorders—and pharmacy’s role—are evolving?

 

Pause and Ponder: Will biennial controlled substance inventories and the familiar red “C” go the way of manual typewriters and become relics of a bygone era?

 

REGULATION OF CONTROLLED SUBSTANCES

 

Historical Perspective

In the 19th Century, what we now call controlled substances were readily available in retail locations. In the 1890s, the Sears and Roebuck catalog (that’s the 19th Century Amazon for our younger readers) offered a syringe and a small amount of cocaine for purchase for $1.505 (equivalent to about $50 today). Individuals could also order the tonic, Wine of Coca, a mixture of coca-leaf extract and Bordeaux wine, which was promoted as “a genuine rich wine ... well known throughout Europe for its strengthening and nourishing qualities” at retail for 95 cents.5 In addition to cocaine, consumers could also openly purchase morphine and heroin from catalogs, apothecaries, and physicians. 5

 

The popularity of cocaine-infused beverages, tonics, and powders grew in the late 1800s, and were generally held to have therapeutic value for a variety of conditions, including headache and fatigue, constipation, nausea, asthma, and impotence.6 Most pharmacy personnel are probably aware that a pharmacist in Atlanta, John Pemberton, took advantage of prohibition being enacted in parts of Georgia and replaced the wine in Wine of Coca with a sugary syrup and added a kola-nut extract containing caffeine in 1886.7 He named the concoction Coca-Cola and described it as a temperance drink.7

 

Although frequently denied by the company, Coca-Cola contained a small amount of cocaine (and likely the precursor, ecgonine) and became one of the world’s most popular tonic/beverage sold at retail, often at pharmacy soda fountains.6,8 Early in the 20th Century, public opinion about cocaine began to turn negative and the company (by then owned by another pharmacist, Asa Candler), tried to remove cocaine from the beverage but it would not become completely cocaine-free until 1929 when newer extraction methods were developed.6

 

Recently, the well-known billionaire, Elon Musk, jokingly(?) tweeted “Next I’m buying Coca-Cola to put the cocaine back in.”8 Current legislative changes discussed below suggest that this notion is not so far-fetched.

 

During the early part of the 20th Century, there were no federal agencies that regulated medical and pharmacy practice, and physicians could freely prescribe cocaine and morphine as treatment for pain.9 Drug abuse became increasingly common and emerged as a significant social and public health issue, and a less permissive attitude towards drugs began to take hold.9

 

The first federal law to ban the non-medical use of a substance was the Smoking Opium Exclusion Act in 1909; it prohibited the possession, importation, and use of opium for smoking, although it could continue to be used medically.10 A more significant step was the passage of the Harrison Narcotic Tax Act in 1914 which regulated “narcotics” (defined as opiates and cocaine) by imposing a special tax upon anyone who produced, imported, manufactured, sold, dispensed, distributed, or compounded these substances.11 Note that the act was an economic regulation to comply with treaty obligations and did not directly prohibit the use nor sale of opiates and cocaine.1

 

The Harrison Act required physicians and pharmacists who prescribed or dispensed “narcotics” to be registered and pay a fee of $1 to $24 per year11,12 (equivalent to $29 to $700 today). The act mandated special order forms and record keeping whenever narcotic drugs were sold. They could only be provided from packages bearing a government stamp.12

 

By using the federal government’s taxing power to restrict the use of opiates to professional practices, the Harrison Act effectively created the first class of prescription drugs.11 (The Food Drug and Cosmetic Act in 1938 formally established prescription-only drugs and the 1951 Durham-Humphrey Act [sponsored by two pharmacist-legislators] gave the U.S. Food and Drug Administration (FDA) authority to designate which drugs would require prescriptions.13)

 

After 1919, oversight by the Treasury Department expanded to define the scope of professional practice.11 Previously, physicians interpreted terms in the act such as “legitimate medical purposes,” “professional practice,” and “prescribed in good faith” to mean that they could provide narcotics to ease the suffering of withdrawal in addicts who were regarded as having a disease.12 However, the Treasury Department interpreted the Harrison Act to mean that any prescription for an addict for the purpose of relieving the trauma of addiction was illegal, and the Courts supported this position.12 Consequently, the only source available for an addict to obtain narcotics was through illegal means.12

 

The law also established the first federal narcotics agents, although their enforcement powers were limited. The Federal Bureau of Narcotics (FBN) was established in 1930 and was given the authority to enforce the Harrison Act and other anti-drug laws and later also oversaw the Marijuana Tax Act (see below).14 President Herbert Hoover appointed Harry J. Anslinger to be Commissioner of Narcotics, a position he would hold under four U.S. presidents for more than three decades. He became the face of the government’s hardline approach to eradicate drug abuse.14

 

Later, the 18th Amendment of the Constitution and the Volstead Act banned the manufacture, transportation, or sale of alcohol in 1919.10,15 (By this time, many states had already banned the sale of alcohol.) Prohibition was overturned by the 21st Amendment in 1933.

 

By 1930, 30 states had also prohibited the use of marijuana, beginning with California in 1913 and Utah in 1914.16 (Ironically, California became the first state to approve the medical use of marijuana 83 years later.) In 1937, Congress passed the Marihuana Tax Act which was modeled after the Harrison Act.55 The law didn’t specifically criminalize the use or possession of marijuana, but it required practitioners register and pay a tax, and imposed a fine of up to $2000 (about $40,000 today) and five years in prison for non-payment.10,17 There is a widely held feeling that the push for stricter control of marijuana was fueled by non-health concerns. Those concerns included

  • commercial interests
  • anti-immigrant and racial bias
  • exaggerated fear about violence and crime
  • hysteria about the drug’s alleged contribution to moral decay, and
  • pressure from the Federal Bureau of Narcotics

All of these factors played major roles in the push for stricter control of marijuana.17,18 Such feelings persist today and are part of the effort towards deregulation. The Act was ruled unconstitutional in 1969 in a suit brought by Harvard psychology professor and psychedelic guru, Timothy Leary.19

 

Today, drugs subject to abuse are regulated by the Controlled Substances Act (CSA), signed into law by then-President Richard Nixon in 1970, which, among other things, established the now-familiar five schedules. This will be discussed further below.

 

REGULATION OF RECREATIONAL DRUGS – INTERNATIONAL

 

The United States is a party to three United Nations (U.N.) drug control treaties20:

  • the 1961 Single Convention on Narcotic Drugs
  • the 1971 Convention on Psychotropic Substances, and
  • the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.

These are designed to establish effective control over international and domestic trafficking in opiates, coca leaf, cocaine, marijuana, stimulants, depressants, and hallucinogens by limiting the international production and trade of psychotropic substances and their chemical precursors.9,20 The treaties also establish international mechanisms to monitor treaty adherence.20 More than 95% of U.N. Member States are participants in these international treaties.20 Under the CSA, treaty obligations may require the U.S. Attorney General to control or reschedule a substance if existing limits in the U.S. are less stringent than those required by a treaty.9

 

Despite these international agreements, more than two dozen countries have moved toward some form of decriminalization of recreational drugs.21 The SIDEBAR differentiates decriminalization and legalization.

 

SIDEBAR: Decriminalization and Legalization

Decriminalization is not the same as legalization.

 

When a drug is legalized, it may be restricted but there is no punishment for possession or use. Typically, regulations may exist regarding where and how the legal drug can be produced, sold, and consumed. Criminal or civil penalties may apply if production, sale, or consumption take place outside of regulations (think alcohol).

 

When a drug is decriminalized, possession and use are still “illegal” but, there are no criminal penalties (e.g., incarceration) for use or possession. Instead, there may be civil penalties (e.g., fines, or mandated treatment or educational programs), and usually, possession limits. In addition, use or possession do not lead to a criminal record that might affect employment, housing, or travel opportunities if a substance is decriminalized. Selling or manufacturing drugs would normally still carry criminal penalties.22

 

 

Most people will bring up the Dutch city of Amsterdam when discussing lax drug policies. Indeed, people 18 years of age or older can purchase marijuana and other “soft” drugs (magic mushrooms, Salvia, Peyote cactus) legally and openly in coffee shops and other establishments in The Netherlands. .23 Smoking tobacco products are also tolerated in public places except near schools or playgrounds.

 

Dutch drug policy rests on two principles.23 (Note that Dutch policy applies nation-wide, but most people think of Amsterdam when this topic arises.) One is the fundamental belief that all human beings may decide about matters relating to their own health and includes acceptance of euthanasia for terminally ill patients. The other is that concealing socially negative phenomena does not cause those practices to disappear and instead makes them far more difficult to influence and control.

 

The Dutch divide drugs into two groups, soft and hard drugs, based on their human health impact. Hard drugs such as cocaine, LSD, morphine, and heroin are forbidden in the Netherlands. Soft drugs are tolerated but strict laws limit quantities, conditions of sale, and use. For example, driving under the influence of a soft drug is treated similarly to driving under the influence of alcohol. Large scale growing, processing, and trading in marijuana is forbidden, but Dutch courts bestow milder penalties than in most other countries.23

 

Another frequently cited model is Portugal. On July 1, 2001, Portugal became the first country in the world to decriminalize all drugs, including methamphetamine and heroin, removing the distinction between soft and hard drugs.24,25 Possession is decriminalized for personal use within certain limits, depending on the drug.24 Generally, the limits are based on a hypothetical 10-day supply for an average individual.25 Drug use became an administratively sanctionable misdemeanor under the responsibility of the Ministry of Health, rather than involving law enforcement.25 The intent of the law was to focus police resources on those who profit from the drug trade, rather than their victims, while also providing a public health approach to drug users.24

 

Individuals caught possessing drugs for personal use in Portugal are sent to a commission composed of health experts and a legal expert.26 The commission evaluates the person’s drug use and, if necessary, will refer them to voluntary treatment. (While most treatment is voluntary, in some cases, the commission can choose to issue a fine or mandate some form of therapy.) Additionally, the country expanded access to treatment and harm reduction services like needle exchanges.26

 

However, selling drugs is still illegal. Portuguese law considers it a crime if someone produces, buys, or transports an illicit drug that is above the legal amount for personal use.24 For example, possession of more than 5 grams of hashish could potentially lead to arrest and prosecution for drug trafficking. A conviction for drug trafficking in Portugal can be subject to between one and five years in prison.24

 

Beginning January 31, 2023, drug users 18 years of age and older in British Columbia, Canada who possess up to 2.5 grams of illegal drugs for personal use will not be arrested, charged, nor have their drugs confiscated.27 Drugs include heroin, fentanyl, cocaine, methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy). While those substances will remain illegal, police will offer users information on available health and social services. The province said it asked for the change in its request to the Canadian government for the drug laws exemption in order "to remove the shame that often prevents people from reaching out for life-saving help."27

 

Canada’s intent is to use the province as a potential model for similar changes elsewhere in the country as part of a multi-faceted health-based strategy to end Canada’s drug overdose crisis, which reached record highs during the COVID-19 pandemic. The program has some exemptions; it will not apply to drug use on primary and secondary school grounds, child-care facilities, airports, or to members of Canada's military. The pilot program is set to run until January 31, 2026.27

 

On the other hand, some countries have very harsh drug laws. In Malaysia, you can be fined, jailed, or deported for having drugs in your possession and those who sell drugs can be punished with death.28 Execution is also the penalty for some drug crimes in China, Vietnam, and The Philippines. In Dubai, you can be imprisoned for possession of many prescription drugs that are legal in other parts of the world and failing a drug test can be grounds for incarceration even if the individual is not in possession of any drugs.28 In Russia, even Americans in possession of vape cartridges containing hashish oil can be subject to arrest and detention, as WNBA star Brittney Griner discovered.29

 

U.S. RECREATIONAL DRUG REGULATION

 

Controlled Substances Act

As noted above, in the early 1900s, drugs could be purchased at retail outlets with few, if any, limitations. Strong restrictions emerged later in the 20th Century. In the 1960s, attention was being paid to a medical approach to preventing and treating drug abuse along with a powerful emphasis on law enforcement.9 By 1969, newly elected President Richard Nixon made reducing drug abuse, especially heroin abuse, one of his top priorities.9 Nixon feared that drugs were undermining the integrity of America’s youth and was convinced that abuse and addiction gave rise to crime, the biggest issue in his 1968 campaign.30 Nixon sensed a need to restore control to a broken system and declared a “war on drugs.” Dismissing the current laws as “inadequate and outdated,” he called for a single, modern law to confine drug use to legitimate medical purposes.30

 

One weapon in the war was the enactment of the CSA.9 The CSA was part (Title II) of an omnibus bill (a proposed law covering a number of diverse or unrelated topics) called the Comprehensive Drug Abuse Prevention and Control Act of 1970. The new legislation offered a more systematic approach to regulation of abused drugs and provided additional law enforcement resources.9

 

Congress, in enacting the CSA, dealt with two competing interests related to drug regulation.31 They recognized that while improper use of controlled substances can be detrimental to Americans' health and general welfare, many of these substances have a useful and legitimate medical purpose and are necessary to maintain health and well-being. The Act simultaneously aims to protect the public from the dangers of controlled substances while also ensuring access for legitimate purposes.31 To achieve both goals, the statute created two complementary legal schemes. One provision required individuals and entities working with controlled substances to register with the government, report certain information to regulators, and have a responsibility to prevent diversion and misuse of controlled substances.31 The act also contained provisions to prevent trafficking in controlled substances by establishing penalties for the production, distribution, and possession of controlled substances outside the legitimate scope of the registration structure.31 CSA policies that were intended to curtail illegitimate use of these drugs included prescription refill limitations, security standards, recordkeeping requirements, order forms, production quotas, and the registration of importers and exporters of controlled substances.11,30 The new law was, however, not exclusively punitive; it eliminated mandatory minimum sentences for drug crimes.30

 

Moreover, Title I of the comprehensive act had more of a public health focus.30 It provided authority and funding to permit the Department of Health, Education, and Welfare to deliver prevention and treatment efforts through community mental health centers and public health service hospitals. It authorized the National Institute of Mental Health to increase substance abuse research and training.30 It also protected subjects’ privacy rights under the care of approved researchers.

 

Over the next few decades, public concern over drug abuse increased and Congress responded by enacting policies that created a harsher system of drug control and served as a basis of the ensuing “War on Drugs.” 30 Congress repeatedly amended the law to address the heightened concern, and it became more punitive and criminally focused and less directed towards rehabilitation and improved treatment.30

 

A new Federal Agency, the Drug Enforcement Administration (DEA), was created in 1973 to enforce the new law. This was done in part to coordinate federal and state enforcement activities and to reduce inter-agency rivalries.9,30 After the CSA was enacted, there were nearly 500,000 importers, exporters, manufacturers, distributors, and practitioners covered by the law, making the DEA the largest administrative agency in the U.S.11

 

Scheduling

The centerpiece of the CSA, as pharmacists are aware, was the creation of a scheduling system that provided a means for assigning regulated substances into one of five categories based upon the drug’s medical risks, therapeutic use, and potential for abuse and dependence.9,31 The classification system also establishes the obligations and penalties of the law.31 The most restrictive category is Schedule I which is comprised of drugs with high potential for abuse, but no accepted medical use.32 The placement of a drug in a schedule is fluid, and drugs can be moved to a different schedule, either up or down, added to the controlled substances list, or deleted.30 Any individual, not just regulatory officials or health care providers, can request that the DEA add, remove, or change a drug’s scheduling.9

 

In determining into which schedule a drug or other substance should be placed, or whether a substance should be re-scheduled or decontrolled, certain factors must be considered. The DEA is required to seek a scientific and medical evaluation of the substance from the Department of Health and Human Services  to apply what is known as the eight-factor test when determining scheduling.32 These factors are

(1) Its actual or relative potential for abuse
(2) Scientific evidence of its pharmacological effect, if known
(3) The state of current scientific knowledge regarding the drug or other substance
(4) Its history and current pattern of abuse
(5) The scope, duration, and significance of abuse
(6) What, if any, risk there is to the public health
(7) Its psychic or physiological dependence liability
(8) Whether the substance is an immediate precursor of a substance already controlled

 

These criteria help to stratify the seriousness of the public health concern among the controlled substances. Will new regulatory strategies remove these distinctions?

 

PAUSE AND PONDER: Do the “C” schedules serve a purpose?

 

DECRIMINALIZATION – STATE AND LOCAL ACTIONS

 

While the general trend at the federal level for the past five decades has been a toughening of the restrictions on abused drugs, especially opioids, one exception is marijuana. States have led the way by actively relaxing restrictions on marijuana, first by legalizing medical use and later permitting limited non-medical use.

 

The medical use of marijuana has been legalized in 37 states plus the District of Columbia (D.C.), Puerto Rico, Guam, the Northern Mariana Islands, and the U.S. Virgin Islands.33 The medical marijuana movement began in California in 1996, but it wasn’t until 2012 that Colorado and Washington became the first two states to decriminalize the non-medical use of marijuana (for people 21 years of age or older).33 (California voters had rejected a proposition in 2010.) In the 2022 election, two additional states, Maryland and Missouri, approved the recreational use of marijuana. bringing the total up to 21 (plus D.C.) although similar proposals were rejected in Arkansas, North Dakota, and South Dakota.33

 

Beyond Marijuana

 

More recently, states and municipalities have gone beyond marijuana and have decriminalized other controlled substances. In May 2019, Denver, Colorado became the first governmental entity in the U.S. to decriminalize a (non-Cannabis) Schedule I drug, the psychedelic ingredient from mushrooms, psilocybin.34 The proposal was placed on the municipal ballot after garnering almost 9500 petition signatures and was supported by 50.5% of voters in the election.34 Denver was also the first major U.S. city to legalize the possession of small amounts of marijuana in 2005.34

 

The new ordinance states that the “enforcement of any laws imposing criminal penalties for the personal use and personal possession of psilocybin mushrooms... shall be the lowest law enforcement priority in the City and County of Denver.” It mandates that “no department... shall use any city funds or resources to assist in the enforcement of laws imposing criminal penalties for the personal use and personal possession of psilocybin mushrooms by adults.”35 Adult is defined as an individual 21 years of age or older.

 

One advocacy group (Decriminalize Denver) noted its support for the ordinance by stating that “Humans have used these mushrooms for thousands of years for healing, rites of passage, spiritual insight, strengthening community, and raising consciousness.” Decriminalize Denver has argued that “One arrest is too many for something with such low and manageable risks for most people, relative to its potential benefits.”34 In contrast, opponents have warned that “Denver is quickly becoming the illicit drug capital of the world” and that the long-term health effects of these drugs are unknown.34

 

Other municipalities have followed the same path as Denver. Oakland and Santa Cruz, California also decriminalized psilocybin in 2019 and 2020, respectively. In both cases, their respective City Councils took the action rather than mounting a referendum.36,37 The Santa Cruz ordinance is very similar to what was enacted in Denver preventing resources from being used to investigate and arrest people 21 years of age and older solely for the personal use and possession of “entheogenic plants and fungi”37 (a psychoactive, hallucinogenic substance or preparation especially when derived from plants or fungi and used in religious, spiritual, or ritualistic contexts38). Community testimony from people sharing mental health struggles and treatment likely contributed to the Council’s decision. Santa Cruz later extended its policy and banned enforcement actions against individuals using peyote and other mescaline-containing cacti. Oakland also decriminalized mescaline cacti, ayahuasca and ibogaine.39 The City Council in Ann Arbor, Michigan also unanimously approved mushroom decriminalization in 2020.40

 

Voters in Washington D.C. also approved similar measures in 2020, termed the Entheogenic Plant and Fungus Policy Act, which would decriminalize natural psychedelics including magic mushrooms, ayahuasca, and mescaline, and makes arrests for their possession or use the lowest priority for DC police. Due to D.C.’s unique status, implementation of the act was delayed for Congressional review and approval. D.C. received approval in 2021 but not before one member of Congress threatened to derail the process.41

 

In late 2021, Seattle became the largest city (to date) to decriminalize Schedule I psychedelic drugs.39,42 The City Council unanimously passed a resolution that “the investigation, arrest, and prosecution of anyone engaging in entheogen-related activities should be among The City of Seattle’s lowest enforcement priorities.” Its City Council asked the city’s police department to codify that practice as departmental policy.39 The resolution was limited to natural substances, notably psilocybin and ayahuasca, and later peyote; it excluded synthetic materials such as LSD.39,42 In support of its approval, the resolution noted both the therapeutic potential of psychedelics and protection of indigenous peoples who use these compounds for cultural and spiritual practices.42 More than 100 additional cities are moving to decriminalize psychedelic mushrooms.43

 

States are also supporting decriminalization measures and Oregon is at the forefront of these activities. In the 2020 election, voters in the state passed two companion referenda that significantly changed the state’s drug policy. Measure 109 approved the use of a psychedelic mushroom for medical use by authorizing the Oregon Health Authority to create a program to permit licensed service providers to administer psilocybin-producing mushroom and fungi products to individuals 21 years of age or older.44 The new law will allow anyone age 21 or older who passes a screening procedure to access the services for “personal development."45 A client does not need to be diagnosed with or have any particular medical condition to receive psilocybin. Clients would complete a preparatory session and then attend a session at a psilocybin service center where they would receive and consume the psilocybin product under the supervision of the service facilitator.44

 

Unlike the cities that decriminalized psychedelic drugs for personal use, the Oregon measure took a medical approach with the purpose of improving the physical, mental, and social well-being of people in the state and reducing the prevalence of mental illness conditions among adults who have not been helped by more mainstream therapies.44,46 The measure restricts psilocybin sales to licensed service providers and does not permit sales directly to users. Individual counties can opt out of the program.46

 

In the 2022 election, Colorado became the second state to approve psychedelics.47 The proposition legalizes regulated access to natural medicines for people 21 years of age or older, including plants or fungi that impact an individual's mental health and provides civil and criminal immunity for providers and users.47

 

Pharmacy staff should note that there is a growing interest in the potential therapeutic applications of psychedelic drugs to help many psychiatric disorders and these may become FDA-approved pharmaceutical products.48

 

While several municipalities and states have authorized the decriminalization of mushrooms and other psychedelics and justified their actions due to their healing and spiritual value, there have been other movements to expand decriminalization beyond those with potential medical benefits.

 

In the same election that decriminalized mushrooms, voters in Oregon approved another measure (110) to become the first state to lighten penalties for possession of both large and small amounts of a wide assortment of scheduled substances.4

 

Under the new law, the penalty for possession of larger amounts of controlled substances was reduced from a felony offense to a Class A misdemeanor punishable by up to 364 days of imprisonment and a fine of up to $6,250. For possession of smaller amounts of controlled substances, the measure reduced the penalty from a criminal misdemeanor to a new, Class E violation, which is punishable by a $100 fine. In lieu of a fine, a person charged with a violation may instead complete a health assessment at an Addiction Recovery Center.4

 

The threshold differentiating large from small amount are defined for different substances. For cocaine, the Class E violation applies to unauthorized possession of less than two grams. For oxycodone, it is unauthorized possession of fewer than 40 pills, tablets, or capsules. Someone in possession of less than 1 gram heroin would be subject to the new Class E penalty.4 The new measure also removes penalty enhancements for possession of small amounts of controlled substances where the individual previously had a felony conviction or multiple previous convictions for possession.4,45

 

The new program is loosely based on Portugal’s model, described above, but was modified in accordance with recommendations from Oregon’s recovery community.26 Oregon’s approach will focus on diversion and harm reduction for people who use drugs while retaining punitive approaches for drug trafficking. A goal of the new program is to improve Oregon’s ranking as one of the worst states at providing treatment for addiction.26 In 2016 and 2017, Oregon ranked first in the country for analgesic drug misuse, second in the U.S. for methamphetamine misuse, and fourth for cocaine and alcohol misuse while ranking 48th in access to treatment.26 In all, almost 10% of the state’s population had a substance use disorder.

 

The state is expanding its addiction recovery centers and anyone will be able to access them whether or not they have received a citation.26 The funding for expanded services will come from a higher than anticipated yield from marijuana taxes, which has exceeded $100 million per year.26

 

Oregon’s program has produced mixed results. In the first year after decriminalization took place, police issued approximately 2000 citations, but, despite the waiver of the fine if a person calls the hotline for a health assessment and counseling, only 92 of those ticketed called the hotline and only 19 of them requested resources for services.50 Almost half of people receiving a citation failed to make a court appearance. State health officials reported 473 opioid overdose deaths in the first 8 months of 2021, surpassing the total for all of 2020, and nearly 200 deaths more than the state saw in 2019.50 The state also reported that visits to emergency rooms and urgent care centers for opioid overdose have been increasing. The Oregon Health Authority cites an upturn in fentanyl abuse and a pandemic-related downturn in reporting in 2020 as possible reasons for the disappointing results. In addition, Oregon’s inpatient facilities, detox clinics and recovery-focused nonprofits were adversely affected by issues related to COVID-19 including workforce shortages; there is uncertainty whether providers can adequately expand to meet increased needs.51

 

Pause and Ponder: Is there a role for pharmacists in improving outcomes?

 

However, it has also been suggested that the more lenient rules take away the threat of jail time that some individuals need to encourage them to get into recovery while fewer low-level offenders will be forced into court-ordered behavioral health services.51 Portugal takes a more robust approach than Oregon, having “dissuasion commissions” that pressure anyone caught using drugs, including marijuana, to seek treatment. Tools include fines, prohibiting drug users from visiting certain venues or from traveling abroad, seizure of personal property, community work, and having to periodically report to health services or other facilities.50

 

California, Maine, and New Jersey, among others, have also been considering enacting decriminalization measures.52,53 A bill pending approval in California would decriminalize most psychedelics. The bill would allow people aged 21 and older to possess psilocybin, DMT, ibogaine, mescaline, LSD, and MDMA for personal use and “social sharing.”52 The bill advanced to the final step of Assembly approval when the sponsor removed ketamine from the list of substances due to concerns over date rape. The bill prohibits sharing drugs with anyone under 21 years of age or possessing them on school grounds. It would also allow personal cultivation of mushrooms. Proponents touted the benefits to individuals who would be aided by the use of psychedelics to treat trauma including military veterans. Opponents argued that social sharing could result in more overdoses from contaminated products and give drug dealers a built-in defense.52

 

PROS AND CONS

 

Why have states and municipalities chosen to decriminalize drugs? Although a detailed discussion of the benefits and detriments of lax drug policies is beyond the scope of this activity, it is worth briefly examining some of the arguments that have driven the move towards decriminalization. Table 1 describes the pros and cons frequently used to support the various arguments.

 

 

Table 1. Pros and Cons re: Decriminalization of Recreational Drugs1,16,54,55,56,57

 

Justifications for decriminalization Justifications for continuing prohibition of recreational drugs
·       A sense that the “War on Drugs” is expensive, harmful to society, and not working

·       The suggestion that a medical model will be more effective

·       Decriminalization will reduce profits for drug traffickers

·       More than half of people in prison have untreated substance use disorders and

o   Imprisonment actually leads to increased illicit drug and medication misuse following a period of incarceration with a much higher risk of drug overdose upon release

o   Relapse to drug use in someone with an untreated opioid use disorder can be fatal due to loss of opioid tolerance that may have occurred while the person was behind bars

o   A criminal conviction or a record of imprisonment can significantly hamper a person’s employment prospects and other opportunities

·       Risk of endorsing or encouraging risky behaviors

·       Decriminalization would drive down the cost of drugs, making them more accessible

·       Few non-violent users are actually imprisoned

·       A black market will still exist for users under the permitted statutory age

·       The current treatment infrastructure is inadequate to accommodate the anticipated increased demand

·       The threat of incarceration is an incentive to seek treatment

·       If restrictions are abandoned, other social costs will increase

 

As a proponent for decriminalization, Mayor Schmoke proposed that the abuse of drugs should be “dealt with as a moral and medical problem than as a criminal problem ... a problem for the surgeon general, not the attorney general.”1 The number of people incarcerated for drug-law violations in state and federal prisons in the United States increased 12-fold between 1980 and 2018. Yet there is no statistically significant relationship between state drug imprisonment rates and three markers of state drug problems: self-reported drug use, drug overdose deaths, and drug arrests.57

 

Pause and Ponder: Should recreational drugs be regulated like alcohol?

 

Many advocates recommend an approach similar to the policy in Portugal and treat illicit drug use the way most states regulate alcohol and marijuana, by making it legal for stores to sell such drugs to adults.57 In Portugal, which has led the way towards decriminalization, the use of cocaine among young adults (15-34) is 0.3% compared with 2.1% in the European Union (EU) countries.58 Amphetamine and MDMA use are also lower. The overall overdose death rate in Portugal is five times lower than in the EU (which has a lower rate than in the U.S.).58 HIV infection rates among IV drug users have also dropped.58

 

Where Will This Lead?

Are the localities decriminalizing recreational drug use an anomaly or do they represent the tip of the iceberg for liberalization of personal drug use? The movement could follow the path taken by marijuana.

 

States have pursued a pattern of first decriminalizing and/or allowing medical use of marijuana before finally proposing legalization.16,59 States used their experiences with the intermediate steps as a means to anticipate the expected effects of total legalization.16 The liberalized marijuana policies in medical marijuana states exposed the public to more open marijuana use and may have changed attitudes towards the drug, along with a sense that prohibition is too costly.59

 

Efforts are ongoing to legalize marijuana at the federal level. Congress is currently considering the Marijuana Opportunity Reinvestment and Expungement (MORE) Act. It would remove marijuana from the list of scheduled substances under the Controlled Substances Act and eliminate criminal penalties for an individual who manufactures, distributes, or possesses marijuana.3 It would also establish a process to expunge convictions and conduct sentencing review hearings for individuals previously convicted of federal cannabis offenses. It would establish and fund a grant program to provide resources to administer services for individuals adversely impacted by the War on Drugs, including job training, legal aid, reentry services, and health education programs and would levy a 5% tax on the sale of cannabis products.3

 

Will legalizing marijuana serve as a model for other C-I drugs to follow? Indeed, a bipartisan bill was recently introduced in the U.S. Senate calling on the DEA to reclassify breakthrough therapies such as psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) as Schedule II drugs.60

 

SUMMARY AND CONCLUDING COMMENTS

 

The pendulum of drug control may be swinging closer to the more lenient approach that existed 100 years ago. In a decade, the U.S. moved from no state permitting recreational use of marijuana to almost half of the states doing so, along with decriminalization being debated at the federal level. Will additional recreational drugs follow the same path? Several municipalities and a few states have already made significant strides in that direction. In particular, Oregon and the nation of Portugal have established programs making controlled substances a medical and public health issue rather than a law enforcement issue, although with mixed results. Will the distinction between “hard” and “soft” drugs disappear in the U.S., as more states adopt measures aimed at decriminalizing drugs?

 

If so, there will be many questions about how pharmacy may be affected. Will drugs for which there is some evidence for medical applications like cannabinoids and psychedelics such as psylocibin, find their way to the pharmacy shelf? If Oregon’s medical model for psychedelics is followed by other states, will it enable new opportunities for pharmacists? Will cocaine and heroin once again be available as OTC products in pharmacies?

 

It is important for pharmacy staff to stay abreast of regulatory changes in their own states and nationally. They should become part of the conversation about the direction such regulations should take.

 

 

 

Pharmacist Post Test (for viewing only)

Law: Getting Soft on “Hard” Drugs?

Post-test

After completing this activity, pharmacists and pharmacy technicians should be able to
• DESCRIBE regulation of controlled substances and how it has changed over time
• INDICATE how drugs are regulated internationally
• CHARACTERIZE state and local actions that are loosening the regulation of controlled substances
• DISCUSS the pros and cons of drug decriminalization

1. What was the first Schedule I drug (after marijuana) to be decriminalized by a U.S. city?
A. Cocaine
B. Psilocybin
C. Heroin

2. What is the guiding principle behind Amsterdam’s drug policy?
A. Individuals should be able to decide about matters relating to their own health
B. It is too expensive to try to crack down on the use of recreational drugs
C. Individuals need the threat of punishment in order to seek help for addiction

3. What was the first country to decriminalize all drugs?
A. Canada
B. The Netherlands
C. Portugal

4. Jose is talking with Mike. Jose says more than half of the people in American prisons have untreated substance use disorders and in these people, incarceration is associated with a much higher risk of drug overdose upon release. Jose also says a criminal conviction can significantly hamper a person’s employment prospects and other opportunities. Mike argues that the threat of incarceration is an incentive to seek treatment and few non-violent users are actually imprisoned. He says that the current treatment infrastructure is inadequate to accommodate the influx of people who would need treatment if Jose’s proposal passes. What positions are they arguing?
A. Jose is a proponent of legalization of all drugs; Mike is against legalization of drugs.
B. Jose supports decriminalization of all drugs; Mike is against decriminalization of drugs.
C. Jose supports legalization of all drugs, while Mike is a proponent of decriminalization.

5. The first significant regulation of opioids in the U.S. was the Harrison Act. What did this act do?
A. Empowered the FBI to seize all opioids entering the U.S. at all ports
B. Required pharmacists who dispensed “narcotics” to be registered and pay a fee
C. Prohibited the dispensing of cocaine from pharmacies or other healthcare venues

6. What significant change occurred as a result of the enactment of the CSA?
A. Possession of marijuana became illegal
B. The “C” Schedules were established
C. Public health remedies for addiction were curtailed

7. Many factors apply to the decision to control drugs under the CSA. Which of the following correctly describes one of these factors?
A. The CSA may require the DEA to comply with international treaty obligations when assigning a drug to a schedule
B. Only law enforcement or federal employees may ask the DEA to consider adding or deleting a drug from a schedule
C. The DEA must request a scientific/medical evaluation from the Centers for Disease Control and Prevention when deciding on scheduling

8. A young woman is stopped for speeding in Oregon and the officer sees she has a baggie with 12 Oxycontin tablets on the passenger’s seat, and she admits she does not have a prescription. The officer explains that under Oregon’s current laws, she may pay a fine for the unauthorized possession of small amounts of prescription opioids. What can she do in lieu of a monetary penalty?
A. Perform 20 hours of community service at an addiction recovery center
B. Attend an educational program about the risks of drug abuse
C. Complete a health assessment at an addiction recovery center

9. What was Oregon’s goal in decriminalizing the possession of controlled substances?
A. Raise revenue by taxing the sale of all recreational drugs
B. Improve the provision and use of addiction treatment services
C. Make sales from illegal sources economically unworkable

10. What would the proposed Marijuana Opportunity Reinvestment and Expungement (MORE) Act do?
A. Reclassify marijuana from the C-1 category to a C-II drug
B. Allow Medicare to pay for over-the-counter cannabidiol
C. Remove marijuana from the list of scheduled substances

Pharmacy Technician Post Test (for viewing only)

Law: Getting Soft on “Hard” Drugs?

Post-test

After completing this activity, pharmacists and pharmacy technicians should be able to
• DESCRIBE regulation of controlled substances and how it has changed over time
• INDICATE how drugs are regulated internationally
• CHARACTERIZE state and local actions that are loosening the regulation of controlled substances
• DISCUSS the pros and cons of drug decriminalization

1. What was the first Schedule I drug (after marijuana) to be decriminalized by a U.S. city?
A. Cocaine
B. Psilocybin
C. Heroin

2. What is the guiding principle behind Amsterdam’s drug policy?
A. Individuals should be able to decide about matters relating to their own health
B. It is too expensive to try to crack down on the use of recreational drugs
C. Individuals need the threat of punishment in order to seek help for addiction

3. What was the first country to decriminalize all drugs?
A. Canada
B. The Netherlands
C. Portugal

4. Jose is talking with Mike. Jose says more than half of the people in American prisons have untreated substance use disorders and in these people, incarceration is associated with a much higher risk of drug overdose upon release. Jose also says a criminal conviction can significantly hamper a person’s employment prospects and other opportunities. Mike argues that the threat of incarceration is an incentive to seek treatment and few non-violent users are actually imprisoned. He says that the current treatment infrastructure is inadequate to accommodate the influx of people who would need treatment if Jose’s proposal passes. What positions are they arguing?
A. Jose is a proponent of legalization of all drugs; Mike is against legalization of drugs.
B. Jose supports decriminalization of all drugs; Mike is against decriminalization of drugs.
C. Jose supports legalization of all drugs, while Mike is a proponent of decriminalization.

5. The first significant regulation of opioids in the U.S. was the Harrison Act. What did this act do?
A. Empowered the FBI to seize all opioids entering the U.S. at all ports
B. Required pharmacists who dispensed “narcotics” to be registered and pay a fee
C. Prohibited the dispensing of cocaine from pharmacies or other healthcare venues

6. What significant change occurred as a result of the enactment of the CSA?
A. Possession of marijuana became illegal
B. The “C” Schedules were established
C. Public health remedies for addiction were curtailed

7. Many factors apply to the decision to control drugs under the CSA. Which of the following correctly describes one of these factors?
A. The CSA may require the DEA to comply with international treaty obligations when assigning a drug to a schedule
B. Only law enforcement or federal employees may ask the DEA to consider adding or deleting a drug from a schedule
C. The DEA must request a scientific/medical evaluation from the Centers for Disease Control and Prevention when deciding on scheduling

8. A young woman is stopped for speeding in Oregon and the officer sees she has a baggie with 12 Oxycontin tablets on the passenger’s seat, and she admits she does not have a prescription. The officer explains that under Oregon’s current laws, she may pay a fine for the unauthorized possession of small amounts of prescription opioids. What can she do in lieu of a monetary penalty?
A. Perform 20 hours of community service at an addiction recovery center
B. Attend an educational program about the risks of drug abuse
C. Complete a health assessment at an addiction recovery center

9. What was Oregon’s goal in decriminalizing the possession of controlled substances?
A. Raise revenue by taxing the sale of all recreational drugs
B. Improve the provision and use of addiction treatment services
C. Make sales from illegal sources economically unworkable

10. What would the proposed Marijuana Opportunity Reinvestment and Expungement (MORE) Act do?
A. Reclassify marijuana from the C-1 category to a C-II drug
B. Allow Medicare to pay for over-the-counter cannabidiol
C. Remove marijuana from the list of scheduled substances

References

Full List of References

References

    REFERENCES
    1. Schmoke KL. An Argument in Favor of Decriminalization. Hofstra Law Rev. 1990; 18(3):501-525. Accessed March 21, 2023. https://scholarlycommons.law.hofstra.edu/cgi/viewcontent.cgi?article=1668&context=hlr
    2. Support for Legal Marijuana Holds at Record High of 68%. Gallup. November 4, 2021. Accessed March 21, 2023. https://news.gallup.com/poll/356939/support-legal-marijuana-holds-record-high.aspx
    3. H.R. 3884. MORE Act of 2020. 116th Congress (2019-2020). Accessed March 21, 2023.
    https://www.congress.gov/bill/116th-congress/house-bill/3884
    4. Lantz M, Nieubuurt B. Measure 110 (2020) Background Brief. State of Oregon Legislative Policy and Research Office. December 9, 2020. Accessed March 21, 2023.
    https://www.oregonlegislature.gov/lpro/Publications/Background-Brief-Measure-110-(2020).pdf
    5. Holzwarth L. The Most Unexpected Items People Used to Buy via Catalog. History Collection. January 31, 2019. Accessed March 21, 2023.
    https://historycollection.com/the-most-unexpected-items-people-used-to-buy-via-catalog/10/
    6. Palermo E. Does Coca-Cola Contain Cocaine? Live Science. December 13, 2016. Accessed March 21, 2023.
    https://www.livescience.com/41975-does-coca-cola-contain-cocaine.html
    7. Hamblin J. Why We Took Cocaine Out of Soda. Atlantic. January 31, 2013. Accessed March 21, 2023.
    https://www.theatlantic.com/health/archive/2013/01/why-we-took-cocaine-out-of-soda/272694/
    8. Browne E. Fact Check: Was There Ever Cocaine in Coca Cola, As Elon Musk Implied? Newsweek. April 29, 2022. Accessed March 21, 2023.
    https://www.newsweek.com/elon-musk-tweet-twitter-coca-cola-cocaine-ingredient-1701864
    9. Sacco LN. Drug Enforcement in the United States: History, Policy, and Trends. Congressional Research Service. October 2, 2014. Accessed March 21, 2023. https://fas.org/sgp/crs/misc/R43749.pdf
    10. War on Drugs. History.com. Updated December 17, 2019. Accessed March 21, 2023.
    https://www.history.com/topics/crime/the-war-on-drugs#:~:text=Drug%20use%20for%20medicinal%20and,had%20not%20yet%20been%20outlawed
    11. Spillane JF. Debating the Controlled Substances Act. Drug Alcohol Depend. 2004;76(1):17-29.
    12. Cantor DJ. The Criminal Law and the Narcotics Problem. J. Crim. L. Criminology & Police Sci. 1961;51(5):512-527. Accessed March 21, 2023.
    https://scholarlycommons.law.northwestern.edu/cgi/viewcontent.cgi?article=4977&context=jclc
    13. U.S. Food and Drug Administration. Milestones of Drug Regulation in the United States. Accessed March 21, 2023.
    https://www.fda.gov/media/109482/download#:~:text=1951%20Durham%2DHumphrey%20Amendment%20defines,prescription%20by%20a%20licensed%20practitioner
    14. Narcotics Enforcement in the 1930s. DEA Museum. Accessed March 21, 2023.
    https://museum.dea.gov/exhibits/online-exhibits/anslinger/narcotics-enforcement-1930s
    15. Volstead Act. Britannica. Accessed March 21, 2023.
    https://www.britannica.com/topic/Volstead-Act
    16. Dills A, Goffard S, Miron J, Partin E. The Effect of State Marijuana Legalizations: 2021 Update. Cato Institute. February 2, 2021. Accessed March 21, 2023.
    https://www.cato.org/policy-analysis/effect-state-marijuana-legalizations-2021-update
    17. Musto DF. The history of the Marijuana Tax Act of 1937. Arch Gen Psychiat. 1972; 26(2): 101-108. Accessed March 21, 2023. http://www.druglibrary.org/schaffer/hemp/history/mustomj1.html
    18. Brecher EM. Marijuana is Outlawed. The Consumers Union Report on Licit and Illicit Drugs. Chapter 56. 1972. Accessed March 21, 2023. https://www.druglibrary.org/schaffer/library/studies/cu/cu56.html
    19. Leary v. United States, 395 U.S. 6 (1969). Accessed March 21, 2023.
    https://supreme.justia.com/cases/federal/us/395/6/
    20. Rosen LW. International Drug Control Policy: Background and U.S. Responses. Congressional Research Service. March 16, 2015.
    https://sgp.fas.org/crs/row/RL34543.pdf
    21. Approaches to Decriminalizing Drug Use & Possession. Drug Policy Alliance. February 2015. Accessed March 21, 2023.
    https://www.unodc.org/documents/ungass2016/Contributions/Civil/DrugPolicyAlliance/DPA_Fact_Sheet_Approaches_to_Decriminalization_Feb2015_1.pdf
    22. Overview: Decriminalisation vs Legalisation. Alcohol and Drug Foundation. Accessed March 21, 2023.
    https://adf.org.au/talking-about-drugs/law/decriminalisation/overview-decriminalisation-legalisation/
    23. Amsterdam Drugs Laws. Amerstam.info. Accessed March 21, 2023.
    https://www.amsterdam.info/drugs/
    24. Silva L. Portugal Drug Laws under Decriminalization: Are Drugs Legal in Portugal? Portugal.com. April11, 2022. Accessed March 21, 2023.
    https://www.portugal.com/op-ed/portugal-drug-laws-under-decriminalization-are-drugs-legal-in-portugal/
    25. Rêgo X, Oliveira MJ, Lameira, C. et al. 20 Years of Portuguese Drug Policy - Developments, Challenges and the Quest for Human Rights. Subst Abuse Treat Prev Policy. 2021;16:Art 59. Accessed March 21, 2023.
    https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-021-00394-7
    26. Abraham R. How Oregon’s Radical Decriminalization of Drugs Was Inspired by Portugal. Next City. January 5, 2021. Accessed March 21, 2023.
    https://nextcity.org/urbanist-news/how-oregons-radical-decriminalization-of-drugs-was-inspired-by-portugal?gclid=CjwKCAjwlqOXBhBqEiwA-hhitF2WD4yaDXh2LLfgppfmqe5xh5gl2q00t16uM6l0T8oDrbP38JipShoCN7sQAvD_BwE
    27. BBC. Canada Trials Decriminalising Cocaine, MDMA and Other Drugs. BBC.com. June 1, 2022. Accessed March 21, 2023. https://www.bbc.com/news/world-us-canada-61657095
    28. American Addiction Centers. The 20 Countries with the Harshest Drug Laws in the World. Updated July 16, 2021. Accessed March 21, 2023.
    https://drugabuse.com/blog/the-20-countries-with-the-harshest-drug-laws-in-the-world/
    29. Ganguli T, Abrams J, Bubola E. What We Know About Brittney Griner’s Case in Russia. NY Times. October 25, 2022. Accessed March 21, 2023.
    https://www.nytimes.com/article/brittney-griner-russia.html#:~:text=Griner%2C%2031%2C%20who%20has%20played,a%20professional%20women%27s%20basketball%20team
    30. Courtwright DT. The Controlled Substances Act: How a "Big Tent" Reform Became a Punitive Drug Law. Drug Alcohol Dependence. 2004;76(1):9–15.
    31. Lampe JR. The Controlled Substances Act (CSA): A Legal Overview for the 117th Congress. Congressional Research Service. February 5, 2021. Accessed March 21, 2023.
    https://sgp.fas.org/crs/misc/R45948.pdf
    32. U.S. Drug Enforcement Administration. The Controlled Substances Act. Accessed March 21, 2023.
    https://www.dea.gov/drug-information/csa
    (8 factor) Ref 58
    33. State Medical Cannabis Laws, National Conference of State Legislatures. Accessed March 21, 2023.
    https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx
    34. Chavez N, Prior R. Denver Becomes the First City to Decriminalize Hallucinogenic Mushrooms. CNN. May 9 2019. Accessed March 21, 2023.
    https://www.cnn.com/2019/05/08/us/denver-magic-mushrooms-approved-trnd
    35. BallotPedia. Denver, Colorado, Initiated Ordinance 301, Psilocybin Mushroom Initiative (May 2019). Retrieved from:
    https://ballotpedia.org/Denver,_Colorado,_Initiated_Ordinance_301,_Psilocybin_Mushroom_Initiative_(May_2019
    Mush 51.
    36. Kennedy M. Oakland City Council Effectively Decriminalizes Psychedelic Mushrooms. NPR. June 5, 2019. Accessed March 21, 2023.
    https://www.npr.org/2019/06/05/730061916/oakland-city-council-effectively-decriminalizes-psychedelic-mushrooms
    37. York JA. Santa Cruz Decriminalizes Natural Psychedelics. Santa Cruz Sentinel. January 29, 2020. Retrieved from: Accessed March 21, 2023.
    https://www.santacruzsentinel.com/2020/01/29/santa-cruz-decriminalizes-natural-psychedelics/
    38. “Entheogen.” Merriam-Webster.com Dictionary, Merriam-Webster. Accessed March 21, 2023.
    https://www.merriam-webster.com/dictionary/entheogen
    39. Adlin B. Seattle Becomes Largest U.S. City to Decriminalize Psychedelics. Marijuana Moment. October 4, 2021. Accessed March 21, 2023.
    https://www.marijuanamoment.net/seattle-becomes-largest-u-s-city-to-decriminalize-psychedelics/
    40. Stanton R. Why Ann Arbor Officials Decided to Decriminalize Psychedelic Mushrooms, Plants. Michigan Live. September 22, 2020. Accessed March 21, 2023.
    https://www.mlive.com/news/ann-arbor/2020/09/why-ann-arbor-officials-decided-to-decriminalize-psychedelic-mushrooms-plants.html
    41. Beaujon A. Magic Mushrooms are Decriminalized in DC as of Today. Washingtonian. March 15, 2021. Accessed March 21, 2023.
    https://www.washingtonian.com/2021/03/15/magic-mushrooms-are-decriminalized-in-dc-as-of-today/
    42. Miller C. Seattle City Council Votes in Favor of Decriminalizing Psychedelic Drugs. King 5. October 7, 2021. Accessed March 21, 2023.
    https://www.king5.com/article/news/local/seattle/seattle-city-council-favor-decriminalize-psychedelic-drugs/281-23bee413-1898-41fd-8850-31ecc38ea621
    43. Kelly D. Denver Dabbles with Magic Mushrooms, but Using them to Treat Mental Health Disorders Remains Underground. LA Times. April 5, 2021. Accessed March 21, 2023.
    https://www.latimes.com/world-nation/story/2021-04-05/denver-dabbles-with-magic-mushrooms-but-using-them-to-treat-mental-health-disorders-remains-underground
    44. Oregon Measure 109, Psilocybin Mushroom Services Program Initiative (2020). Ballotpedia. Accessed March 21, 2023.
    https://ballotpedia.org/Oregon_Measure_109,_Psilocybin_Mushroom_Services_Program_Initiative_(2020)
    45. Acker L. Oregon Becomes First Stat to Legalize Psychedelic Mushrooms. Oregonian. Updated November 4, 2020. Accessed March 21, 2023.
    https://www.oregonlive.com/politics/2020/11/oregon-becomes-first-state-to-legalize-psychedelic-mushrooms.html
    46. McInally M. Many Oregonians Will Have to Vote Again on Psilocybin. Oregon Capital Chronicle. August 8, 2022. Accessed March 21, 2023.
    https://oregoncapitalchronicle.com/2022/08/08/many-oregon-voters-will-have-to-decide-again-on-a-psilocybin-program/
    47. Martin S. In Colorado Election, Voters Legalize Psychedelic Mushrooms for Medicinal Purposes. USA Today. November 11, 2022. Accessed March 21, 2023.
    https://www.usatoday.com/story/news/politics/2022/11/11/colorado-election-magic-mushrooms-health-approved/10669400002/
    48. Nutt D, Erritoze D, Carhart-Harris R. Psychedelic Psychiatry’s Brave New World. Cell. 2020; 181: 21-28.
    49. National Survey on Drug Use and Health. 2016-2017 National Survey on Drug Use and Health National Maps of Prevalence Estimates, by State. Accessed March 21, 2023.
    https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHsaeMaps2017/NSDUHsaeMaps2017.pdf
    50. Selsky A. Oregon's Pioneering Drug Decriminalization Law Draws Mixed Results. KGW8. April 4, 2022. Accessed March 21, 2023.
    https://www.kgw.com/article/news/local/mixed-results-oregon-drug-decriminalization/283-0980d8b1-a514-425a-8989-889b027f5a95
    51. Quinton S. Oregon’s Drug Decriminalization May Spread, Despite Unclear Results. Pew Stateline. November 3, 2021. Accessed March 21, 2023.
    https://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2021/11/03/oregons-drug-decriminalization-may-spread-despite-unclear-results
    52. Thompson D. California Advances Decriminalizing Psychedelic Substances. AP News. June 29, 2021.
    Accessed March 21, 2023.
    https://apnews.com/article/california-health-government-and-politics-c3eb439025f5f0b50090c73f22183cd0?utm_id=32439&sfmc_id=4213507
    53. An Act to Make Possession of Scheduled Drugs for Personal Use a Civil Penalty. Maine Legislature Legislative Document 967. First Regular Session, 2021. Accessed March 21, 2023.
    https://legislature.maine.gov/legis/bills/getPDF.asp?paper=HP0713&item=1&snum=130
    54. Weatherburn D. Australian & New Zealand Journal of Criminology. 2014;47(2)176–189. Accessed March 21, 2023.
    https://idhdp.com/media/362647/1408-weatherburn-article.pdf
    55. ProCon.Org. Should Illegal Drugs Legalized? Accessed March 21, 2023.
    https://aclu.procon.org/questions/should-illegal-drugs-be-legalized/
    56. Volkow ND. Addiction Should be Treated, Not Penalized. Neuropsychopharmacology. 2021;46:2048-2050.
    57. Gelb A. Pew Charitable Trust Letter to Chris Christie. June 19, 2017. Accessed March 21, 2023.
    https://www.pewtrusts.org/~/media/assets/2017/06/the-lack-of-a-relationship-between-drug-imprisonment-and-drug-problems.pdf
    58. Atkins S, Mosher C. Oregon Just Decriminalized All Drugs – Here's Why Voters Passed This Groundbreaking Reform. US News. December 10, 2020. Accessed March 21, 2023.
    https://www.usnews.com/news/best-states/articles/2020-12-10/oregon-just-decriminalized-all-drugs-heres-why-voters-passed-this-groundbreaking-reform
    59. History of Recreational Marijuana. ProCon.Org. Accessed March 21, 2023.
    https://marijuana.procon.org/history-of-recreational-marijuana/
    60. DeFuedis N. Congress Takes Another Look at Reclassifying Psilocybin and MDMA. Endpoints News. November 18, 2022. Accessed March 21, 2023.
    https://endpts.com/push-to-reclassify-psilocybin-and-mdma-gains-bipartisan-support/

    Patient Safety: Medication Refusal: Understanding the Why “They Just Say No”

    Learning Objectives

     

    After completing this application-based continuing education activity, pharmacists will be able to

    Recognize and define types and leading causes of treatment/medication refusal
    Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
    Determine treatment alternatives for patients with dietary, religious, or other restrictions
    Identify and implement key components of a medication refusal protocol

      After completing this application-based continuing education activity, pharmacy technicians will be able to

      Recognize and define types and leading causes of treatment/medication refusal
      Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
      Determine treatment alternatives for patients with dietary, religious, or other restrictions
      Identify and implement key components of a medication refusal protocol

       

      Release Date: October 17, 2023

      Expiration Date: October 15, 2026

      Course Fee

      Pharmacists: $7

      Pharmacy Technicians: $4

      There is no grant funding for this CE activity

      ACPE UANs

      Pharmacist: 0009-0000-23-047-H05-P

      Pharmacy Technician: 0009-0000-23-047-H05-T

      Session Codes

      Pharmacist:  20YC80-TRX39

      Pharmacy Technician:  20YC80-XRT42

      Accreditation Hours

      2.0 hours of CE

      Accreditation Statements

      The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-047-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

       

      Disclosure of Discussions of Off-label and Investigational Drug Use

      The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

      Faculty

      Danielle Haskins, PharmD
      CVS Pharmacy Manager
      Santee, CA

       

      Ming May Zhang, PharmD Candidate 2022
      University of Connecticut School of Pharmacy
      Storrs, CT

      Faculty Disclosure

      In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

      Danielle Haskins and Ming May Zhang  do not have any financial relationships with ineligibile companies.

       

      ABSTRACT

      Based on the principle of informed consent, competent patients always
      have the right to refuse medical treatment. Patients may refuse treatment
      for a variety of reasons, including dietary restrictions, religious reasons, medical
      misconceptions, a desire to avoid adverse effects, and mistrust of the medical
      team. Patient refusals can create serious dilemmas in the healthcare setting. On
      the one hand, clinicians have an ethical and legal obligation to honor patient autonomy.
      On the other hand, a patient’s refusal of treatment often leads to adverse
      medical outcomes, resulting in harm to the patient. Healthcare
      professionals should search for acceptable treatment alternatives that honor patients’
      wishes while meeting their medical needs. Every institution—whether in
      the community, long-term care, or inpatient setting—should have a protocol to
      guide and standardize the approach to managing treatment refusals. In complex
      cases, it may be beneficial to use expert ethics consultations.

      CONTENT

      Content

      ONLY PDF version is Available for this CE

       

       

      Pharmacist Post Test (for viewing only)

      Medication Refusal: Understanding the Why "They Just Say No"
      After participating in this activity, pharmacists and pharmacy technicians will be able to
      1. Recognize and define types and leading causes of treatment/medication refusal
      2. Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
      3. Determine treatment alternatives for patients with dietary, religious, or other restrictions
      4. Identify and implement key components of a medication refusal protocol

      1. Which of the following is an example of ACTIVE medication refusal?
      a. A patient ingests her medication when the caregiver administers it, but secretly spits it out half an hour later.
      b. A patient states that she does not wish to take her oral medication, then refuses to open her mouth to ingest the medication.
      c. A patient initially refuses to take her medication, but concedes when the caregiver repeatedly asks her to.

      2. A patient states that he is vegetarian and wishes to avoid animal products. Which of the following excipients is INAPPROPRIATE for this patient?
      a. Gelatin
      b. Peanut oil
      c. Mannitol

      3. Which of the following best describes motivational interviewing?
      a. An interviewing style that involves the use of ethics counselors, who help healthcare professionals navigate complicated cases
      b. The process by which patients are educated about a treatment’s risks, benefits, and alternatives
      c. A behavioral technique that motivates patients to change by empowering them and motivating them with their own values

      4. Which of the following statements is FALSE about the practice of covert medication?
      a. It refers to administering medications without a patient’s knowledge, such as by concealing medications in food or drink.
      b. It is justifiable in mentally competent patients who refuse treatment against medical advice.
      c. It may be better received than more aggressive methods, such as forced injections.

      5. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which of the following best describes her reasons for refusing Medication X?
      a. Dietary restriction
      b. Medical misconception
      c. Mistrust of the medical team

      6. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which is the best resource to refer her to?
      a. Pillbox, so she can research medications’ ingredients and avoid those containing animal products
      b. The primary literature and PubMed or GoogleScholar, so she can find the most recent data
      c. The patient should not be referred; Medication X is the most effective option for her illness, and she should take it regardless of her beliefs

      7. Why might an ethics consultation be useful in certain instances of treatment refusal?
      a. Ethics counselors are authorized to make healthcare decisions on behalf of incompetent patients.
      b. Ethics counselors are compensated based on patient outcomes, so they persuade patients to choose the most medically effective option.
      c. Ethics counselors are trained in core ethics and healthcare competencies and can help navigate difficult situations.

      8. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. This is an example of:
      a. Beneficence
      b. Primum non nocere
      c. Autonomy

      9. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. Which of the following is the LEAST appropriate response to BT?
      a. Inform BT of the risks and benefits of OTC products, and show him how to interpret the Drug Facts labels.
      b. Identify BT’s reason for refusal—ask about his beliefs, perceptions, and concerns. Counsel him accordingly.
      c. Inform BT that you will request an ethics consultation to advise in this situation, which in your opinion is untenable.

      10. Patient WG is prescribed a new medication and told to take one capsule twice a day. WG misunderstands—he takes two capsules once a day, instead. Which of the following best describes WG’s behavior?
      a. Intentional non-adherence
      b. Unintentional non-adherence
      c. Passive refusal

      11. Patient AU tells you, “Dr. S prescribed five different pills for me, but I’m not taking any of them. I’m a regular churchgoer and I know I should love and respect all people, but I don’t have a good feeling about Dr. S. I think she has it out for me. I’m going to get the meds from Dr. G instead.” Based on this statement, AU’s primary reason for refusal is:
      a. Religious refusal
      b. Lack of belief in the medications’ effect
      c. Mistrust of the medical provider

      12. Patient LG is a 5-year-old female who requires a life-saving blood transfusion. Her caretaker refuses to consent to the procedure since it goes against her religious beliefs. Which of the following statements is TRUE of this situation?
      a. The attending physician must request an ethics consultation, since this is legally required for all cases involving a minor.
      b. LG’s caretaker has the ultimate say in her medical decisions but LG’s doctors are ethically obligated do what is beneficial for the patient.
      c. Since LG does not suffer from any brain disorders, she can make her own medical decisions. The medical team only needs LG’s consent, not the caretaker’s.

      Pharmacy Technician Post Test (for viewing only)

      Medication Refusal: Understanding the Why "They Just Say No"
      After participating in this activity, pharmacists and pharmacy technicians will be able to
      1. Recognize and define types and leading causes of treatment/medication refusal
      2. Describe the ethical and legal principles associated with medication refusal, covert medication, and surreptitious prescribing
      3. Determine treatment alternatives for patients with dietary, religious, or other restrictions
      4. Identify and implement key components of a medication refusal protocol

      1. Which of the following is an example of ACTIVE medication refusal?
      a. A patient ingests her medication when the caregiver administers it, but secretly spits it out half an hour later.
      b. A patient states that she does not wish to take her oral medication, then refuses to open her mouth to ingest the medication.
      c. A patient initially refuses to take her medication, but concedes when the caregiver repeatedly asks her to.

      2. A patient states that he is vegetarian and wishes to avoid animal products. Which of the following excipients is INAPPROPRIATE for this patient?
      a. Gelatin
      b. Peanut oil
      c. Mannitol

      3. Which of the following best describes motivational interviewing?
      a. An interviewing style that involves the use of ethics counselors, who help healthcare professionals navigate complicated cases
      b. The process by which patients are educated about a treatment’s risks, benefits, and alternatives
      c. A behavioral technique that motivates patients to change by empowering them and motivating them with their own values

      4. Which of the following statements is FALSE about the practice of covert medication?
      a. It refers to administering medications without a patient’s knowledge, such as by concealing medications in food or drink.
      b. It is justifiable in mentally competent patients who refuse treatment against medical advice.
      c. It may be better received than more aggressive methods, such as forced injections.

      5. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which of the following best describes her reasons for refusing Medication X?
      a. Dietary restriction
      b. Medical misconception
      c. Mistrust of the medical team

      6. A practicing Sikh patient tells you that her religion prevents her from consuming Medication X, which contains animal by-products. She wants to know what alternatives are available, and what she should avoid. Which is the best resource to refer her to?
      a. Pillbox, so she can research medications’ ingredients and avoid those containing animal products
      b. The primary literature and PubMed or GoogleScholar, so she can find the most recent data
      c. The patient should not be referred; Medication X is the most effective option for her illness, and she should take it regardless of her beliefs

      7. Why might an ethics consultation be useful in certain instances of treatment refusal?
      a. Ethics counselors are authorized to make healthcare decisions on behalf of incompetent patients.
      b. Ethics counselors are compensated based on patient outcomes, so they persuade patients to choose the most medically effective option.
      c. Ethics counselors are trained in core ethics and healthcare competencies and can help navigate difficult situations.

      8. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. This is an example of:
      a. Beneficence
      b. Primum non nocere
      c. Autonomy

      9. Patient BT is newly diagnosed with a disease. His doctor recommends Treatment X and describes the treatment’s risks and benefits. BT refuses his doctor’s suggestion. Instead, he decides to try natural OTC products. Which of the following is the LEAST appropriate response to BT?
      a. Inform BT of the risks and benefits of OTC products, and show him how to interpret the Drug Facts labels.
      b. Identify BT’s reason for refusal—ask about his beliefs, perceptions, and concerns. Counsel him accordingly.
      c. Inform BT that you will request an ethics consultation to advise in this situation, which in your opinion is untenable.

      10. Patient WG is prescribed a new medication and told to take one capsule twice a day. WG misunderstands—he takes two capsules once a day, instead. Which of the following best describes WG’s behavior?
      a. Intentional non-adherence
      b. Unintentional non-adherence
      c. Passive refusal

      11. Patient AU tells you, “Dr. S prescribed five different pills for me, but I’m not taking any of them. I’m a regular churchgoer and I know I should love and respect all people, but I don’t have a good feeling about Dr. S. I think she has it out for me. I’m going to get the meds from Dr. G instead.” Based on this statement, AU’s primary reason for refusal is:
      a. Religious refusal
      b. Lack of belief in the medications’ effect
      c. Mistrust of the medical provider

      12. Patient LG is a 5-year-old female who requires a life-saving blood transfusion. Her caretaker refuses to consent to the procedure since it goes against her religious beliefs. Which of the following statements is TRUE of this situation?
      a. The attending physician must request an ethics consultation, since this is legally required for all cases involving a minor.
      b. LG’s caretaker has the ultimate say in her medical decisions but LG’s doctors are ethically obligated do what is beneficial for the patient.
      c. Since LG does not suffer from any brain disorders, she can make her own medical decisions. The medical team only needs LG’s consent, not the caretaker’s.

      References

      Full List of References

      References

         

        These can be found on the pdf version of the CE

        Pet Allergies

        Learning Objectives

         

        After completing this application-based continuing education activity, pharmacists will be able to

        ·       Outline the causes of pet allergies in dogs, cats, and other less common species
        ·       Differentiate between allergic sensitization, allergy, and cross sensitivity
        ·       Paraphrase facts that prove that currently, hypoallergenic dogs and cats are a myth
        ·       Compare nonpharmacologic, over the counter, and prescription treatments in terms of dosing, effectiveness, and cost

        After completing this application-based continuing education activity, pharmacy technicians will be able to

        ·       Outline the causes of pet allergies in dogs, cats, and other less common species
        ·       Differentiate between allergic sensitization, allergy, and cross sensitivity
        ·       Paraphrase facts that prove that currently, hypoallergenic dogs and cats are a myth
        ·       Identify patients whose complaints indicate they may need referral to a pharmacist

        Cartoon of boy blowing nose with cat next to him

         

        Release Date: March 15, 2023

        Expiration Date: March 15, 2026

        Course Fee

        FREE

        There is no grant funding for this CE activity

        ACPE UANs

        Pharmacist: 0009-0000-23-008-H01-P

        Pharmacy Technician: 0009-0000-23-008-H01-T

        Session Codes

        Pharmacist:   23YC08-JKT44

        Pharmacist Technician:  23YC08-TKX48

        Accreditation Hours

        2.0 hours of CE

        Accreditation Statements

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-23-008-H01-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

         

        Disclosure of Discussions of Off-label and Investigational Drug Use

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Faculty

        Yangzhou (Marina) Li, MS, PharmD
        Medical Writing Scientist
        Janssen of Pharmaceutical Companies of Johnson and Johnson,
        Boston, MA

         

        Dylan DeCandia, BS
        PharmD Candidate 2023
        University of Connecticut
        Storrs, CT

        Faculty Disclosure

        In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

        Dr. Li is a full time employee of Janssen Pharmaceutical of Johnson and Johnson and previously worked for Nest Bio and LegendBiotech. Dylan DeCandia does not have any relationships with ineligible companies and therefore has nothing to disclose.

         

        ABSTRACT

        Many American households have pets, and many others would like to have pets but family members have pet allergies. Allergies to cats and dogs are common (an estimated 15% to 30% of people are allergic to companion pets), and allergies to unusual or exotic pets have increased over the last decade. Pet allergy is an allergic reaction to proteins (allergens) found in animals’ skin cells (dander), saliva, urine, or sweat on their fur. Most animal allergens belong to one of three primary protein families. Pet allergies are currently incurable. The treatment goal is to control symptoms and improve patients’ functional status and well-being. Options include nonpharmacologic interventions like cleaning and bathing the pet and pharmacologic management with antihistamines, corticosteroids, anticholinergic nasal sprays, mast cell stabilizers, or leukotriene modifiers. Allergists will consider allergy-specific immunotherapy when medications and/or avoidance measures fail.

        CONTENT

        Content

         

        Introduction and Epidemiology

        The American Pet Products Association (APPA) estimates that approximately 70% of Americans keep pets in their household, equating to 90.5 million homes. Dogs and cats are the most popular and live in around 69.0 and 45.3 million U.S. households, respectively, followed by 11.8 million households for freshwater fish, 9.9 million households for birds, and 3.5 million households for horses.1 Public, residential, leisure, and specific occupational environments (e.g., farms, laboratories, pet shops) have high concentrations of pet allergens because of the high prevalence of community pet-keeping and Americans’ tendency to live indoors. Allergic reactions to pets have been recognized for at least 100 years.2 Risk factors for developing asthma and rhinitis include allergies to furry animals, especially cats and dogs.3 Direct or second-hand pet exposure increases the likelihood of exacerbating disease in pet-sensitive people. However, evidence also shows that early childhood exposure to dogs or cats before one year of age may have protective effects in preventing allergic sensitization.4

        Notably, allergies to unusual or exotic pets have increased over the last decade.5 In many urban areas, apartment complexes prevent owning large pets or charge a fee for owning cats and dogs, leading to the choice of smaller, more unusual animals. Some examples of uncommon pets are rodents (mice, rats [which allegedly make very good pets], guinea pigs, and other mammals like ferrets, pigs), amphibians (axolotl [a Mexican salamander], dart frogs, and fire belly newts), and reptiles (snakes).6 The allergic signs and symptoms or diseases associated with uncommon pets are like those manifested in cat and dog allergies. In addition, patients may present with respiratory symptoms induced by bird allergens and gastrointestinal symptoms after consuming bird eggs; this is called a bird-egg syndrome.7

        Overall, the incidence of specific allergy to exotic or uncommon pets is unknown because literature only includes isolated cases or small series. In the United States, an estimated 15% to 30% of people are allergic to their pets.8 Among people with pet allergies, a fraction is sensitized to more than one animal. Moreover, according to the Asthma and Allergy Foundation of America, cat allergies are reported twice as often as dog allergies. Animals are also recognized as the third leading cause of allergic asthma, after mites and pollens.8 Many people adopt ferrets or rabbits, believing they are hypoallergenic. They are not, and pharmacy staff should be aware of that fact.9,10 The most frequent allergic reactions result from inhalation, contact, or bites.

        This continuing education activity summarizes knowledge of pet allergens, including those from uncommon pets; the allergy reaction mechanism and its signs and symptoms; current advances in diagnosis and treatment methods such as immunotherapy; and recommendations for patient education and counseling.

        Pause and Ponder: When patients ask about medication for pet allergies, what kinds of questions should you ask?

        PET ALLERGENS

        Allergy Mechanisms

        Compared with other conditions’ mechanisms, allergy mechanisms are simple and encompass three specific paths: allergic sensitization, allergy, and cross-reactivity.11

        • Allergic sensitization is the presence of immunoglobulin E (IgE) antibodies to an allergen.
        • Allergy is the occurrence of reproducible symptoms or signs initiated by exposure to a defined stimulus at a dose tolerated by nonallergic persons and mediated by specific immunologic mechanisms. If no symptoms develop, a person could be sensitizing to a particular allergen but not be allergic.
        • Cross-reactivity is the process of IgE antibodies (originally developed against a given allergen) binding to homologous molecules originating from a different allergen source.

        Characterizing Pet Allergens

        Allergies to pets are common. Pet allergy is an allergic reaction to proteins (allergens) found in animals’ skin cells (dander), saliva, urine, or sweat on their fur.5 Allergens within the same protein family can cause cross-reactivity. Most allergens are spread via airborne particles. Dander contains allergens formed in sebaceous gland secretions and saliva. Secretions containing allergens adhere to the hair and stratum corneum of the skin. When an animal sheds, tiny particles disperse into the air and remain buoyant for an extended period of time. After the particles slowly settle onto the floor, furniture, or other items, they can be easily re-dispersed into the air. As a result, pet-sensitive people could experience allergy symptoms in the nose, eyes, and respiratory tract even if the pet is not present.5 Additionally, people can carry pet allergens that settled onto their clothing or hair.

        For cats and dogs, the primary allergen sources are dander and saliva. Similarly, the primary allergen source in rabbits is saliva. In contrast, the primary allergen source is urine in rodents (e.g., mouse, rat,) and Mustelidae (ferrets and minks).

        Rodents are an interesting case study. Most research laboratories experience a very high rate of staff turnover because lab workers develop allergies to rodents. Children who are exposed to rodent urine can develop this allergy, too. Male rodents produce a larger quantity of and more condensed urine than female rodents. This explains why people who commonly come in contact with male rodents are more likely to develop allergic symptoms. Allergy to rodents acts as an occupational hazard for researchers. Mouse urine is the most concentrated of all urines—far more concentrated than any other species.12 One study showed that 30% of people exposed to mice and 13.7% of people exposed to rats suffered from allergy symptoms.12 Symptoms range from conjunctivitis to asthma to skin reactions, which makes working with these animals difficult.

        Most animal allergens belong to one of three primary protein families. Within the three families, lipocalin-like proteins and the serum albumin family are the two most widely studied. Other identified allergens are considered minor, including gelatins, immunoglobulins, and transferrins presented in secretions and dandruff. Knowledge of these allergens’ allergenicity and cross-activity is essential to improve treatment and prevent allergic reactions. Table 1 summarizes partially characterized pet allergens, including those generated by exotic pets, because not all allergens are fully characterized.5

         

        Table 1. Summary of Characterized Pet Allergens13-22

        Common Name of Animal Source Allergen Family
        Dog Dander, saliva, hair Can f 1 (major allergen)

        Can f 2

        Can f 4

        Can f 6

        Can f 3

        Can f 5

        Can f 7

        Can f 8

        Lipocalin

        Lipocalin

        Lipocalin

        Lipocalin

        Albumin

        Arginine esterase (kallikrein)

        Epididymal secretory protein E1 or Niemann Pick type C2 protein

        Cystatin

        Cat Sebaceous, anal, and salivary gland Fel d 1 (major allergen)

        Fel d 2

        Fel d 4

        Fel d 7

        Fel d 3

        Fel d 5w

        Fel d 8

        Fed d 6w

        Uteroglobin

        Albumin

        Lipocalin

        Von Ebner gland protein

        Cystatin

        Cat IgA

        Latherin-like

        IgM

        Horse Dander, sublingual, submaxillary salivary glands, and urine Equ c 1 (major allergen)

        Equ c 2

        Equ c 4

        Equ c 3

        Equ c 6

        Lipocalin

        Lipocalin

        Latherin

        Albumin

        Lysozyme

        Chinchilla Epithelia, saliva, urine Chi La

        Chi Lb

        Protein kinase inhibitor

        Lipocalin

        Guinea pig 

         

        Cav p 1 (major allergen)

        Cap p 2 (major allergen)

        Cap p 3

        Cap p 4

        Cap p 6

        Lipocalin

        Lipocalin

        Lipocalin

        Serum albumin

        Lipocalin

        Gerbil

         

        Epithelial, salvia, urine, sleep bed Mer un 23kDa

        Mer un 4

        Lipocalin

        Serum albumin

        Siberian hamster Epithelial, saliva, urine Phod s 1 Lipocalin
        Rat Rat n 1 (major allergen)

        Rat n 4

        Rat n 7

        Lipocalin; alpha-2u-glubulin

        Serum albumin

        Immunoglobulin

        Mouse Mus m 1 (major allergen)

        Mus m 2

        Mus m 4

        Mus m 7

        Lipocalin; urinary prealbumin

        Unknown

        Serum albumin

        Immunoglobulin

        Rabbit Ory c 1

        Ory c 2

        Ory c 3

        Ory c 4

        Lipocalin

        Lipocalin

        Secretoglobin

        Lipocalin

        Ferret Mus p 17

        Mus p 66

        Unknown

        Serum albumin

        Pig Meat Sus s 1

        Sus s 5

        Sus s 6

        Serum albumin

        Lipocalin

        Serum albumin

        Lipocalin Superfamily

        More than 50% of allergens identified from furry animals belong to the lipocalin superfamily and are found in animal dander, saliva, and urine.23 Lipocalins are large proteins and can induce IgE production in a large proportion of atopic individuals (people who have enhanced immune response to common allergens) who are exposed to the allergen source.24

        Serum Albumin Family

        Serum albumin is a globular protein prone to participation in IgE-mediated cross-reactions.24 Serum albumin is commonly found in pet dander and saliva and causes an allergic reaction by inhalation and ingestion.

        Secretoglobin Superfamily

        Secretoglobins are the most potent allergens in cats (e.g., Fel d 1) and other pets (e.g., rabbit Ory c 3). Produced by the skin, salivary and lacrimal glands, these proteins have an unknown function. Dried saliva and dandruff are spread as airborne particles and cause sensitization in susceptible people.25

        SIGNS AND SYMPTOMS OF PET ALLERGIES

        The most frequently observed pet allergies result from inhalation, contact, and bites. The main allergic symptoms are similar across both common and uncommon pet types. They present as rhinitis, conjunctivitis, urticaria (red, itchy welts that result from a skin reaction), and lower and upper respiratory symptoms, which can be mild to severe and rarely cause anaphylactic shock.5

        Hypoallergenic Pets

        “Hypoallergenic” is defined as possessing decreased risk of causing an allergy in people, which means that hypoallergenic animals could still elicit allergies in humans.9 To make hypoallergenic animals, breeders or researchers combine breeds that produce less allergen (in dogs, breeders use breeds that shed less than other breeds, or have hair rather than fur). However, animals often have different mechanisms of allergenicity, so infrequent shedding does not solve all allergy problems.

        In a dog allergen study, homes that included hypoallergenic dogs had no statistically significant difference in dog allergen levels compared to homes that included non-hypoallergenic dogs. The common allergen in dogs, Can f 1, was reported at similar levels in all groups.25 The frequency of shedding varies in different dog breeds, but all dogs can elicit allergies in humans.

        The main allergen in cats, Fel d 1 protein, comes from their saliva and sweat glands. Because of its small size and adhesiveness, Fel d 1 floats around and sticks to everything, making it almost impossible to remove physically. In fact, Fel d 1 measures in at less than one-tenth the size of ribosome; it’s so small, it easily navigates its way deep into the lungs and can precipitate asthma.26 For this reason, making a completely hypoallergenic cat has proven impossible, however vaccines to decrease the production of Fel d 1 protein have been studied; one vaccine is a combination of recombinant Fel d 1, tetanus toxoid protein, and a snippet of the coat of a plant virus.27 Researchers are unsure as to the purpose of Fel d 1 in cats or why levels of Fel d 1 vary.

        Ferrets—which are related to otters, minks, weasels—are considered hypoallergenic because they are less likely to cause an allergic reaction compared to other animals. However, they can still provoke allergies in people. Allergies to ferrets come from their hair, saliva, and urine. Ferret hair and saliva is usually easy to control because they shed infrequently and do not lick people like dogs and cats often do. However, urine is harder to control and can cause allergies when owners clean crates.9

        Rabbits produce allergens through dander, hair from shedding, and saliva. They tend to shed more often than ferrets, around every three months, so keeping up with cleaning may be difficult. Rabbit hair isn’t naturally allergenic, but when rabbits lick their fur, they transfer a saliva protein that is contaminated with the protein allergen.10

        DIAGNOSIS

        Skin Prick Test

        Allergists (allergy specialists) use skin prick tests together with medical history and physical examinations to rule out or confirm a suspected IgE-mediated animal allergy.28 Manufacturers prepare skin prick tests by extracting natural allergens from animal hair, dander, and urine. The doctor or nurse will prick the patient’s skin on the forearm or upper back and determine if an allergic reaction occurs within 15 minutes. If a patient develops a red, itchy bump where the pet allergen extract is pricked into the skin, the patient is allergic to that pet allergen. Diagnosticians should first use a skin prick test as it is inexpensive, easy to use, and quick to perform. However, allergen concentrations and components are inconsistent, varying among similar commercial tests from different manufacturers. Healthcare providers should be aware that patients’ test results may be inconsistent if they use different skin prick tests at different times.28

        Serum-specific IgE Test

        Allergists can use a serum-specific IgE (blood) test when patients’ symptoms and skin test results are contradictory or when patients’ skin conditions prevent a skin test. Serum-specific IgE tests can only determine if a patient is sensitized to a specific pet allergen, but it cannot determine if a patient is allergic to that allergen. Serum-specific IgE tests are highly sensitive, but prone to false-positive results. From this perspective, serum-specific IgE tests may be less accurate than skin prick tests.29

        Molecular Diagnosis

        Recent scientific advances have allowed molecular diagnosis to differentiate patients who are allergic to a single species or sensitized due to cross-reactivity. This method can aid targeted recommendations for avoidance and assess the choice and composition of immunotherapy.28

        PET ALLERGY MANAGEMENT

        Pet allergies cannot currently be cured. The treatment goal is to control symptoms and improve patients’ functional status and well-being.

        Nonpharmacologic Treatment – Avoid & Minimize Allergen Exposure

        Current recommendations for managing pet allergy symptoms start with exposure avoidance. Starting when animals are young, bathing them at least once weekly can reduce allergens and eliminate reactions in humans who are exposed to them (see SIDEBAR).30 Immediate removal of animals from the household will not alleviate symptoms if the owner has carpeting and other pieces of furniture/items that the pet slept or sat on. Mammalian allergens are stable and can persist in house dust for up to six months.32 Additionally, using high-efficiency particulate air (HEPA) filters and mattress encasement, vacuuming, and chemically treating carpet are alternative methods for reducing exposure to contaminated materials, but may not reduce disease severity.33

        Pause and Ponder: When patients have pet allergies, which symptoms are best treated with antihistamines?

        SIDEBAR: To Bathe or Not to Bathe…26,31

        Bathing a cat or dog regularly appears to reduce the quantity of allergen harbored by the pet. To effectively lower Can f 1 concentrations, owners need to bathe the animal at least twice every week because Can f 1 concentrations rise rapidly, approaching baseline concentrations within three days after washing. Twice-weekly bathing can reduce the amount of recoverable Can f 1 on dogs by more than 80%, but researchers note that ideally, one would bathe the dog two to three times every week. Airborne Can f levels can fall by ruff-ly 40% but will quickly escalate.

        However, the beneficial effects of reducing allergen levels by regular bathing are more likely associated with dogs, because their allergen burden returns faster than that of cats. So, bathing animals reduces the amount of allergen far better than vacuuming.

        But should companion animals be bathed so often?

        Most cats are notoriously averse to bathing, although some breeds like water (i.e., the Bengal). Dogs vary in the response to bathing—some like it, others do not. People who plan to bathe their cats or dogs regularly should do three things:

        • Check with a veterinarian or a breed advocacy group. The American Kennel Club indicates that how often an owner should bathe a dog depends on the dog’s coat type and presence or absence of an undercoat (in the latter case, frequent bathing can affect a dog’s temperature regulation). Bathing an animal is not just about a human’s allergies, the animal’s health and welfare should be a primary concern.
        • Consider the labor and time involved in bathing a pet often, safely, and well.
        • Start when the animal is young.

         

        An allergen reducing cat food (Pro Plan LiveClear) is now available, and its manufacturer indicates it reduces the number of allergens in cat hair and dander by 47% after three weeks of feeding.34 It is produced using eggs that contain an anti-Fel d1 antibody. When cats consume the food, the egg powder binds to and neutralizes Fel d1 in the cat’s saliva.34

        Pharmacologic Treatment

        When avoidance and reducing allergens are not enough, depending on the severity of signs, over the counter (OTC) medications like antihistamines or local/topical steroids may provide temporary relief of allergy symptoms.35 Those symptoms include runny/itchy nose or throat, sneezing, and itchy, red or watery eyes. Combination products that contain both an antihistamine and a decongestant or an analgesic are available but should be used with caution due to the increased risk of adverse effects. Other allergy medications, besides the ones mentioned above, are used less often, including mast cell stabilizers and leukotriene antagonists. Table 2 summarizes common medications (both OTC and prescription) for treating mild to moderate allergy symptoms.35

        Table 2. Medications to Treat Allergy Symptoms36

        Medication Mechanism of Action Adverse Effects Notes
        Antihistamines
        1st generation (nonselective, more sedating) *

        Diphenhydramine, chlorpheniramine, clemastine

        2nd generation (less sedating, less drowsiness):

        Cetirizine,* desloratadine,* fexofenadine,* levocetirizine,* and loratadine*

        Azelastine has nasal spray* and eye drop formulation. Epinastine and olopatadine* are formulated as eye drops.

        Blocks histamine and its binding to receptors, prevents histamine-caused redness, swelling, itching, and changes in secretions during an allergic response ·       Drowsiness

        ·       Fatigue

        ·       Headache

        The 2nd generation antihistamines are preferred over 1st generation based on safety and efficacy data.

         

        Corticosteroids
        Available as tablets, liquids, nasal spray, topical creams for skin allergies, topical eye drops for conjunctivitis.

         

        Some steroids include:

        beclomethasone, ciclesonide, fluticasone furoate,* mometasone, budesonide,* triamcinolone,* dexamethasone ophthalmic, prednisone, etc.

        Anti-inflammatory effect Short-term use:

        Weight gain, fluid retention, high blood pressure

         

        Long-term use:

        Growth suppression, diabetes, cataracts of the eye, osteoporosis, muscle weakness

         

        Side effects of inhaled steroids:

        Cough, hoarseness, fungal infection of the mouth

         

        Highly effective for allergies but must be taken regularly. It may take 1 to 2 weeks before the full effect.
        Decongestants
        Available as nasal sprays, eye drops, liquids, and tablets

         

        Some decongestants include:

        pseudoephedrine,* phenylephrine,* and oxymetazoline* nasal sprays

         

        Shrinks swollen nasal tissues and blood vessels to relieve the symptoms of nasal swelling, congestion, mucus secretion, and redness ·       Increased blood pressure

        ·       Insomnia

        ·       Anxiety, feeling nervous, restlessness

        Relieve congestion and are often prescribed with antihistamines for allergies

         

        Contraindicated in patients with severe coronary artery disease, severe hypertension, and who concomitantly use monoamine oxidase inhibitors

         

        Short-term use only (~5 days). Long-term use can make symptoms worse.

        Combination Allergy Drugs
        Some combination drugs include:

        cetirizine/pseudoephedrine,* fexofenadine/ pseudoephedrine,* diphenhydramine/ pseudoephedrine,* loratadine/pseudoephedrine,* pseudoephedrine/triprolidine* for nasal allergies, and naphazoline/pheniramine* for allergic conjunctivitis

         

        Effects from each component Side effects from each component Use with caution due to increased risk of adverse effects
        Anticholinergic Nasal Spray
        Ipratropium bromide nasal spray to control nasal discharge Antisecretory properties in the nasal mucosa ·       Bitterness of the mouth

        ·       Dry nose, nosebleeds, or irritation

        ·       Dizziness

        ·       Headache

        ·       Sore throat

        ·       Respiratory tract infection

        Some patients may feel better right away. For others, it may take 1 to 2 weeks before the medicine helps. It is important for patients to continue use of this medication as instructed.
        Mast Cell Stabilizers
        Available as eye drops for allergic conjunctivitis and nasal sprays for nasal allergy symptoms

         

        Some mast cell stabilizers include cromolyn sodium,* iodoxamide-tromethamine, nedocromil, pemirolast, etc.

        Prevents histamine release from mast cells Throat irritation, coughing, skin rashes

         

        For eye drops may cause blurred vision, stinging, and burning

        For mild to moderate symptoms

        Not as effective as steroids

        Leukotriene Modifiers
        Montelukast*:

        Indicated for adults and pediatric patients six months or older with perennial allergic rhinitis.

        May be less effective than loratadine or cetirizine for reducing daytime nasal symptoms

        Montelukast binds to leukotriene receptors in the human airway (smooth muscle cells and macrophages), preventing airway edema, smooth muscle contraction, and other respiratory inflammation ·       Stomach pain or upset

        ·       Headache

        ·       Stuffy nose

        ·       Cough

        ·       Fever

        ·       Rash

        ·       Irritability

        Warn patients to report behavior changes, including suicidal ideation or suicidal behavior

        Avoid concomitant use of aspirin or NSAIDs in aspirin-sensitive patients

        *Indicates over the counter (OTC) medication

         

        In general, for conditions eligible for self-care, e.g., allergic rhinitis, patients should start taking OTC allergy medications one week before they expect symptoms from a predictable exposure or as soon as possible before allergen exposure (for episodic exposure).35 Prescribers should tailor the pharmacologic therapy and length of treatment based on symptoms and severity. Usually, complete relief takes two to four weeks. Intranasal steroids control nasal symptoms more effectively than antihistamines, as they inhibit multiple cell types and mediators, and should be recommended for moderate or persistent allergic rhinitis. Decongestants are effective in nasal congestion but have little effect on other symptoms. Intranasal and ocular preparations are available for nasal and eye symptoms. Intranasal cromolyn is the preferred initial choice for pregnant or lactating patients, as the body does not absorb it based on the route of administration. As mentioned in the table, fluticasone and triamcinolone nasal sprays are available over the counter.35

        If a patient has persistent allergies, allergy medication is more effective when taken regularly.35 For example, if a patient with moderate or severe persistent allergic rhinitis has completed two to four weeks of treatment with intranasal corticosteroids or oral antihistamine and achieved symptomatic control, healthcare providers can optimize the treatment’s effect by reducing the dose and continuing treatment for one additional month. If a patient’s symptoms are uncontrolled after two to four weeks of OTC treatment, pharmacists should assess the patient’s adherence and refer for prescription therapy if necessary.35

        Pause and Ponder: Which providers in your area provide allergen-specific immunotherapy? What should patients expect if they take this route?

        Allergy Immunotherapy

        Allergen-specific immunotherapy has been used in pet allergies for years and has proven efficacy to help control symptoms and prevent disease progression. Allergists will consider allergy-specific immunotherapy when symptoms are uncontrolled by medications and/or avoidance measures, when adverse drug effects are intolerable, or when patients want to reduce long-term use of allergy medications.37

        The basis for allergen-specific immunotherapy is gradual reprogramming of the immune system to build a tolerance to allergens. This class comes in three forms:

        • Sublingual allergy immunotherapy (SLIT) tablets
        • SLIT drops, and
        • subcutaneous allergy immunotherapy (SCIT)

        As of 2022, the FDA has approved four SLIT tablets to treat allergic rhinitis with or without allergic conjunctivitis caused by ragweed, northern pasture grasses, and dust mites in susceptible individuals; the FDA has not approved SLIT tablets for pet allergies.22

        SLIT drops are made from FDA-approved allergy extracts used to make SCIT shots. However, these extracts are only FDA-approved for injection use under the skin, and they are not approved for use under the tongue. Therefore, SLIT drops are not FDA-approved and are off-label in the United States, and Medicare or Medicaid does not cover these treatments in most cases. Despite not having FDA approval, patients can still receive SLIT drops from some prescribers who prepare a custom-mixed formulation but must pay out of pocket. Research indicates SLIT is safe and effective.39

        The FDA has approved SCIT for cat allergies, but not for other pet allergies. Patients who receive SCIT usually call it “allergy shots.” One systemic review evaluated 88 trials that enrolled 3,459 asthmatic patients and exposed them to SCIT. One case of deterioration in asthma symptoms was avoided for every three patients treated with SCIT (95% CI, 3-5), and one patient would avoid increasing symptomatic medication use for every four patients treated (95% CI, 3-6).40 Another study found that SCIT can reduce the need for systemic steroids in allergic rhinitis patients.41 Usually, the patient receives a solution for injection with 10,000 bioequivalent allergy units (BAUs) per milliliter (standardized extract) of lyophilized cat hair and dander added to glycerol and human serum albumin (0.03%). A clinician administers one to two subcutaneous injections every week starting at low doses (1:10,000 dilution) and titrating up to a seemingly effective maintenance dosing. Then, the prescriber extends the injection interval gradually to every 2 weeks to 4 weeks. For cat allergens, the effective maintenance dose usually falls within the 1000 to 4000 BAU range.42

        SCIT sometimes can cause treatment-related systemic allergic reactions; however, near-fatal or severe reactions are rare, and most reactions are local and mild (swelling, pruritis, and redness at injection site).43 SCIT should not be recommended to patients who have severe uncontrolled heart problems or asthma if they take beta-blockers, which are associated with more frequent reactions, more severe reactions, and reactions that are refractory to epinephrine. Additionally, allergy shots should not be recommended for pregnant women unless discussed with their obstetricians.43

        Both SCIT and SLIT require gradual up-titration of dosages with ongoing and multiple treatments and may take three to five years to reach desensitization. Also, for SCIT, based on its route of administration (subcutaneous injections are invasive), patients will need to visit the doctor's office more frequently and may experience the treatment-associated side effects.

        SLIT has been increasingly recommended because of its ability to modify the immune system for the long term while reducing allergy symptoms. SLIT also showed a safer profile, only associated with mild mouth symptoms, and improved adherence compared to SCIT.44 When compared to traditional allergy treatments, SLIT tablets showed similar clinical efficacy to nasal corticosteroids and greater clinical efficacy than second-generation antihistamines and montelukast.45

        What About Cost?

        In adherent patients, SCIT and SLIT have proven to be an economically viable option. The annual cost of using SCIT depends on patients’ insurance: Medicare ($1021.70), Medicaid ($758.16), and the commercial average ($1722.24). Yearly treatment costs for SLIT are self-pay because treatment is not FDA approved and costs around $679.25.46 Because SLIT drops are administered at home by patients, they tend to be more affordable than the cost of SCIT. Patient preference might be for a once monthly administration, rather than taking oral antihistamines  daily.

        OTC medications are less expensive than immunotherapy, but costs vary. In a comparison of second-generation antihistamines versus montelukast, levocetirizine (Xyzal) had the best efficacy per cost value. Generic fexofenadine (Allegra), although similar in efficacy, was more expensive than levocetirizine.44

        CONCLUSION

        Healthcare providers should counsel patients about reducing allergen exposure and help patients to choose OTC medications for self-care based on individual patient needs and conditions to optimize treatment effects. Pharmacy staff should refer patients to allergists when necessary to identify the cause of their allergy symptoms. If a patient's allergy does not allow him or her to have pets at home and the patient owns a pet, suggest that the patient ask family members or friends about placement before contacting the local animal shelters.

        Pharmacist Post Test (for viewing only)

        Pet Allergies
        Pharmacist Post-test
        After completing this continuing education activity, pharmacists will be able to
        1. Outline the causes of pet allergies in dogs, cats, and other less common species
        2. Differentiate between allergic sensitization, allergy, and cross sensitivity
        3. Paraphrase facts that prove that currently, hypoallergenic dogs and cats are a myth
        4. Compare nonpharmacologic, over the counter, and prescription treatments in terms of dosing, effectiveness, and cost

        1. What is the major allergen in dogs?
        A. Can f 3
        B. Can f 1
        C. Fel d 1

        2. When comparing allergy immunotherapies (SCIT, SLIT) and traditional allergy treatments, how do they differ?
        A. Traditional allergy treatments are more clinically efficacious, SCIT and SLIT therapies should not be considered in treatment
        B. Traditional allergy treatments are more effective, but with the recent FDA approval of SLIT, it should be considered more often
        C. Although not FDA approved, SLIT showed similar clinical efficacy to nasal corticosteroids and more clinical efficacy to second-generation antihistamines in trials

        3. What is the best way to define hypoallergenic animals?
        A. Animals that are less likely to cause allergies in humans.
        B. Animals that cannot cause allergies in humans
        C. Animals that do not cause conjunctivitis, but other common symptoms may still occur

        4. A mother brings her young son to the pharmacy and says that the allergist indicates he has an allergy to their cat. She asks what this means. What is the BEST answer?
        A. Her son has immunoglobulin G (IgG) antibodies to an allergen.
        B. Her son will experience reproducible symptoms when exposed to the cat.
        C. Her son will have symptoms when exposed to any furry animal.

        5. Lance, a college student who lives in a group house, comes in and says that he has tried several medications for allergic symptoms linked to his roommate’s three cats. The medications relieved the symptoms but caused so much drowsiness, he couldn’t study. His allergist is now recommending he start immunotherapy. What is the MOST LIKELY reason the allergist is making this recommendation?
        A. Lances’ symptoms are uncontrolled by medications
        B. Lance is experiencing intolerable adverse effects
        C. Lance want to reduce his use of allergy medications.

        6. Lance returns to the pharmacy to pick up his atenolol for hypertension and he said the allergist has asked him to decide if he wants to take SCIT or SLIT. He asks you which factors he should consider. What is the BEST answer?
        A. Advise him to consider cost, dosing frequency, and route of administration
        B. Advise him to consider cost and convenience alone as they are both effective
        C. Advise him to tell his allergist he is taking a beta blocker, so SLIT is preferred

        7. Emily and her mom come to the pharmacy and they are very excited. They are considering adopting a dog! Emily has asthma and multiple allergies, and the pediatrician has told them she is probably allergic to or will become allergic to dogs. As Mom chatters, she tells you that the 9-year-old dog, Raven, is an Alaskan Malamute (a breed that has a heavy undercoat) that weighs 95 pounds. She said that a friend told her that if she washes the dog two or three times a month, allergies will not be a problem. She says, “I think I can find time to wash a dog twice a month.” What is the MOST IMPORTANT FACT you should bring to her attention?
        A. Before adopting Raven, check with a veterinarian or a breed advocacy group to determine if bathing is a good idea.
        B. Bathing a pet two to three times a month is not frequent enough to reduce the allergen load—you have to bathe them two to three times a week.
        C. Look for a younger Alaskan Malamute—maybe a puppy—so the dog will get used to being bathed so often.

        8. Adele, who is 7 months pregnant, is experiencing an allergic reaction to a visiting ferret. She asks you to recommend an OTC product to reduce her nasal stuffiness and itchy eyes. Which is the BEST product to recommend?
        A. Intranasal cromolyn
        B. Oral levocetirizine
        C. Oral diphenhydramine

        9. Which of the following have similar effectiveness for pet allergies, but different cost effectiveness?
        A. Fluticasone and fexofenadine
        B. Montelukast and loratadine
        C. Levocetirizine and fexofenadine

        10. Which medication class should be used for no longer than five days at a time?
        A. Decongestants
        B. First generation antihistamines
        C. Nasal corticosteroids

        Pharmacy Technician Post Test (for viewing only)

        Pet Allergies

        Pharmacy Technician Post-test

        After completing this continuing education activity, pharmacy technicians will be able to
        • Outline the causes of pet allergies in dogs, cats, and other less common species
        • Differentiate between allergic sensitization, allergy, and cross sensitivity
        • Paraphrase facts that prove that currently, hypoallergenic dogs and cats are a myth
        • Identify patients whose complaints indicate they may need referral to a pharmacist

        1. What is the major allergen in dogs?
        A. Can f 3
        B. Can f 1
        C, Fel d 1

        2. When comparing allergy immunotherapies (SCIT, SLIT) and traditional allergy treatments, how do they differ?
        A. Traditional allergy treatments are more clinically efficacious, SCIT and SLIT therapies should not be considered in treatment
        B. Traditional allergy treatments are more effective, but with the recent FDA approval of SLIT, it should be considered more OFTEN?
        C. Although not FDA approved, SLIT showed similar efficacy to nasal corticosteroids and more clinical efficacy to second-generation antihistamines in trials

        3. What is the best way to define hypoallergenic animals?
        A. Animals that are less likely to cause allergies in humans.
        B. Animals that cannot cause allergies in humans
        C. Animals that do not cause conjunctivitis, but other common symptoms may still occur

        4. A mother brings her young son to the pharmacy and says that the allergist indicates he has an allergy to their cat. She asks what this means. What is the BEST answer?
        A. Her son has immunoglobulin G (IgG) antibodies to an allergen.
        B. Her son will experience reproducible symptoms when exposed to the cat.
        C. Her son will have symptoms when exposed to any furry animal.

        5. Lance, a college student who lives in a group house, comes in and says that he has tried several medications for allergic symptoms linked to his roommate’s three cats. The medications relieved the symptoms but caused so much drowsiness, he couldn’t study. His allergist is now recommending he start immunotherapy. What is the MOST LIKELY reason the allergist is making this recommendation?
        A. Lances’ symptoms are uncontrolled by medications
        B. Lance is experiencing intolerable adverse effects
        C. Lance want to reduce his use of allergy medications.
        Links to LO #4 Answer found on page 10

        6. Lance returns to the pharmacy to pick up his atenolol for hypertension and he said the allergist has asked him to decide if he wants to take SCIT or SLIT. He asks you which factors he should consider. What is the BEST answer?
        A. Advise him to consider cost, dosing frequency, and route of administration
        B. Advise him to consider cost and convenience alone as they are both effective
        C. Advise him to tell his allergist he is taking a beta blocker, so SLIT is preferred

        7. Emily and her mom come to the pharmacy, and they are very excited. They are considering adopting a dog! Emily has asthma and multiple allergies, and the pediatrician has told them she is probably allergic to or will become allergic to dogs. As Mom chatters, she tells you that the 9-year-old dog, Raven, is an Alaskan Malamute (a breed that has a heavy undercoat) that weighs 95 pounds. She said that a friend told her that if she washes the dog two or three times a month, allergies will not be a problem. She says, “I think I can find time to wash a dog twice a month.” What is the MOST IMPORTANT FACT should you bring to her attention?
        A. Before adopting Raven, check with a veterinarian or a breed advocacy group to determine if bathing is a good idea.
        B. Bathing a pet two to three times a month is not frequent enough to reduce the allergen load—you have to bathe them two to three times a week.
        C. Look for a younger Alaskan Malamute—maybe a puppy—so the dog will get used to being bathed all the time.

        8. Adele., who is 7 months pregnant, is experiencing an allergic reaction to a visiting ferret. She asks you to recommend an OTC product to reduce her nasal stuffiness and itchy eyes. Which is the BEST product to recommend?
        A. Intranasal cromolyn
        B. Oral levocetirizine
        C. Oral diphenhydramine

        9. Which of the following have similar effectiveness for pet allergies, but different cost effectiveness?
        A. Fluticasone and fexofenadine
        B. Montelukast and loratadine
        C. Levocetirizine and fexofenadine

        10. Which medication class should be used for no longer than five days at a time?
        A. Decongestants
        B. First generation antihistamines
        C. Nasal corticosteroids

        References

        Full List of References

        1. 2021-2022 APPA National Pet Owners Survey. Accessed January 17, 2022. https://www.americanpetproducts.org/press_industrytrends.asp
        2. Ownby D, Johnson C. Recent Understandings of Pet Allergies [version 1; peer review: 2 approved]. F1000Research. 2016;5(108)doi:10.12688/f1000research.7044.1
        3. Perzanowski MS, Rönmark E, Platts-Mills TA, Lundbäck B. Effect of cat and dog ownership on sensitization and development of asthma among preteenage children. Am J Respir Crit Care Med. 2002;166(5):696-702. doi:10.1164/rccm.2201035
        4. Ownby DR, Johnson CC, Peterson EL. Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age. JAMA. 2002;288(8):963-72. doi:10.1001/jama.288.8.963
        5. Díaz-Perales A, González-de-Olano D, Pérez-Gordo M, Pastor-Vargas C. Allergy to uncommon pets: new allergies but the same allergens. Front Immunol. 2013;4:492-492. doi:10.3389/fimmu.2013.00492
        6. Curin M, Hilger C. Allergy to pets and new allergies to uncommon pets. Allergol Select. 2017;1(2):214-221. Published 2017 Aug 4. doi:10.5414/ALX01842E
        7. Villas F, Compes E, Fernández-Nieto M, Muñoz MP, Bartolome B, de las Heras M. Bird-egg syndrome caused by Agapornis species (lovebird). J Investig Allergol Clin Immunol. 2009;19(1):71-2.
        8. Quirce S. Asthma in Alergológica-2005. J Investig Allergol Clin Immunol. 2009;19 Suppl 2:14-20.
        9. Ferret allergies: Are ferrets hypoallergenic animals? Accessed July 12, 2022. https://friendlyferret.com/ferret-hypoallergenic-allergies/
        10. Are rabbits hypoallergenic? All your questions answered. Hypoallergenic Home. Accessed July 12, 2022. https://hypoallergenichomes.com/hypoallergenic-pets/rabbits/
        11. Konradsen JR, Fujisawa T, van Hage M, et al. Allergy to furry animals: New insights, diagnostic approaches, and challenges. J Allergy Clin Immunol. Mar 2015;135(3):616-25. doi:10.1016/j.jaci.2014.08.026
        12. Kang SY, Won HK, Park SY, Lee SM, Lee SP. Prevalence and diagnostic values of laboratory animal allergy among research personnel [published online ahead of print, 2021 Jul 11]. Asian Pac J Allergy Immunol. 2021;10.12932/AP-220321-1094. doi:10.12932/AP-220321-1094
        13. Grönlund H, Saarne T, Gafvelin G, van Hage M. The major cat allergen, Fel d 1, in diagnosis and therapy. Int Arch Allergy Immunol. 2010;151(4):265-74. doi:10.1159/000250435
        14. Fernández-Parra B, Bisson C, Vatini S, Conti A, Cisteró Bahima A. Allergy to chinchilla. J Investig Allergol Clin Immunol. 2009;19(4):332-3.
        15. De las Heras M, Cuesta-Herranz J, Cases B, et al. Occupational asthma caused by gerbil: purification and partial characterization of a new gerbil allergen. Ann Allergy Asthma Immunol. 2010;104(6):540-542.
        16. De las Heras M, Cuesta J, De Miguel J, et al. Occupational rhinitis and asthma caused by gerbil. J Allergy Clin Immunol. 2002;109(1):S326.
        17. Hunskaar S, Fosse RT. Allergy to laboratory mice and rats: a review of the pathophysiology, epidemiology and clinical aspects. Lab Anim. 1990;24(4):358-379.
        18. Sathish JG, Sethu S, Bielsky M-C, et al. Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov. 2013;12(4):306-324.
        19. Phipatanakul W. Rodent allergens. Curr Allergy Asthma Rep. 2002;2(5):412-416.
        20. Gonzáles de Olano D, Pastor Vargas C, Cases Ortega B, et al. Identification of a novel 17-kDa protein as a ferret allergen. Ann Allergy Asthma Immunol.. 2009;103(2):177-178.
        21. Posthumus J, James HR, Lane CJ, et al. Initial description of pork-cat syndrome in the United States. J Allergy Clin Immunol.. 2013;131(3):923-925.
        22. FDA Allergen Extract Sublingual Tablet. Cited 21 February 2022 Accessed https://www.fda.gov/vaccines-blood-biologics/allergenics/allergen-extract-sublingual-tablets.
        23. Jesner S. (2022, June 28). Sublingual immunotherapy faqs. Sublingual Immunotherapy FAQs. Accessed July 8, 2022. https://www.hopkinsmedicine.org/otolaryngology/specialty_areas/sinus_center/sublingual_immunotherapy.html#:~:text=Immunotherapy%20treats%20the%20cause%20of,as%20drops%20under%20the%20tongue.
        24. Malandain H. IgE antibody in the serum--the main problem is cross-reactivity. Allergy. 2004;59(2):229-230. doi:10.1046/j.1398-9995.2003.00395.x
        25. Nicholas CE, Wegienka GR, Havstad SL, et al. Dog allergen levels in homes with hypoallergenic compared with nonhypoallergenic dogs. Am J Rhinol Allergy. 2011;25(4):252-6. doi: 10.2500/ajra.2011.25.3606
        26. Dance A. The race to deliver the hypoallergenic cat. Nature. 2020;588(7836):S7-S9. doi:10.1038/d41586-020-02779-3
        27. Hypoallergenic cats. Blue Cross. (n.d.). Accessed July 8, 2022. https://www.bluecross.org.uk/advice/cat/hypoallergenic cats#:~:text=Despite%20popular%20belief%2C%20hypoallergenic%20cats,how%20much%20protein%20they%20produce
        28. Skin prick tests. FoodAllergy.org. Accessed August 1, 2022. Skin Prick Tests - FoodAllergy.org
        29. de Vos G. Skin testing versus serum-specific IgE testing: which is better for diagnosing aeroallergen sensitization and predicting clinical allergy?. Curr Allergy Asthma Rep. 2014;14(5):430. doi:10.1007/s11882-014-0430-z
        30. Hodson T, Custovic A, Simpson A, Chapman M, Woodcock A, Green R. Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week. J Allergy Clin Immunol. Apr 1999;103(4):581-5. doi:10.1016/s0091-6749(99)70227-7
        31. Latz K. How Often Should You Bathe Your Dog? Accessed July 13, 2022. https://www.akc.org/expert-advice/health/how-often-should-you-wash-your-dog/
        32. Aalberse RC. Mammalian airborne allergens. Chem Immunol Allergy. 2014;100:243-247. doi:10.1159/000358862
        33. Wood RA, Johnson EF, Van Natta ML, Chen PH, Eggleston PA. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med. 1998;158(1):115-120. doi:10.1164/ajrccm.158.1.9712110
        34. Discover ProPlan LiveClear Allergen Reducing Cat Food. Purina. Accessed July 12, 2022. https://www.purina.com/pro-plan/cats/liveclear-cat-allergen-reducing-food
        35. Scolaro KL. Chapter 11: Colds and Allergy. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 20th Edition.
        36. Product Information: SINGULAIR(R) oral tablets, oral chewable tablets, oral granules, montelukast sodium oral tablets, oral chewable tablets, oral granules. Merck & Co (Per FDA); 2012.
        37. Clark J, White ND. Immunotherapy for Cat Allergies: A Potential Strategy to Scratch Back. Am J Lifestyle Med. 2017;11(4):310-313. doi:10.1177/1559827617701389
        38. Allergenics. U.S. Food and Drug Administration. Accessed July 29, 2022. https://www.fda.gov/vaccines-blood-biologics/allergenics
        39. Sublingual Immunotherapy. Johns Hopkins Medicine. Accessed July 13, 2022. https://www.hopkinsmedicine.org/otolaryngology/specialty_areas/sinus_center/sublingual_immunotherapy.html#:~:text=Immunotherapy%20treats%20the%20cause%20of,as%20drops%20under%20the%20tongue.
        40. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;(8):Cd001186. doi:10.1002/14651858.CD001186.pub2
        41. Aasbjerg K, Torp-Pedersen C, Backer V. Specific immunotherapy can greatly reduce the need for systemic steroids in allergic rhinitis. Allergy. 2012;67(11):1423-9. doi:10.1111/all.12023
        42. Ling M, Long AA. Pet dander and difficult-to-control asthma: therapeutic options. Allergy Asthma Proc. 2010;31:385-391.
        43. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1-55. doi:10.1016/j.jaci.2010.09.034
        44. Goodman MJ, Jhaveri M, Saverno K, Meyer K, Nightengale B. Cost-effectiveness of second-generation antihistamines and montelukast in relieving allergic rhinitis nasal symptoms. Am Health Drug Benefits. 2008;1(8):26-34.
        45. Aboshady OA, Elghanam KM. Sublingual immunotherapy in allergic rhinitis: efficacy, safety, adherence and guidelines. Clin Exp Otorhinolaryngol. 2014 Dec;7(4):241-9. doi: 10.3342/ceo.2014.7.4.241.
        46. Hardin FM, Eskander PN, Franzese C. Cost-effective Analysis of Subcutaneous vs Sublingual Immunotherapy From the Payor's Perspective. OTO Open. 2021 Oct 25;5(4):2473974X211052955. doi: 10.1177/2473974X211052955.

        Patient Safety: Seven Secrets for Patient Safety with Dietary Supplements

        Learning Objectives

         

        After completing this application-based continuing education activity, pharmacists will be able to

        ·       Discuss the importance of knowing about a patient’s dietary supplement usage
        ·       Identify commonly used dietary supplements, their regulation, and the value of certification
        ·       Recognize potential medication-dietary supplement interactions
        ·       Demonstrate the ability to locate different sources of information about dietary supplements

        After completing this application-based continuing education activity, pharmacy technicians will be able to

        ·       Discuss the importance of knowing about a patient’s dietary supplement usage
        ·       Identify commonly used dietary supplements, their regulation, and the value of certification
        ·       Recognize potential medication-dietary supplement interactions
        ·       Recognize the need for pharmacist counseling when a patient is taking a dietary supplement

        a dinner plate with a variety of colorful capsules with a fork and spoon on the table

         

        Release Date: January 16, 2026

        Expiration Date: January 16, 2029

        Course Fee

        Pharmacists: $7

        Pharmacy Technicians: $4

        There is no grant funding for this CE activity

        ACPE UANs

        Pharmacist: 0009-0000-26-002-H05-P

        Pharmacy Technician: 0009-0000-26-002-H05-T

        Session Codes

        Pharmacist:  23YC01-FKE24

        Pharmacy Technician:  23YC01-EFK68

        Accreditation Hours

        2.0 hours of CE

        Accreditation Statements

        The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-26-002-H05-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

         

        Disclosure of Discussions of Off-label and Investigational Drug Use

        The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

        Faculty

        Jennifer Salvon, RPh
        Clinical Pharmacist
        Mercy Medical Center

        Springfield, MA

        Adjunct Faculty Member
        University of Connecticut School of Pharmacy
        Storrs, CT

        Faculty Disclosure

        In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

        Jennifer Salvon does not have any relationships with ineligible companies and therefore has nothing to disclose.

         

        ABSTRACT

        Consumer consumption of dietary supplements is at an all-time high. Available products number in the tens of thousands, generating millions in annual spending. Increasing interest in overall health and wellness, preventive medicine, and immune function contribute to the rise in usage. It is a common misconception that dietary supplements are safe because they are “natural.”
        Ingestion of dietary supplements poses serious health risks including adverse reactions, drug interactions, and toxicity. Adulterated, mislabeled, and contaminated products exist in the marketplace, further increasing consumer risk. Existing federal regulation and oversight for supplements differs from prescription and over-the-counter medications, occurring primarily on a post-marketing basis. Self-reporting by consumers, healthcare professionals, and industry personnel identifies these issues. Patients often omit dietary supplements from medication histories, leaving healthcare professionals unaware that patients are using them. While misinformation abounds on the Internet, many online clinically-backed sources exist.

        CONTENT

        Content

        Introduction

         

        Consuming natural substances to produce a desired effect on the body dates back thousands of years to ancient Egypt, Rome, China, and many other cultures. Records from early Mesopotamia include written formulas using many oils still in use today, including cedar, cypress, and licorice. Around 300 B.C., the Greek philosopher Theophrastus described the medicinal benefits of natural substances in his History of Plants. Throughout the centuries, many philosophers, scientists, and physicians continued collecting, combining, and documenting the use of natural products to treat different illnesses.1

         

        As the science of medicine developed, so did the science of pharmacology. Isolation of the active ingredients found in herbal substances lead to the development of synthetic compounds with similar properties. The first synthetic medication, chloral hydrate, derived from chloroform and discovered in the 1800s by German chemist Justus von Lieberg, is still in use today.2

         

        Fast forward to modern day, and the interest and use of prescription medications, over-the-counter (OTC) products, and dietary supplements are at an all-time high. In 2020, consumers filled 6.3 billion prescriptions in the United States3 (U.S.) and purchased more than 6 billion OTC products.4 The dietary supplement market reached an unprecedented level in 2020 with a global spend of $61.2 billion. Experts predict it will reach $128.64 billion by 2028.5

         

        The COVID-19 pandemic, caused by the SARS-CoV-2 acute respiratory coronavirus, significantly impacted our perception and approach to healthcare.6 More and more people use complementary and alternative approaches to healthcare than ever before.7 For example, sales of elderberry supplements more than doubled and zinc products quadrupled shortly after the pandemic's start.8

         

        Pharmacists, widely recognized as drug information experts, and pharmacy technicians routinely field consumers' questions about dietary supplements. Many pharmacists lack the necessary knowledge or don't know where to look to answer these questions. Pharmacy schools educate future pharmacists on prescription and OTC medications with courses about nutrition and dietary supplementation, if offered, available as electives. This continuing education activity presents information about dietary supplements through a series of seven common pharmacy situations and lets learners in on seven secrets they can apply to their practices.

         

         

         

        Situation: Continuing education is a professional requirement many pharmacists find tedious. Looking through the UCONN online CE library and seeing a new continuing education activity entitled ‘Seven Secrets of Patient Safety with Dietary Supplements,’ a pharmacist remarks to the pharmacy team, "What a waste, no one even takes dietary supplements."

         

        Secret #1: Almost 60% of people in the United States used a dietary supplement in the last 30 days.11,12

         

        Dietary supplements crowd the aisles in drug stores, supermarkets, warehouse clubs, and even corner convenience stores. The sheer number of products is staggering. The Dietary Supplement Database (DSLD) is an online, searchable database developed by the Office of Dietary Supplements (ODS) at the National Institutes of Health (NIH). The database contains product labeling information on dietary supplements sold in the United States, including both on and off-market products. DSLD currently lists more than 140,000 labels.9

         

        In the early 1960s, the National Center for Health Statistics began a program named the National Health and Nutrition Examination Survey (NHANES). NHANES is a continuous program focusing on various health and nutritional measurements and assesses adults' and children's health and nutritional status in the U.S.10 Scientific and technical journals publish the study results.

         

        One section of the program assesses dietary supplement use among adults. Results from the 2017-2018 NHANES show that11,12

        • 57.6% of adults 20 years or older used a dietary supplement in the past 30 days
        • Women (63.8%) had a higher utilization than men (50.8%)
        • Use of dietary supplements increased with age, with women 60 years or older reporting the highest usage at 80.2%
        • Use of multiple dietary supplements increased with age
        • Most common dietary supplements used by all age groups include multivitamin-mineral supplements, vitamin D, and omega-3 fatty acids

         

        The Council for Responsible Nutrition (CRN) is a trade association for the dietary supplement and functional food industry. Annually, the CRN performs a survey gathering data on consumer use of dietary supplements. The 2019 survey conducted by the CRN underscored dietary supplement usage with the following results13:

        • 77% of US adults take dietary supplements, including 79% of American women and 74% of males
        • Top reasons for taking supplements included:
          • Energy
          • Immune health
          • Filling nutrient gaps
          • Healthy aging
          • Heart health

         

        The COVID-19 pandemic significantly impacted our perception and approach to healthcare.6 As of August 5, 2022, SARS-CoV-2 has infected more than 580 million people worldwide.14 Interest in boosting our overall immunity and protecting ourselves from viral infections has dramatically increased as a result.7 Many vitamins and minerals play essential roles in proper immune function.7,15 Sales of supplements associated with boosting immunity increased over the last two years, including vitamins C and D, zinc, omega-3, garlic, ginger, and turmeric.16

         

        Table 1. Common Dietary Supplements and Potential Uses7,17,18

         

        Dietary Supplement Potential Use
        Black Cohosh Menopausal symptoms
        Calcium Dyspepsia

        Osteoporosis

        Premenstrual syndrome

        Echinacea Prevention and treatment of the common cold

        Promotion of wound healing

        Elderberry Prevention of upper respiratory tract infections

        Reduction in duration and severity of symptoms of the common cold

        Folic acid Folate deficiency

        Kidney failure

        Neural tube defects

        Ginkgo Anxiety

        Dementia

        Memory improvement

        Premenstrual syndrome

        Ginger Dysmenorrhea

        Nausea and vomiting

        Osteoarthritis

        Ginseng Cognitive function

        Erectile dysfunction

        Iron Anemia

        Restless leg syndrome

        Magnesium Constipation

        Dyspepsia

        Melatonin Sleep disorders
        Multivitamin with minerals General supplementation
        Omega-3 fatty acids

         

         

        Alzheimer’s disease

        Cardiovascular disease

        Dementia

        Depression

        Reduction of triglycerides

        Potassium Hypokalemia

        Hypertension

        Kidney stones

        Probiotics

         

         

        Atopic dermatitis

        Antibiotic-associated diarrhea

        Irritable bowel syndrome

        St. John’s Wort Anti-depressant

        Menopausal symptoms

        Turmeric Allergic rhinitis

        Osteoarthritis

        Pruritis

        Valerian Insomnia
        Vitamin A Aging skin

        Healthy vision

        Vitamin B-12 Vitamin B-12 deficiency
        Vitamin C Anemia

        Antioxidant effects

        Prevention of the common cold

        Vitamin C deficiency

        Vitamin D Osteomalacia

        Osteoporosis

        Vitamin D deficiency

        Vitamin E Alzheimer's disease

        Dysmenorrhea

        Premenstrual syndrome

        Zinc Acne

        Depression

        Diabetes

        Diarrhea

        Treatment of common cold

         

         

        Eating a healthy diet is essential for good health and nutrition. The Dietary Guidelines for Americans advise professionals, including policymakers, health care providers, and nutrition educators, about what to eat to meet the body’s nutritional needs. It emphasizes eating a diet rich in nutrient-dense foods, such as fruits and vegetables, as the best way to meet the body’s nutritional needs. The guideline identifies specific populations in which dietary supplementation may be necessary, such as women who are pregnant or lactating and adults older than 50.19

         

        In addition to these defined special populations, many pharmacy patients may find it necessary to take specific vitamins or minerals due to medication-induced nutrient deficiencies.

         

        Table 2. Examples of Nutrient Depletion Induced by Medications7,17

         

        Nutrient Medication(s) Mechanism
        Vitamin D Anticonvulsants

         

        Increase hepatic metabolism
        Bile acid sequestrants

         

        Decrease absorption
        Orlistat

         

        Decrease absorption
        Magnesium

         

        Estrogens

         

        Decrease serum levels by increasing uptake into tissues
        Loop diuretics

         

        Increase excretion
        Proton pump inhibitors

         

        Decrease absorption
        Vitamin B12

         

         

        Biguanides

         

        Decrease absorption
        Proton pump inhibitors

         

        Decrease absorption
        H-2 blockers

         

        Decrease absorption
        Potassium Loop diuretics

         

        Increase excretion
        Thiazide diuretics

         

        Increase excretion
        Corticosteroids

         

        Increase excretion

         

        The pharmacist's dismissal of dietary supplement education is understandable. No one wants to waste precious time on irrelevant continuing education. However, the facts presented here illustrate the need for pharmacist education on dietary supplements.

        Pause and ponder: A patient presents information about taking lemon and baking soda tea to prevent COVID-19 infection and asks you if it really works. How would you approach this conversation?

         

        Situation: Sunday afternoons sometimes (but not often!) present the opportunity to catch up on administrative activities. While completing an inventory reconciliation of the vitamin section, a technician inquires, "Why does the FDA approve so many different products?" Looking up distractedly from the CII safe count, the pharmacist pauses, then replies in a weary voice, "You know, I’m not sure, probably just to make it more confusing for us."

         

        Secret #2: Regulatory oversight of dietary supplements differs from prescription and OTC medications.

         

        What is a Dietary Supplement?

         

        On the most basic level, a dietary supplement is a substance consumed to add nutrients to a diet or to lower the risk of certain health problems. The use of natural substances has been around for millennia, but it is only within the last five decades that countries worldwide have formalized language and regulations around dietary supplements. Terminology, quality control, and safety assessment differ depending on the country and governing legislative body.20

         

        In 1994, the United States Congress passed the Dietary Supplement Health and Education Act (DSHEA), an amendment to the Food, Drug, and Cosmetic Act. DSHEA defines the term dietary supplement as a product intended for ingestion and containing an ingredient that supplements the diet. Dietary supplement labeling must include the term ‘dietary supplement’ or an equivalent term such as ‘herbal supplement’ or ‘magnesium supplement.’ DSHEA also stipulates that a dietary supplement must be free of contamination, adulteration, and properly labeled.21 We will discuss dietary supplement product integrity and labeling later in this activity.

         

        According to DSHEA, dietary supplements include vitamins, minerals, herbs, other botanicals, amino acids, and live microbials (probiotics). Dietary supplements are available in many different formulations including tablets, capsules, soft gels, gel caps, powders, and liquids.21

         

        DSHEA defined the term ‘new dietary ingredient’ as an ingredient that meets the above criteria and was unavailable in the U.S. before October 15, 1994. If manufacturers want to market a product containing a new dietary ingredient, they must notify the U.S. Food and Drug Administration (FDA) before marketing. The FDA then reviews the product for safety but not effectiveness.21

         

        Regulation of Dietary Supplements

         

        The FDA and the Federal Trade Commission (FTC) share regulation and oversight of dietary supplements. The FDA is responsible for the information provided on dietary supplement product labeling, including the package labeling, product inserts, and information available at the point of sale. The FTC monitors dietary supplement advertising, ensuring advertisements are truthful, substantiated, and not misleading. Both agencies have the authority to address violations and work together to ensure their efforts are consistent with one another.22

         

        The FDA does not have the authority to approve dietary supplement products before manufacturers market, distribute, and sell them to consumers. Manufacturers are responsible for ensuring the products they produce and distribute meet all quality standards defined by federal law. Quality standards include22

        • Ensuring the safety of the dietary ingredients used in the product
        • Following current Good Manufacturing Practices (cGMP)
        • Meeting all product labeling requirements
        • Ensuring substantiation of all claims made about the product
        • Ensuring products are free of adulteration or misbranding

         

        cGMP, defined and regularly updated by the FDA, establish the minimum requirements for manufacturing, packaging, and labeling products to ensure product quality. cGMP includes guidance on obtaining quality ingredients, operating procedures, and quality controls.23 Failure to follow cGMP results in possible product contamination.

         

        While the FDA may not have the authority to approve dietary supplements before the product marketing and distribution, it can monitor products via post-marketing surveillance and auditing. The FDA routinely performs manufacturer inspections, monitors the marketplace, and investigates adverse event reports. Follow-up includes working with the manufacturer to bring the product into compliance, issuing warning letters, and recalling products.21

         

        Reporting Issues with Dietary Supplements

         

        Post-marketing surveillance is essential for documenting and monitoring any issues with dietary supplements. Information about severe reactions and product quality are important issues to report. The FDA Safety Reporting Portal is an online tool used to report safety issues on several categories of products, including pet or livestock foods, tobacco products, animal drugs, and dietary supplements.24

         

        The website address for the portal is https://safetyreporting.hhs.gov. Anyone can use the portal to report issues, including consumers, healthcare professionals, manufacturers, and researchers. Generating a new report starts on the home screen. The reporter chooses to file the report as a guest or by creating an account. Creating an account streamlines data entry and allows the reporting individual to save a draft of the report, follow up on a report, and view previous submissions.24

         

        Generation of an Individual Case Safety Report ID (ICSR) occurs after report submission. The ICSR allows the reporter to identify the report for future reference including submission of a follow-up report with additional information. FDA reviewers assess the seriousness of the reported issue and assign follow-up. Submission of this information allows the FDA to identify potentially dangerous products and potentially remove them from the market.24

         

        Traditionally, insurance companies limit coverage to prescription medications. Recent trends show an expansion of coverage to include some dietary supplements. Insurance coverage of dietary supplements blurs the regulatory differences between prescription medications and dietary supplements. Understanding the differences in oversight is beneficial and allows the pharmacy staff to counsel patients effectively.

        Situation: While running back to the pharmacy after a much-needed bathroom break, a pharmacist stops when approached by a customer asking for advice about an iron supplement. Overhearing the inquiry, another customer comments, "You should buy that online; it’s cheaper, and the quality is just as good." The pharmacist nods assent, turns, and hurries back to the pharmacy amid the erupting sounds of chaos behind the counter.

         

        Secret #3: Product integrity fluctuates between manufacturers and sources of dietary supplements.

         

        Integrity of Dietary Supplements

         

        The lack of government oversight opens the door for substandard products to flood the market. Poor ingredient quality, heavy metal or microbial contamination, adulteration, and mislabeling occur regularly. In the current economy, with rising prices, consumers are turning to less expensive options, and cheaper is not necessarily better, especially with dietary supplements.

         

        In the literature, many studies exist that analyze dietary supplement product integrity. A study published in 2021 tested multiple bottles of 29 herbal supplements for consistency of ingredient activity and the presence of metal and fungal contaminants. The analysis showed inconsistent ingredient activity not only between bottles of the same product manufactured by the same company, but also between bottles manufactured by different companies. Assaying for metal contamination found zinc in 88% of bottles and nickel in 40% of bottles. In 37 of 58 bottles tested, fungal contamination was present, with 21 bottles having multiple strains.25

         

        Another study analyzed 41 dietary supplements for the presence of cadmium, lead, and mercury. Results revealed that 68.3% of samples contained contamination with cadmium and lead, and 29.3% with mercury.26 One research team evaluated 121 dietary supplements along with 49 prescription drugs for levels of toxic element contamination. A small percentage of the dietary supplement products exceeded safety levels for mercury, lead, cadmium, arsenic, or aluminum. None of the prescription products exceeded these safety levels.27

         

        Adulterated products contain substances not listed on the product labeling, substitution of inferior materials for active ingredients, or may contain a lesser amount of ingredients. Weight loss, sports enhancement, and sexual function supplements commonly contain banned substances.28

         

        The FDA created and currently maintains the Health Fraud Product Database to increase awareness. This database contains information about products cited in warning letters, advisory letters, recalls, public notifications, and press announcements for various issues. Issues cited include products claiming to cure, treat, or prevent a disease and products containing undeclared ingredients or a new dietary ingredient.29 The database is available in the consumer section of the FDA website at https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database.

         

        On January 2, 2022, the FDA issued a warning letter to the manufacturers of Nasitrol, a nasal spray based on the ingredient iota carrageenan. A review of the product’s website found claims that the product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. Federal regulations define products making these claims as drugs and subject to review by the FDA before approval and subsequent marketing. As discussed earlier, this is in direct violation of federal regulations.30

         

        In another example, on July 15, 2022, the FDA issued a public notice advising consumers to refrain from purchasing Adam’s Secret Extra Strength Amazing Black, a product promoted for sexual enhancement. Laboratory analysis found that the product contained tadalafil, a prescription medication used for erectile dysfunction.31 Due to the potential for severe side effects such as hypotension, tadalafil administration requires medical supervision by a physician.32

         

        A study published in 2018 analyzed FDA warning letters issued from 2007 through 2016, using data from the Health Fraud Product Database. During this time frame, the FDA found 776 adulterated dietary supplements from 146 different companies. A total of 157 products contained more than one unapproved ingredient. Products marketed for sexual enhancement accounted for 45.5% of letters, weight loss 40.9%, and muscle building 11.9%. Unapproved ingredients included sildenafil in sexual enhancement, sibutramine in weight loss, and synthetic steroids or steroid-like ingredients in muscle building supplements.33

         

        One way for consumers to know they are purchasing a valid product is by looking for a certified product. The certification process involves an independent, third-party company testing a company’s products, offering quality assurance for dietary supplements. Parameters tested include34

        • Product contains the ingredients stated on the label
        • Presence of harmful ingredients
        • Presence of contamination
        • Proper dissolution
        • cGMP followed during manufacture

         

        Three independent, private, third-party certifying organizations operate in the United States: the US Pharmacopeial Convention (USP), NSF International, and Consumerlabs.com. All three companies offer product certification programs for a fee. Each company allows products passing certification to display a seal on product labeling. Table 3 summarizes information about each organization.

         

        Table 3. Dietary Supplement Certification Organizations

         

        Certifying Organization US Pharmacopeial Convention NSF International Consumerlab.com
        Website www.usp.org

        www.qualitysupplements.org

         

        www.nsf.org www.consumerlab.com
        Services offered Dietary supplement verification program including GMP facility audits, product QCM process evaluation, and product testing Product and ingredient certification

        GMP Certification

        Certified for Sport

        Product reviews

        Quality Certification Program

        Information available on the website Program information, list of verified products, and educational resources Program information, product search engine, and educational resources Product reviews, health condition information
        GMP = Good Manufacturing Practice

        Source: adapted from reference 33

         

        Online product ordering is a convenient shopping option rapidly gaining popularity in recent years, especially during the pandemic. While tempting to order the least expensive product, investigating the source and quality of dietary supplements available online is essential. Proactive training of the entire pharmacy team aids in providing patients with accurate information.

        Situation: A weary technician finally finishes ringing out the last customer after two hours straight at the register. A sigh of relief quickly turns into a disgruntled groan as another customer approaches. With a bottle labeled ‘Menopausal Support’ in hand, the customer points to the bottle label and asks, "What does ‘proprietary blend’ mean?" The technician glances over her shoulder, sees the pharmacist engaged in an intense phone conversation, and replies to the customer, "The bottle label clearly lists the ingredients."

         

        Secret #4: Federal regulations define required dietary supplement label information. Unfortunately, ambiguity still exists, making it challenging to identify exactly what the product contains.

         

        Federal regulations define the information required on dietary supplement product labeling in detailed, specific terms. Product labeling must include35

        • Product name
        • The term ‘dietary supplement’ or similar term (i.e., herbal supplement)
        • Name and location of the manufacturer, along with a domestic address and phone number for reporting serious adverse events
        • Nutrition labeling in the form of a “Supplement Facts” panel with the following information (see Figure 1):
          • Serving size
          • Number of servings per container
          • Listing of each dietary ingredient in the product
          • Amount of dietary ingredient per serving (Exception: ingredients in a proprietary blend)
          • Amount per serving listed as a quantitative amount by weight, as a percentage of the Daily Value, or as both
        • A list of other ingredients not declared on the Supplement Facts label (usually excipients such as preservatives or dyes)
        • Net quantity of contentsImage of a Supplemental Facts label found on dietary products.

        Figure 1. Supplemental Facts Label (sourced from reference 36)

        One area of ambiguity in dietary supplement product labeling is the listing of a proprietary blend. The term proprietary blend refers to a blend of dietary ingredients unique to a manufacturer and product. Federal labeling regulations allow the listing of proprietary blends on dietary supplement products, however, only the total weight of the blend is required, not the weight of individual ingredients.35 There is no way for the healthcare professional or consumer to know exactly how much of a particular ingredient the proprietary blend contains.

         

        Consumerlabs.com cautions consumers about products containing proprietary blends or formulas. In many instances, the blend's name sounds like a desired, expensive ingredient that is only a small part of the formula. Marketing of products containing proprietary blends may mislead the consumer with claims meant to impress the consumer and drive sales of the product.37

         

        FDA regulations do allow structure/function claims on dietary supplement labeling. Structure/function claims describe how a nutrient or dietary ingredient may affect or act to maintain the structure or function of the body.35 Examples of structure/function claims include35

        • Calcium builds strong bones
        • Antioxidants maintain cell integrity
        • Fiber maintains bowel integrity

         

        If a dietary supplement label contains a structure/function claim it must also contain the following statement: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."35

         

        The example in this situation involved a product marketed for menopausal support. Menopausal symptoms affect more than 1 million women in the US annually and include symptoms such as hot flashes and sleep disturbances.38 A search of the DSLD using the term ‘menopausal support’ and filtering for on-market products containing the ingredient ‘proprietary blend’ returned almost 3,000 products.9 This abundance of products illustrates the ambiguity that exists on dietary supplement labeling.

         

        Pharmacy technicians are often the first line of contact at the pharmacy. Training and development of pharmacy technicians on the facts surrounding dietary supplements empower technicians, allowing them to answer factual questions and provide effective patient education.

         

        Situation: The pharmacy phone constantly rings throughout the day, and today is no exception. The new COVID vaccine is out, and everyone wants to know if the pharmacy has it in stock. Answering yet another call, the technician is surprised when a patient asks to talk to the pharmacist, complaining about dizziness. The pharmacist checks the patient’s profile, finding no underlying causative medication. Further questioning the patient, the pharmacist uncovers the recent addition of melatonin at night for sleep.

         

        Secret #5: Like prescription medications, dietary supplements have pharmacologic and physiologic effects on the body, potentially resulting in health risks and side effects.

         

        Consumers perceive dietary supplements as safe due to their source from natural substances. While generally well tolerated, dietary supplements affect the body like prescription medications, capable of producing an undesired effect. Lack of regulatory oversight allows products to reach consumers without adequate safety evaluation.

         

        Information describing adverse effects of dietary supplements is anecdotal, derived from case reports and reports submitted through the FDA Safety Reporting Portal. Most dietary supplements have not been studied in pregnant or lactating women or children.

         

        A study published in 2015 evaluated ten years of emergency room data to assess the number of annual visits resulting from dietary supplement adverse events. The authors calculated an average of more than 23,000 emergency room visits stemmed from the consumption of dietary supplements, resulting in more than 2,000 hospitalizations annually.39

         

        Events in older adults accounted for the highest percentage of visits, with 40% of visits due to difficulty swallowing. Incidence in young adults aged 20 to 34 was significant at 28% and primarily involved weight loss and energy products. Side effects reported include heart palpitations, chest pain, and tachycardia.39

         

        Unsupervised child ingestions accounted for 21% of visits. Unlike prescription medications, regulations do not require child-resistant packaging for dietary supplements, except for iron-containing products.39 The authors note the numbers evaluated in the study are likely underreported as patients do not always include dietary supplements with the current medication list.39

         

        Table 4. Adverse Effects of Common Dietary Supplements7,17

         

        Supplement Adverse Effects
        Black Cohosh

         

        Breast tenderness, diarrhea, gastrointestinal upset, nausea/vomiting
        Calcium

         

        Burping, constipation, gastrointestinal upset
        Echinacea

         

        Diarrhea, constipation, gastrointestinal upset/pain, heartburn, nausea/vomiting, skin rashes
        Ginseng Gastrointestinal side effects, headache, sleep difficulty
        Ginger

         

        Burping, diarrhea, heartburn
        Iron

         

        Abdominal pain, constipation, diarrhea, nausea/vomiting
        Magnesium

         

        Diarrhea, gastrointestinal irritation, nausea/vomiting
        Melatonin

         

        Dizziness, drowsiness, headache
        Omega-3 fatty acids Bad breath, headache, heartburn, nausea, diarrhea, unpleasant taste
        Potassium

         

        Abdominal pain, burping, diarrhea, nausea/vomiting
        St. John’s Wort

         

        Diarrhea, dizziness, dry mouth, fatigue, headache, insomnia
        Turmeric

         

        Constipation, dyspepsia, gastrointestinal reflux, nausea/vomiting
        Vitamin C

         

        Abdominal cramping, heartburn, kidney stones (if history of kidney stones)
        Zinc

         

        Abdominal cramping, diarrhea, metallic taste, nausea/vomiting

         

         

        Patients often fail to report usage of dietary supplements and most pharmacy software lacks the ability to note dietary supplement usage in the patient profile. In this situation, the pharmacist took the extra time to further question the patient about dietary supplement usage and successfully identified the causative agent.

         

        Pause and Ponder: In what ways could you incorporate activities into the daily workflow to increase awareness of patients’ use of dietary supplements?

         

        Situation: Today, the workload in the pharmacy is lighter than usual. With a grateful sigh, the pharmacist sinks onto a stool reaching for a quick snack. Then the phone rings… The caller is a triage nurse from the local hospital to verify a patient’s medication profile. Pulling up the profile, the pharmacist verifies the list of medications, including digoxin. The triage nurse confirms atrial fibrillation as the cause for admission, adding that the patient recently started taking St. John’s Wort for depression.

         

        Secret #6: Some dietary supplements affect the CYP450 liver enzymes, potentially altering the pharmacokinetics of medications, leading to treatment failure and/or toxicity.

         

        Dietary supplement-drug interactions

         

        Drug-drug interactions result in altered absorption, metabolism, or excretion. Drug-dietary supplement interactions occur through the same pathways as those used by FDA-approved drugs. The cytochrome P450 (CYP P450) enzymes in the liver are responsible for the metabolism of most medications.41,42 The ability of a drug to either induce or inhibit these enzymes is a significant factor in drug-drug interactions. The natural ingredients found in dietary supplements are capable of inhibition or induction, also having the potential to interact with medications.

         

        St. John’s Wort, an herbal commonly taken for the relief of mild to moderate depression, induces the activity of CYP3A4.43,44 This induction increases the clearance of medications metabolized by CYP3A4. Examples of medications cleared by CYP3A4 include alprazolam, atorvastatin, cyclosporine, oral contraceptives, oxycodone, and warfarin.43,44 Patients need counseling about potential drug interactions with St. John’s Wort.

         

        Limited clinical studies evaluating the impact of drug-dietary supplement interactions exist. Many interactions are theoretical, based on limited clinical evidence, animal research, and case reports.

         

        Table 5. Examples of Potential Drug-Dietary Supplement Interactions7,17

         

        Dietary Supplement Medication Interaction
        Calcium

         

         

        Quinolone and tetracycline antibiotics Decreased antibiotic efficacy

        Take antibiotic 2 hours before or 4-6 hours after calcium

        Dolutegravir

        Elvitegravir

        Reduced serum levels

        Take medication 2 hours before or 2 hours after calcium

        Ginseng Diabetes medications Increase risk of hypoglycemia
        Immunosuppressants Decreased effectiveness of immunosuppressant
        Ginkgo

         

        Anticoagulants Increased risk of bleeding
        Iron

         

        Quinolone and tetracycline antibiotics Decreased levels of antibiotics due to decreased absorption

        Take antibiotics 2 hours before or 4-6 hours after iron

        Magnesium

         

        Bisphosphonates Decreased absorption

         

        Levodopa/carbidopa Decreased bioavailability of levodopa/carbidopa
        Niacin

         

         

         

        Statins Increased risk of myopathy or rhabdomyolysis
        Thyroid hormones Antagonize the effects of thyroid hormone replacement
        Antihypertensive medications Increased risk of hypotension due to niacin’s vasodilating effects
        St. John’s Wort Alprazolam Decreased effects of alprazolam
        Oral Contraceptives Decreased efficacy

        Counsel patients to use other forms of contraception

        Digoxin Decreased levels of digoxin
        Omeprazole Decreased effects of omeprazole
        Valerian CNS depressant drugs Additive sedative effects
        Vitamin B6

         

        Phenytoin Decrease levels and clinical effects of phenytoin
        Vitamin D

         

        Atorvastatin Decreased absorption of atorvastatin
        Vitamin E

         

        Anticoagulants Increased risk of bleeding
        Zinc

         

        Quinolone antibiotics Decreased levels and effects of antibiotics

        Take antibiotic 2 hours prior or 4-6 hours after zinc

         

        Pharmacy training emphasizes the importance of drug-drug interactions. It is important to remember that any substance introduced to the body, including food, beverages, and dietary supplements, has the potential to interact with medications.

        Situation: It is another busy day in the pharmacy; prescriptions cover the bench, the phone rings constantly, and a pickup queue extends around the corner. A technician nervously approaches the pharmacist about a patient at the counter with a question regarding a supplement. The pharmacist throws down the spatula, muttering angrily about lacking the knowledge and training to answer the question properly. Sighing, he says, "I’ll just Google it."

         

        Secret #7: Many websites provide clinically backed information on dietary supplements (and Google is not one of them!).

         

        The vast amount of health information available via the Internet with just a few clicks of the keyboard is both a blessing and a curse. Google is now a verb, and a simple search returns millions of results in seconds. While this may seem like a blessing, the curse lies in the searcher's inability to recognize valid, accurate sources of information. In many searches, ads appear as search results adding to the confusion.

         

        In addition to the Internet, consumers turn to social media for health information. Social media use increased from 27% in 2009 to 86% in 2019.45 Information posted on social media provides communication about healthcare issues, potentially resulting in improved health care.45 Unfortunately, inaccurate information abounds on the Internet and social media platforms, leading to consumer misinformation.47-49

         

        The FDA recently launched a new dietary supplement education initiative geared towards consumers, healthcare professionals, and teachers. The program, Supplement Your Knowledge, presents information about dietary supplements through a series of three videos. Educational materials, including fact sheets and infographics, are available in English and Spanish.50

         

        Many government agencies provide free access to information about dietary supplements and their side effects, toxicity, and drug interactions. There are also several paid subscription resources available. Table 6 lists many of the available information options.

         

        Table 6. Sources of Information about Dietary Supplements

         

        Resource Website Information
        Dietary Supplement Education Program https://www.fda.gov/food/healthcare-professionals/dietary-supplement-continuing-medical-education-program

         

        • Continuing medical education program
        • Collaboration between FDA and AMA
        • Series of 3 videos about dietary supplements
        • Also contains links to educational materials and other websites with information about dietary supplements
        Dietary Supplement Label Database https://dsld.od.nih.gov

         

        • Current and historical label information on dietary supplement products marketed in the United States
        • Useful to determine the contents of dietary supplement products
        Food and Drug Administration https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements

         

        • Information for consumers on using dietary supplements
        • Links to educational resources and materials, consumer updates, alerts, recalls and other information
        Google Scholar

         

        https://scholar.google.com/

         

        • Source of information from many avenues including journals, books, and conference proceedings
        Lexi-Comp

        Natural Products Database

        Available via mobile app
        • Requires a paid subscription
        • Alphabetical, searchable natural product database
        Memorial Sloane Kettering Cancer Center https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs

         

        • Information on herbs, botanicals, and other products for both consumers and healthcare professionals
        • Dietary supplement monographs
        • IOS app: About Herbs
        • Part of an online integrative medicine resource center
        National Cancer Institute Office of Cancer Complementary and Alternative Medicine https://cam.cancer.gov

         

        • Information for consumers and healthcare professionals about CAM as it relates to cancer therapy
        • Information on current NCI CAM research
        National Center for Complementary and Integrative Health https://www.nccih.nih.gov

         

        • Information for both consumers and healthcare professionals about complementary health products and practices
        National Library of Medicine - Medline Plus https://medlineplus.gov/druginfo/herb_All.html

         

        • Online health information about drugs, herbs, and supplements for consumers
        • Information sourced from the National Center for Complementary and Integrative Health and Natural Medicines Comprehensive Database
        Natural Medicines Comprehensive Database https://naturalmedicines.therapeuticresearch.com

         

        • Requires a paid subscription
        • Professional monographs including information about effectiveness, safety, adverse effects, and interactions
        • Information on specific commercial products
        • Interaction checker
        • Patient handouts in English, Spanish and French
        Office of Dietary Supplements https://ods.od.nih.gov
        • Information for both consumers and healthcare professionals
        • General supplement information
        • Information on supplements for specific purposes
        • Fact sheets on dietary supplements and their ingredients
        PubMed https://pubmed.ncbi.nlm.nih.gov

         

        • Search engine for the National Library of Medicine
        • Source of information from journals
        United States Department of Agriculture https://www.nutrition.gov/topics/dietary-supplements

         

        • Links to general information and resources on dietary supplements

         

         

        Performing an Internet search via Google may seem like the quickest and easiest way to find the answer to an inquiry. Engaging with the patient, gaining additional information, and knowing where to look ultimately saves time. It is not necessary for one to be an expert in all dietary supplements, just to self-educate one supplement at a time.

         

        Pause and Ponder: A patient shares the unfortunate news about a recent cancer diagnosis. He asks you about the use of herbs in the treatment of cancer. What advice would you give? 

        Conclusion

        You may have noticed a recurring theme throughout this activity. Education. Dietary supplement education is essential to patient safety given the current usage patterns and accessibility of the retail pharmacy team. Education needs to include the entire pharmacy team. Technicians are often the first point of contact at the pharmacy, commonly fielding patient questions. Knowing when to answer questions and when to involve the pharmacist is a necessary skill. Understanding the differences in oversight, the physiological effects of dietary supplement consumption, and the potential for drug interactions allows effective management and counseling of patients. It is important for healthcare providers to solicit information regarding patient consumption of dietary supplements.

         

         

        Sidebar: Tips for Counseling Patients about Dietary Supplements

         

        Carefully inspect the product to ensure intact product labeling

        Ensure the safety seal is intact

        Check for an expiration date or best used by date

        Check for customer service or return information before ordering

        Buy direct from a reputable company; many reputable companies sell through Amazon, avoid 3rd party resellers

        Check for the presence of a third-party certification seal

        Before purchase, check the company’s website for information on quality standards

        Pay attention to the appearance and smell of the product upon opening

        Child-resistant packaging is not a requirement for dietary supplements; advise on proper storage of product

        Reinforce the importance of including dietary supplements on a current medication list

         

         

         

         

        Pharmacist Post Test (for viewing only)

        Seven Secrets for Patient Safety with Dietary Supplements

        Pharmacist post-test

        After completing this continuing education activity, pharmacists will be able to:

        1. Discuss the importance of knowing about a patient’s dietary supplement usage (K)
        2. Identify commonly used dietary supplements, their regulation, and the value of certification (K, or A?)
        3. Recognize potential medication-dietary supplement interactions (K)
        4. Demonstrate the ability to locate different sources of information about dietary supplements (A)

        1. According to The National Health and Nutrition Examination Survey more than what percentage of adults have used a dietary supplement in the last 30 days?

        A. 45%
        B. 50%
        C. 55%

        2. Which of the following is a commonly used dietary supplement?

        A. Boswellia
        B. Turmeric
        C. Quercetin

        3. Which government agencies regulate dietary supplements?

        A. USDA, FDA
        B. FTC, DEA
        C. FTC, FDA

        4. Patient MW fills a new prescription for bumetanide. Which potential nutrient depletion may occur?

        A. Magnesium
        B. Vitamin D
        C. Vitamin B12

        5. While completing an inventory reconciliation of the vitamin section, a technician inquires, ‘Why does the FDA approve so many different products?’ Which of the following is the most appropriate answer?

        A. ‘The FDA does not have the authority to approve dietary supplements, the FTC approves dietary supplements, including vitamins.’
        B. ‘The FDA does not have the authority to approve dietary supplements before they are marketed, allowing manufacturers to flood the market with products.’
        C. ‘You know, I’m not sure, probably just to make it more confusing for us.’

        6. Which of the following companies offer independent third-party dietary supplement certification services?

        A. Consumer Reports
        B. NSF International
        C. Certified Naturally Grown

        7. Patient ED is a 58-year-old male new to your pharmacy. He provides the pharmacy team with a list of his current medications including:
        • Warfarin 3 mg PO QD
        • Atorvastatin 10 mg PO QD
        • Donepezil 10 mg PO QHS
        • Metformin 1,000 mg PO BID
        Use of which of the following supplements would be cause for concern in this patient?

        A. Ginkgo
        B. Omega-3 fatty acids
        C. Niacin

        8. A patient calls with questions about a supplement recommended by a friend. The name of the supplement is Mind and Memory Essentials, and the patient does not know the product ingredients. Where would you go to find this information?

        A. Dietary Supplement Label Database
        B. Office of Dietary Supplements
        C. United States Department of Agriculture

        9. A patient asks you about the potential side effects of taking turmeric. Where would you go to find this information?

        A. Google
        B. PubMed
        C. Office of Dietary Supplements

        10. You are verifying a new birth control prescription for a patient, recalling that the patient strongly believes in alternative medicine and dietary supplementation. Thankfully her profile contains a list of dietary supplements. You see St. John’s Wort listed and suspect a drug-supplement interaction. Where would you go to find more information?

        A. Natural Medicines Database
        B. Google Scholar
        C. National Library of Medicine

        11. One of your regular patients stops by the counter to ask your opinion on a dietary supplement product purchased on the Internet. What should you assess when looking over the product?

        A. Product labeling, color of bottle, structure/function disclaimer, certification
        B. Certification, expiration date, product labeling, intact seal
        C. Expiration date, product price, certification, product labeling

        12. Pharmacy patient ML approaches the pharmacy counter to purchase several bottles of oral glucose tablets. When questioned, the patient reveals the recent occurrence of several hypoglycemic episodes. The patient confirms compliance with taking their prescription for metformin 1 gm PO BID. ML reports no changes in other prescriptions or dietary habits but does state they started taking a dietary supplement a few days ago but cannot recall the name. Which product would you suspect based on the information provided?

        A. Vitamin E
        B. Valerian
        C. Ginseng

        Pharmacy Technician Post Test (for viewing only)

        Pharmacy Technician

        After completing this continuing education activity, pharmacy technicians will be able to:

        1. Discuss the importance of knowing about a patient’s dietary supplement usage (K)
        2. Identify commonly used dietary supplements (A)
        3. Define dietary supplement oversight and different levels of quality (K)
        4. Recognize the need for pharmacist counseling when a patient is taking a dietary supplement (K)

        1. Why is it important to ask about a patient’s usage of dietary supplements?

        A. It is not important to ask about dietary supplement usage.
        B. To identify which dietary supplements the pharmacy should feature on the front counter.
        C. Dietary supplements potentially interact with prescription medications.

        2. Which of the following is a commonly used dietary supplement?

        A. Boswellia
        B. Turmeric
        C. Quercetin

        3. Which government agencies regulate dietary supplements?

        A. USDA, FDA
        B. FTC, DEA
        C. FTC, FDA

        4. A patient approaches the counter with 2 different magnesium products and asks your opinion on which to purchase. Which of the following is an appropriate answer?

        A. Let’s look at these a little closer.
        B. Neither, it’s better to buy supplements online.
        C. The one that’s on sale.

        5. Reasons for dietary supplementation include which of the following?

        A. To supplement a poor diet.
        B. Promotion of optimal immune health
        C. No one needs to take dietary supplements.

        6. Which of the following companies offer independent third-party dietary supplement certification services?

        A. Consumer Reports
        B. NSF International
        C. Certified Naturally Grown

        7. You are entering a new patient into the pharmacy system. In addition to asking about allergies, demographics, and current medications, what else should you ask?

        A. How many hours of sleep do you average a night?
        B. Do you take any over-the-counter medications or dietary supplements?
        C. How many children do you have and how old are they?

        8. You are finally heading out for a lunch break and walk past a pharmacy patient in the aisle looking at 2 different brands of St. John’s Wort. What should you do?

        A. Keep going, you already punched out and only have 30 min to eat your lunch.
        B. Stop and offer to accompany them to the pharmacy to talk to the pharmacist.
        C. Stop and help them make a choice between the products.

        9. A patient picks up a medication and purchases a bottle of magnesium at the same time. What should you do?

        A. Advise the patient that there may be an interaction between the prescription and the magnesium.
        B. Ring out the patient as usual.
        C. Touch base with the pharmacist to make sure there are no potential interactions between the products.

        10. Where should adverse reactions or issues with dietary supplements be reported?

        A. FDA Safety Reporting Portal
        B. Federal Trade Commission
        C. Office of Dietary Supplements

        References

        Full List of References

        References

          1. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670-3695. doi:10.1016/j.bbagen.2013.02.008

          2. Jones AW. Early drug discovery and the rise of pharmaceutical chemistry. Drug Test Anal. 2011;3(6):337-344. doi:10.1002/dta.301

          3. Aitken M, Kleinrock M. The Use of Medicines in the U.S. Spending and Usage Trends and Outlook to 2025. IQVIA Institute for Human Data Science. May 2021. Accessed August 5, 2022. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-use-of-medicines-in-the-us/iqi-the-use-of-medicines-in-the-us-05-21-forweb.pdf

          4. OTC Sales Statistics. Consumer Healthcare Products Association. Accessed June 22, 2022. https://www.chpa.org/about-consumer-healthcare/research-data/otc-sales-statistics

          5. Dietary Supplements Market Size, Share & COVID-19 Impact Analysis, By Type (Vitamins, Minerals, Enzymes, Fatty Acids, Proteins, and Others), Form (Tablets, Capsules, Liquids, and Powders), and Regional Forecasts, 2021-2028. Fortune Business Insights. Accessed June 22, 2022. https://www.fortunebusinessinsights.com/dietary-supplements-market-102082

          6. Moynihan R, Sanders S, Michaleff ZA, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021;11(3):e045343. Published 2021 Mar 16. doi:10.1136/bmjopen-2020-045343

          7. Dietary Supplements in the Time of COVID-19. Fact Sheet for Health Professionals. National Institutes of Health, Office of Dietary Supplements. Accessed July 20, 2022. https://ods.od.nih.gov/factsheets/COVID19-HealthProfessional/.

          8. Adams KK, Baker WL, Sobieraj DM. Myth Busters: Dietary Supplements and COVID-19. Ann Pharmacother. 2020;54(8):820-826. doi:10.1177/1060028020928052

          9. US Department of Health and Human Services, National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Label Database (DSLD). Accessed August 5, 2022. https://ods.od.nih.gov/Research/Dietary_Supplement_Label_Database.aspx

          10. About the National Health and Nutrition Examination Survey. National Center for Health Statistics. Accessed July 20, 2022. https://www.cdc.gov/nchs/nhanes/about_nhanes.htm

          11. Mishra S, Stierman B, Gahche JJ, Potischman N. Dietary supplement use among adults: United States, 2017–2018. NCHS Data Brief, no 399. Hyattsville, MD: National Center for Health Statistics. 2021. DOI: https://doi.org/10.15620/cdc:101131external icon

          12. Gahche JJ, Bailey RL, Potischman N, et al. Federal Monitoring of Dietary Supplement Use in the Resident, Civilian, Noninstitutionalized US Population, National Health and Nutrition Examination Survey. J Nutr. 2018;148(Suppl 2):1436S-1444S. doi:10.1093/jn/nxy093

          13. 2019 CRN Consumer Survey on Dietary Supplements. Council for Responsible Nutrition. https://www.crnusa.org/2019survey. Published September 30, 2019. Accessed June 1, 2022.

          14. Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/. Accessed August 5, 2022.

          15. Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal Nutritional Status for a Well-Functioning Immune System Is an Important Factor to Protect against Viral Infections. Nutrients. 2020;12(4):1181. Published 2020 Apr 23. doi:10.3390/nu12041181

          16. Hamulka J, Jeruszka-Bielak M, Górnicka M, Drywień ME, Zielinska-Pukos MA. Dietary Supplements during COVID-19 Outbreak. Results of Google Trends Analysis Supported by PLifeCOVID-19 Online Studies. Nutrients. 2020;13(1):54. Published 2020 Dec 27. doi:10.3390/nu13010054

          17. Natural Medicines. Therapeutic Research Center. Accessed August 2, 2022. https://naturalmedicines.therapeuticresearch.com.

          18. Office of Dietary Supplements Dietary Supplement Fact Sheets. Accessed August 2, 2022. https://ods.od.nih.gov/factsheets/list-all/

          19. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th Edition. December 2020. Available at DietaryGuidelines.gov. https://www.dietaryguidelines.gov/sites/default/files/2021-03/Dietary_Guidelines_for_Americans-2020-2025.pdf

          20. Thakkar S, Anklam E, Xu A, et al. Regulatory landscape of dietary supplements and herbal medicines from a global perspective. Regul Toxicol Pharmacol. 2020;114:104647. doi:10.1016/j.yrtph.2020.104647
          21. FDA 101: Dietary supplements. United States Food and Drug Administration. Accessed July 31, 2022. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements.
          22. Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration. Accessed July 31, 2022. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements.

          23. Facts About the Current Good Manufacturing Practices (cGMPs). U.S. Food and Drug Administration. Accessed July 22, 2022.
          https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps

          24. Safety Reporting Portal. Food and Drug Administration. Accessed August 10, 2022. https://www.safetyreporting.hhs.gov/SRP2/en/Home.aspx?sid=da6dc761-7962-4743-82cd-2e62985492d0

          25. Veatch-Blohm ME, Chicas I, Margolis K, Vanderminden R, Gochie M, Lila K. Screening for consistency and contamination within and between bottles of 29 herbal supplements. PLoS One. 2021;16(11):e0260463. Published 2021 Nov 23. doi:10.1371/journal.pone.0260463

          26. Ćwieląg-Drabek M, Piekut A, Szymala I, et al. Health risks from consumption of medicinal plant dietary supplements. Food Sci Nutr. 2020;8(7):3535-3544. Published 2020 May 19. doi:10.1002/fsn3.1636

          27. Genuis SJ, Schwalfenberg G, Siy AK, Rodushkin I. Toxic element contamination of natural health products and pharmaceutical preparations. PLoS One. 2012;7(11):e49676. doi:10.1371/journal.pone.0049676

          28. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings [published correction appears in JAMA Netw Open. 2018 Nov 2;1(7):e185765]. JAMA Netw Open. 2018;1(6):e183337. Published 2018 Oct 5. doi:10.1001/jamanetworkopen.2018.3337

          29. Health Fraud Product Database. United States Food and Drug Administration. Accessed August 10, 2022. https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database

          30. Warning Letter: Amcyte Pharma, Inc. United States Food and Drug Administration. January 03, 2022. Accessed August 12, 2022. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/amcyte-pharma-inc-623474-01032022

          31. Public Notification: Adam’s Secret Extra Strength Amazing Black contains hidden drug ingredient. United States Food and Drug Administration. July 15, 2022. Accessed August 12, 2022. https://www.fda.gov/drugs/medication-health-fraud/public-notification-adams-secret-extra-strength-amazing-black-contains-hidden-drug-ingredient

          32. Coward, RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008;4(6):1315-1329. Accessed October 3, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643112/pdf/TCRM-4-1315.pdf

          33. Tucker J, Fischer T, Upjohn L, Mazzera D, Kumar M. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings [published correction appears in JAMA Netw Open. 2018 Nov 2;1(7):e185765]. JAMA Netw Open. 2018;1(6):e183337. Published 2018 Oct 5. doi:10.1001/jamanetworkopen.2018.3337

          34. Akabas SR, Vannice G, Atwater JB, Cooperman T, Cotter R, Thomas L. Quality Certification Programs for Dietary Supplements. J Acad Nutr Diet. 2016;116(9):1370-1379. doi:10.1016/j.jand.2015.11.003

          35. Dietary Supplement Labeling Guide, U.S. Food and Drug Administration. https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/dietary-supplement-labeling-guide Accessed July 15, 2022.

          36. Frequently Asked Questions for Industry on Nutrition Facts Labeling Requirements. United States Food and Drug Administration. Accessed August 12, 2022. https://www.fda.gov/media/99158/download

          37. Cooperman, T. 6 Red Flags to Watch Out For When Buying Vitamins & Supplements. October 9, 2021. Accessed August 12, 2022. https://www.consumerlab.com/answers/what-to-watch-out-for-when-buying-vitamins-and-supplements/vitamin-and-supplement-red-flags

          38. Research explores the impact of menopause on women’s health and aging. National Institute of Aging. May 6, 2022. Accessed September 6, 2022. https://www.nia.nih.gov/news/research-explores-impact-menopause-womens-health-and-aging

          39. Geller AI, Shehab N, Weidle NJ, et al. Emergency Department Visits for Adverse Events Related to Dietary Supplements. N Engl J Med. 2015;373(16):1531-1540. doi:10.1056/NEJMsa1504267

          40. Code of Federal Regulations. Title 16, Chapter II, Subchapter E, Part 1700. Amended September 6, 2022. Accessed September 6, 2022. https://www.ecfr.gov/current/title-16/chapter-II/subchapter-E/part-1700/section-1700.14

          41. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093-1108. doi:10.1007/s00216-008-2291-6

          42. Matura JM, Shea LA, Bankes VA. Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations [published online ahead of print, 2021 Nov 4]. Ir J Med Sci. 2021;10.1007/s11845-021-02828-4. doi:10.1007/s11845-021-02828-4

          43. Chrubasik-Hausmann S, Vlachojannis J, McLachlan AJ. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol. 2019;71(1):129-138. doi:10.1111/jphp.12858

          44. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol. 2004;18(2):262-276. doi:10.1177/0269881104042632

          45. Chen J, Wang Y. Social Media Use for Health Purposes: Systematic Review. J Med Internet Res. 2021;23(5):e17917. Published 2021 May 12. doi:10.2196/17917

          46. Moorhead SA, Hazlett DE, Harrison L, Carroll JK, Irwin A, Hoving C. A new dimension of health care: systematic review of the uses, benefits, and limitations of social media for health communication. J Med Internet Res. 2013;15(4):e85. Published 2013 Apr 23. doi:10.2196/jmir.1933

          47. Swire-Thompson B, Lazer D. Public Health and Online Misinformation: Challenges and Recommendations. Annu Rev Public Health. 2020;41:433-451. doi:10.1146/annurev-publhealth-040119-094127

          48. Chou WS, Oh A, Klein WMP. Addressing Health-Related Misinformation on Social Media. JAMA. 2018;320(23):2417-2418. doi:10.1001/jama.2018.16865

          49. Suarez-Lledo V, Alvarez-Galvez J. Prevalence of Health Misinformation on Social Media: Systematic Review. J Med Internet Res. 2021;23(1):e17187. Published 2021 Jan 20. doi:10.2196/17187

          50. Supplement Your Knowledge. Dietary Supplement Education Initiative. United States Food and Drug Administration. May 25, 2022. Accessed July 20, 2022. Reference the Supplement your knowledge program

          Ketamine and Its Kissing Cousins

          Learning Objectives

           

          After completing this application-based continuing education activity, pharmacists and pharmacy technicians will be able to

          ·       Identify patient populations in which ketamine use is justified based on its FDA approved indications and for off-labeled use where it has been sufficiently studied
          ·       Compare the different formulations of ketamine and its “kissing cousins”
          ·       Describe potential risks associated with ketamine use

           

          Image depicting chemical structure of ketamine.

          Release Date:

          Release Date: October 27, 2025

          Expiration Date: October 27, 2028

          Course Fee

          Pharmacists: $7

          Pharmacy Technicians: $4

          There is no grant funding for this CE activity

          ACPE UANs

          Pharmacist: 0009-0000-25-071-H08-P

          Pharmacy Technician: 0009-0000-25-071-H08-T

          Session Codes

          Pharmacist:  22YC62-FXK22

          Pharmacy Technician:  22YC62-KXT46

          Accreditation Hours

          2.0 hours of CE

          Accreditation Statements

          The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit for the online activity ACPE UAN 0009-0000-25-071-H08-P/T  will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

           

          Disclosure of Discussions of Off-label and Investigational Drug Use

          The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

          Faculty

          Alexis Hicks, PharmD.
          CVS Health
          West Hartford, CT

          Canyon Hopkins, PharmD.
          Medical Professional Ethos Cannabis
          Pittsburgh, PA

          Alexis Redfield, PharmD.
          CVS
          Vernon, CT

          Ashley Walsh, PharmD.
          Mohegan Pharmacy
          Uncasville, CT


           

          Faculty Disclosure

          In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

          Drs. Hicks, Hopkins, Redfield, and Walsh do not have any relationships with ineligible companies and therefore have nothing to disclose.

           

          ABSTRACT

          Ketamine is Food and Drug Administration-approved as a general anesthetic. Researchers found higher dose ketamine therapy had a more desirable adverse effect profile than the previously used anesthetic phencyclidine (PCP). N-methyl-D-aspartate (NMDA) antagonism from subanesthetic ketamine doses produces dissociative and analgesic effects. As such, prescribers are exploring off-label uses for ketamine in patients with agitation, depression, and pain while considering potential risks to multiple organ systems. Ketamine has the potential to cause complications and providers need to monitor patients closely. Illicit and inappropriate use by abusers and untrained law enforcement officers highlight ketamine’s potentially harmful effects. Educating patients and healthcare providers is vital to allow potential benefits while minimizing harm.

          CONTENT

          Content

          Introduction

           

          Consider this: It’s 10:30 PM on a Friday night, 30 minutes before you leave for the weekend. Suddenly, from across the emergency department you hear, “Get OFF me! No, I have not t-t-taken anything! If you come ANY CLOSER, things are going to get physical!” Not a moment later, an order pops up for ketamine hydrochloride 500 mg intramuscularly (IM) for severe agitation. Concerned, a colleague asks you, “Is this safe? Is this effective? I have never seen a dose this high before. Isn’t this just for horses?”

           

          Ketamine made its debut in human clinical practice in the 1960s when several chemists at Parke Davis Company were searching for an anesthetic with similar effects to phencyclidine (PCP). PCP, ketamine’s notorious kissing cousin, was a promising new anesthetic in the 1950s because of its dissociative effects. However, the chemists quickly became unimpressed with its adverse effect profile (i.e., long-lasting psychoactive effects after anesthesia). Humans experienced intense prolonged emergence delirium following PCP anesthesia, relegating its use to veterinary practice.1 Chemists searched for a better anesthetic and found ketamine, which has similar dissociative effects without PCP’s negative consequences. Ketamine is a more desirable anesthetic because it has a shorter half-life (2.5 hours) compared to PCP (21 hours) and it causes less delirium.1,2

           

          Prescribers have begun using ketamine for several off-label uses and patients have also started using the drug or structural analogs in a variety of formulations illicitly. Pharmacists and technicians can ensure ketamine’s safe use by keeping current with new formulations and indications, both approved and unapproved. This continuing education activity will dive into the clinical and social consequences of ketamine use.

           

          What’s Ketamine?

          Ketamine is a schedule III-controlled substance approved by the U.S. Food and Drug Administration (FDA) for use as a general anesthetic for diagnostic and surgical procedures.2 Ketamine is commercially available in the United States as a solution/injection under its brand (Ketalar) and as generic ketamine.2 Healthcare providers most often use intravenous (IV) ketamine, but it may be used IM or compounded into an oral solution. 

           

          Healthcare providers also use ketamine off-label for analgesia, agitation, and major depressive disorder. These indications emanate from ketamine’s mechanism of action: it acts specifically on the N-methyl-D-Aspartate (NMDA) receptor as a non-competitive antagonist to block glutamate binding.3 Glutamate, a major excitatory neurotransmitter, binds to receptors throughout the nervous system. The NMDA receptor is an ionotropic receptor responsible for the brain’s neuroplasticity, memory, learning, and recovery.4-6 Blocking this receptor with high ketamine doses (ranging from 0.5 to 2 mg/kg) results in dissociation, decreases in spinal reflexes, and produces a cataleptic state (loss of voluntary movements and reduced consciousness) that is applicable to its current clinical use in anesthesia.2 However, at low doses, ketamine can produce analgesia and stimulate new pathways within the brain that reduce depressive symptoms and improve mood.

           

          Although ketamine has useful applications in medicine, prescribers must be aware of the adverse effects and risk factors associated with use and should consider how these effects apply to their patients before initiating the medication. Ketamine adversely impacts multiple organ systems (see Table 1), including but not limited to the cardiovascular system. Increases in blood pressure and heart rate are important cardiovascular effects associated with ketamine therapy.2 These cardiovascular effects make it a drug of choice for anesthesia induction in patients with cardiovascular shock, where it anesthetizes patients while improving blood pressure and improving organ perfusion. However, clinicians must avoid ketamine use in patients with preexisting hypertensive conditions or other patients who have limited baroreceptor buffering capacity (baroreceptor buffering is the body’s ability to sense blood pressure) because of those same effects mentioned above.6

           

          Table 1. General Adverse Effects of Ketamine2,6

          System Adverse effects
          Cardiovascular Cardiac arrhythmias, increased blood pressure,* increased heart rate
          Central nervous system Prolonged emergence from anesthesia,* psychosis,* dissociation,* drug dependence, increased intracranial pressure
          Dermatologic Injection site irritation
          Gastrointestinal Nausea,* vomiting, anorexia
          Genitourinary Lower urinary tract dysfunction, bladder dysfunction
          Respiratory Laryngospasm,* respiratory depression,* apnea
          Immunologic Anaphylaxis
          Other Hypersalivation, diplopia (double vision), nystagmus (uncontrollable rapid eye movement)

          *Common or serious adverse effects of ketamine use

           

          Further contraindications include hypersensitivity to ketamine or its components.7 The American College of Emergency Physicians (ACEP) does not recommend ketamine use in patients with schizophrenia or in children younger than three months of age. The ACEP also advises against solely using ketamine as an anesthetic in procedures involving the pharynx, larynx, and bronchial tree. This recommendation primarily applies to patients with airway instability because ketamine can cause laryngospasms.5 Table 2 lists additional considerations in special populations.

          Table 2. Special Population Considerations with Ketamine2,6-8

          Special population Concerns Recommendation
          Pregnancy Crosses the placenta; may have potential risk to fetus Avoid use; evaluate benefits vs risk
          Breastfeeding Compatibility and safety unknown Avoid breastfeeding to children with respiratory risk factors
          Pediatrics Can be given with anticholinergics to minimize hypersalivation Refer to pediatric dosing. Avoid in infants < 3 months of age
          Elderly May be sensitive to dissociative adverse effects Refer to adult dosing
          Kidney dysfunction No additional concerns Refer to dosing parameters
          Liver dysfunction Hepatobiliary dysfunction with recurrent use Refer to dosing parameters; monitor LFTs with repeated ketamine use
          LFTs = liver function tests

           

          Healthcare providers should monitor patients' vital signs closely during treatment with ketamine. Anesthesiologists and pharmacists must continuously watch patients undergoing surgical or diagnostic procedures for proper induction and maintenance of dissociative effects.2 In patients who must take repeated doses of ketamine (e.g., for chronic pain management or psychiatric disorders), healthcare providers should order liver function tests at baseline and every one to two days during treatment.2,6,9,10

           

          Ketamine’s Kissing Cousins

          As shown in Figure 1, ketamine is structurally related to many compounds. The drugs in Figure 1 antagonize the NMDA receptor and exhibit a dissociative effect.1 PCP is one of the most notoriously abused drugs. Compared with ketamine, PCP is 10 times more potent and has a longer duration of action due to its strong affinity for the NMDA receptor. Both ketamine and PCP can replicate schizophrenia’s positive, negative, and cognitive symptoms and exacerbate underlying schizophrenia. But because ketamine has lower potency and a shorter duration of action, it induces fewer severe psychiatric effects than PCP.1

          Image depicting the molecular structure of ketamine and structurally related drugs.

          Figure 1. Molecular structure of ketamine and structurally related dissociative drugs11

                     

          Although ketamine’s labeling includes many precautions, it is an emerging option because of its therapeutic benefits. Xi Biopharmaceuticals is developing a sublingual wafer to treat acute pain while Janssen Pharmaceuticals has developed a nasal spray formulation for treatment resistant depression.12,13 Table 3 compares the current ketamine formulations that are FDA-approved or under investigation.

           

          Table 3. Ketamine Counterparts12-14

           Cousins Formulation Use & Dose Approval or Trial Phase
          Ketalar (ketamine hydrochloride) Injectable Anesthesia

          0.25 – 0.35 mg/kg followed by CIVI 1 mg/kg/hr

          FDA-approved
          Wafermine (ketamine) Sublingual Wafer Acute Pain

          25 mg, 50 mg & 75 mg PRN for 12 hrs

          End-of-Phase 2 Clinical Trials
          Spravato (esketamine) Nasal Spray Treatment Resistant Depressive Disorder

          28 mg, 56 mg, 84 mg twice a week

          FDA-approved
          ABBREVIATION: CIVI = continuous intravenous infusion

           

          ABUSE, ADDICTION, DEPENDENCE

           

          Why is Ketamine Dangerous?

          Long-term ketamine abuse is associated with memory, attention, and judgment impairment. The actual risk of ketamine abuse in the general population is low compared to other substances of abuse, but patients with polysubstance abuse disorder tend to use it.15 A study examining polysubstance abuse conducted in New York City found that polydrug use occurred because of an unexpected opportunity to use ketamine after already consuming other drugs. Researchers also determined that polysubstance abusers purposefully used ketamine with another substance to achieve an individually desired effect. Oftentimes polydrug-using events occurred within a group and each member contributed something: ketamine, knowledge, other drugs, or space to use drugs.16

           

          Currently, ketamine is only commercially available as an injectable liquid. Dealers illegally sell ketamine as a recreational injectable substance or a white powder that resembles cocaine. The Department of Justice and Drug Enforcement Administration report that illegally distributed ketamine is diverted or stolen from veterinary clinics or smuggled into the United States from Mexico.17 Dealers can then synthesize ketamine into a powder or sell it as an injectable liquid.18 Prices average from $20-$25 per dose (50 mg to 100 mg).19 Drug abusers find ketamine’s dissociative sensations and hallucinations appealing. Users can inject liquid ketamine, or snort or smoke powdered ketamine.17 Ketamine is a popular drug to facilitate physical or sexual assault because it is a colorless, tasteless, and odorless liquid making it difficult for victims to detect. Additionally, ketamine is known to cause impaired coordination, confusion, and memory loss.20

           

          Ketamine’s IV administration started in the early 1990s. Injection events occur most frequently in large cities with high rates of homelessness, like New York City and Los Angeles.18 Researchers conducted a study with 213 people who abused IV ketamine.18 Among these users, 84% admitted to abusing ‘harder’ drugs first, with heroin predominating. Users reported their first ketamine injection happening among a group of people. This group often included people well known to them who provided knowledge and the materials for injecting.18

           

          What attracts people to a dissociative drug with unknown psychoactive effects? Exactly that: the unknown. With most abused drugs, the user understands the effects they will experience. When someone takes ketamine, the reaction to each dose is unknown. Some users seek variety. Ketamine users have described an out of body experience that expands internal and external realms and realities.18 On the other hand, abusers also describe a “K-Hole”—an experience that they describe as near-death that results when they ingest too much ketamine.17

           

          Timothy Wyllie, a spiritualist, describes ketamine doses as a curve over time through realms. He describes the domains abusers experience as they dose ketamine21:

          • The realm “I,” for internal reality, occurs at doses 30 to 75 mg roughly 10 minutes after injection.
          • The extraterrestrial reality realm, “They,” occurs at doses 75 to 150 mg approximately 15 minutes after injection.
          • The realm “We,” for network creation realm, occurs at doses from 150 to 300 mg mg approximately 15 minutes after injection.
          • An unknown realm exists at doses of more than 300 mg.

          The doses studied for depression fall in the realm of internal reality. At these doses, users can see areas needing self-improvement that they were unaware they had the ability to fix. Drug users prefer subanesthetic doses but those that are higher than doses studied for treating depression. As the dose increases, users become so far removed from reality that “extraterrestrial” experiences begin.21

           

           

          KETAMINE USES

           

          Anesthesia

          Patients unable to maintain and protect their airways require endotracheal intubation. Healthcare providers use ketamine as a sedative to facilitate rapid sequence induction and intubation (RSII), by inducing an anesthetized state, prior to paralyzing the patient. The decision to intubate is based on the patient’s Glasgow Coma Score.22,23 A score of 8 or less qualifies a patient to receive endotracheal intubation.23 Healthcare providers follow a RSII strict algorithm, shown in Table 4, detailing the order in which medications should be administered based upon the onset and duration of action.

          Table 4. Algorithm of Rapid Sequence Induction & Intubation22,23

          Step of RSII What and Why Medications Used
          Premedication* Airway manipulation causes a sympathetic activation due to a pressor response. This sympathetic response leads to an increase in intracranial pressure and mean arterial pressure. alfentanil, fentanyl, lidocaine, sufentanil
          Sedation Used to induce an anesthetic state before a paralytic is used and the airway manipulated. Crucial that a patient is properly sedated before paralyzed. Also known as induction agents: etomidate, ketamine, midazolam, propofol
          Paralytics± Neuromuscular blocking agents are given to relax pharyngeal and diaphragmatic muscles allowing for an endotracheal tube to be placed. rocuronium, succinylcholine, vecuronium

          *: Based upon time constraints/needs this step may be omitted

          ±: It is imperative to confirm a patient is properly sedated before beginning paralysis because if the patient is awake, they may feel the tube insertion

           

          The drugs used in RSII possess unique characteristics, including IV use, quick onset, and short duration of action.23 Traditionally, etomidate has been the gold standard for RSII, but ketamine is quickly becoming a commonly used alternative.23 Table 5 highlights the differences between etomidate and ketamine.

           

          Table 5. Comparison of Etomidate and Ketamine22,23

            Etomidate Ketamine
          Dose for Induction 0.3 mg/kg 1.5 mg/kg or 0.1-0.5 mg/kg/min with 10% given as induction bolus
          Onset of Action 10-15 seconds < 30 seconds
          Duration of Action 4-10 minutes 10-15 minutes
          Benefits Stable hemodynamic profile, decreases metabolic rate, decreases cerebral blood flow, increases generalized seizure threshold Sedative and analgesic properties,* cardiovascular and respiratory stimulation, and smooth muscle relaxation (beneficial in reactive airway disease, hypotensive, volume depleted, and septic patients)
          Risks Adrenal suppression, do not use in septic shock, lowers focal seizure threshold, increased incidence of ARDS Potentiates effect of epinephrine, increases cardiac oxygen demand, may increase ICP,** emergent reactions, infusion related respiratory depression, hypersalivation
          ABBREVIATIONS: ARDS = acute respiratory distress syndrome, ICP = intracranial pressure

           

          * Ketamine can be used as a combined premedication and induction step

          ** Data is conflicting, however, may not be suitable for patients with head trauma

           

          The differences between etomidate and ketamine create a significant role in RSII for both drugs, but for different presenting conditions. Ketamine is gaining popularity for its use in septic patients, hypotensive patients, and those with reactive airway diseases. Choosing etomidate is preferable for patients with a hemodynamically stable profile and patients with traumatic brain injury where it could be cerebroprotective.

           

          Analgesia (pain)

           

          Ketamine’s use in pain management is controversial due to limited data, but this dataset is growing.15,24 Before considering subanesthetic ketamine doses, prescribers should collaborate with patients and other clinical team members to try other approved pain regimens.25 Using ketamine for its analgesic properties should be based on patient-specific criteria. The prescriber must assess the patient’s treatment goals, current medical conditions, pain types, and available protocols.

           

          Ketamine is not discussed in available pain guidelines. Some literature recommends its use after unsuccessful trials of at least two opioids. Data supporting ketamine’s use in both acute and chronic pain management is mixed in its findings.26,27 Most trials conclude ketamine can reduce acute pain exacerbations but note that prescribers must be cautious of its adverse effects.15 Data from small trials indicate using ketamine to overcome opioid withdrawal and opioid-induced-hyperalgesia (neuropathic pain) may be possible. Ketamine has a unique ability to counteract the unfavorable responses patients might experience on chronic high-dose opioids by its mechanism of action.24,28 Overstimulated opioid receptors from high dose opioid use causes more hyperalgesia. Several small case reports describe patients on high-dose chronic opioid therapy who reduced their opioid doses after low-dose ketamine administration.29

           

          An open labeled audit determined that IV ‘burst’ ketamine therapy improved analgesia in neuropathic pain and painful bone metastases. Researchers enrolled 39 cancer patients who were refractory to opioid therapy. Patients received bursts of low-dose ketamine (100 to 500 mg/day) over three to five days and reported somatic and neuropathic pain relief for up to eight weeks.15

           

          Limited evidence supports oral ketamine’s effect in chronic pain and most studies that examine its use are case reports or non-comparative trials. Compared to IV administration, lower oral ketamine concentrations are associated with analgesic effects. Oral ketamine has been associated with higher serum levels of its metabolite, norketamine. This metabolite seems to contribute to oral ketamine’s analgesic effects due to its shorter half-life and ability to reach much higher peak plasma concentrations than after IV administration. However, researchers have not extensively explored this in current literature.29

           

          Healthcare providers and patients face many hurdles when using ketamine for pain relief. Prescribers should avoid high ketamine doses that may cause a range of serious adverse effects. Unlike opioids, ketamine has a ceiling effect and maximum dose. Oral ketamine administration has a low bioavailability and is directly linked with a high rate of adverse effects.15,27

           

          Agitation

          Due to ketamine’s dissociative properties, clinicians are increasingly using ketamine for treating pre-hospital and in-hospital agitation. Lacking a uniform definition for agitation, healthcare providers, institutions, and organizations may use different criteria to choose medication intervention in an agitated patient. Although the picture of agitation may change depending on the situation, validated scales like the Altered Mental Status Scale (AMSS) can define agitation’s severity.30 The AMSS translates agitation into a quantifiable, real concept. The line between agitation and delirium is often unclear but has major ramifications for a patient’s treatment and outcome.30 For example, excited delirium, an agitation subtype, classifies a patient’s agitation past the emotional component and includes psychomotor, metabolic, and contributing disease states as possible reasons for agitation.30

           

          As with most psychiatric disorders, identifying and treating agitation has been suboptimal. Since the 1980s, a popular cocktail of medications, known among emergency department physicians as the “B-52” order, has been the mainstay of agitation treatment in psychiatric facilities and emergency departments.31 When examining the B-52 order’s components, it is easy to see the correlation between the regimen and the American jet-powered strategic bomber from which it derives its name: Benadryl 50 mg IM, haloperidol 5 mg IM, lorazepam 2 mg IM.31 The B-52 order serves as a reminder of the suboptimal approach traditionally taken when confronted with an agitated patient.

           

          Ketamine’s different routes of administration have benefits and disadvantages. Although less invasive, oral ketamine takes a longer time to reach the therapeutic range, something that is undesirable in an overly aggressive patient. Intravenous administration has the quickest onset but is the most invasive. Securing IV access may not always be possible. The IM route is the most often used method for agitation control for its quick “on/off” onset and duration of action, and its applicable dosage form.

           

          A review explains ketamine’s uses and benefits in comparison to other, more traditional agitation treatments.30 In terms of agitation efficacy, ketamine provides the same, if not better, response when compared to its more traditional counterparts.30 Ketamine has a significantly faster onset of action when compared to haloperidol (5 minutes versus 17 minutes) and requires less redosing (5% of patients re-dosed versus 20% of patients re-dosed, respectively).30 However, ketamine continues to show a higher incidence of adverse effects when compared to its anti-psychotic counterpart (percent incidence calculated from six studies where adverse events were recorded as a secondary outcome):30

          • emergence reaction 12.3% (8/65 patients)
            • An “emergence reaction” is an often hostile, psychiatric episode brought about by ketamine use
          • hypersalivation 31.8% (22/69 patients)
          • nausea and vomiting 8.5% (7/82 patients)
          • respiratory complications 7.6% (9/118 patients)

           

          Although studies report a higher incidence of adverse reactions when using ketamine for agitation, it is important to consider study limitations: small patient populations, co-administration of drugs, and lack of adverse event reporting (only half of 12 studies included adverse reactions).30 If used properly, ketamine can be a safe, quick-acting drug to stop agitation when compared to traditional treatments.

           

          Some law enforcement agencies use ketamine. However, when they use ketamine improperly, or when adverse effects arise, ketamine can have dangerous consequences. Over a four-day period during late August of 2019 in Colorado, police gave 23-year-old Elijah McClain and 25-year-old Elijah McKnight excessive ketamine doses for agitation.32 McClain died from cardiac arrest and McKnight survived but required life support in the hospital.32 It is inappropriate to allow untrained police officers to inject ketamine as a law enforcement tool. However, police defend using ketamine saying suspects with mental health issues or suspects taking drugs can be belligerent and dangerous. A Minnesota whistleblower lawsuit filed by a former emergency medical services worker claims police pressured them to allow ketamine use uneccessarily.32 In Minneapolis, ketamine used by police rose from four incidents per year in 2015 to 62 in 2017.32 This marked increase in ketamine use is upsetting many healthcare professionals. Dr. Mary Dale Peterson, president of the American Society of Anesthesiologists, says that ketamine can have “dangerous complications,” just like any other anesthetic. Dr. Peterson points out that justifiably using ketamine occurs very rarely.32

           

          Whistleblowers cite complications from unwarranted ketamine use are associated with emergence reactions, and improper dosages.32 McClain died when he was given a ketamine dose for a 200-pound man but only weighed 143 pounds.32 Pharmacists can play a role in educating other healthcare professionals about proper dosing and management of ketamine’s serious adverse effects.

           

          Major Depressive Disorders

          Generally, major depressive disorder’s (MDD) treatment focuses on pathophysiology and regulates serotonin, norepinephrine, and dopamine.32 Medications such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibits (SNRIs), tricyclics, tetracyclics, and serotonin modulators all target an increase in synaptic neurotransmitter levels.32 Unfortunately, these drugs are not consistently effective for all patients, require an 8-week trial period, and have unfavorable adverse effects. For many providers and their patients, MDD treatment can feel like an awful waiting game—one that they sometimes lose.

           

          Ketamine is becoming increasingly popular for its use in treating refractory depression. However, it requires healthcare providers to understand how it works to avoid putting patients into a “K-hole.” It offers a different approach to the current FDA-approved drugs for MDD. Ketamine prevents glutamate reuptake; excess glutamate produces an antidepressant effect. Ketamine, at subanesthetic doses, produces euphoria, and improves symptoms within 24 hours after infusion.4,14,32,33 Depressive symptoms improve rapidly, but the effects last only a few days to weeks. As a result, ketamine is most useful as an adjunctive treatment option. Patients feel better for a brief period, giving their antidepressants a chance to start working.

           

          In addition, prescribers have few options for patients with MDD who have suicidal behaviors and ideation. Ketamine seems promising for patients at an elevated risk for self-harm. The Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression trial examined ketamine’s potential benefits for 80 suicidal patients with MDD. The results of this randomized controlled study showed that ketamine was superior to midazolam in improving the Scale for Suicidal Ideation (SCI). Patients’ SCI scores improved 4.96 points within 24 hours after a ketamine infusion of 0.5 mg/kg over 40 minutes.32 This suggests clinical use of ketamine as an adjuvant agent for acute episodes of suicide ideation in patients maintained on guideline recommended therapy for MDD may be appropriate. However, patient safety remains a concern (e.g., dissociative effects, abuse potential, respiratory, and cardiovascular effects).

           

          As mentioned earlier, esketamine (Spravato) is ketamine’s S-enantiomer and FDA-approved for treatment-resistant depression.33 In the TRANSFORM-1 randomized controlled trial, the antidepressant/esketamine groups did not have a statistically significant change in Montgomery-Asberg Depression Rating Scale (MADRS) total score (from baseline to study day 28) when compared to the antidepressant placebo group.34,35 However, the changes based on the MADRS were clinically meaningful and showed that esketamine has a beneficial role in treatment-resistant depression when used as an adjuvant agent.36,37 The combination of esketamine with an antidepressant produced desirable outcomes while minimizing adverse effects. Although adverse effects were low, several adverse effects are possible: vertigo, nausea, vomiting, anxiety, sedation, abuse potential, increased blood pressure, dissociation, and suicidal thoughts/behaviors.33

           

          CONCLUSION

          To paraphrase the father of toxicology, Paracelsus, it’s all about the dose. Ketamine is the poster child drug for this statement. Ketamine has the potential to be an important adjuvant therapy for the treatment of a range of conditions. Those listed in this CE—anesthesia, analgesia, and major depressive disorder—are currently the most studied disorders where ketamine and its derivatives may be useful. Due to ketamine’s dissociative and analgesic effects through NMDA antagonism, there may be additional future potential uses for ketamine in pain control and psychiatric disorders. Simply, ketamine treats not only the physical manifestations of these conditions but the emotional component that providers can easily overlook. However, the current data sets are small, many use rating scales instead of final health outcomes, and a larger and longer term series of trials are required to fully determine the place of ketamine in the treatment armamentarium for patients.

           

          Pharmacists and other healthcare providers will need to distinguish between therapeutic use and addiction. Often, these lines are muddled. Providing education is a first step to preventing abuse. Usually, addiction is a manifestation of an untreated, or undertreated, medical condition. Pharmacist intervention helps patients and healthcare providers to make the safest, most informed decisions possible to ensure the best possible outcomes.

           

          Pharmacist Post Test (for viewing only)

          Pharmacist Post-Test
          Objectives:
          1. Identify patient populations in which ketamine use is justified based on its FDA approved indications and for off-labeled use where it has been sufficiently studied
          2. Compare the different formulations of ketamine and its “kissing cousins”
          3. Describe potential risks associated with ketamine use

          1. Patient AV has a GCS score of 8 and requires intubation. He presents with volume depletion, hypotension, and sepsis. What drug would the anesthesiologist probably use for sedation?
          a. Fentanyl
          b. Etomidate
          c. Ketamine

          2. In which patients would you avoid recommending ketamine?
          a. Patients with reactive airway disease
          b. Patients with sepsis or hypotension
          c. Patients with traumatic brain injury

          3. Which formulation of esketamine is FDA-approved for treatment resistant depressive disorder?
          a. Injectable
          b. Nasal spray
          c. Infusion

          4. What is the most commonly used route of administration when using ketamine for agitation?
          a. IV
          b. IM
          c. PO

          5. A clinician asks you about ketamine’s adverse effects. What would you say to start?
          a. Ketamine can cause cardiac arrythmias.
          b. Ketamine can decrease blood pressure.
          c. Ketamine can worsen peptic ulcers.

          6. What is the correct order of administration for RSII medications?
          a. Premedication, sedative, paralytic
          b. Premedication, paralytic, sedative
          c. Sedative, premedication, paralytic

          7. When should prescribers monitor liver function in patients who receive repeated ketamine doses?
          a. At baseline and every 1 to 2 months
          b. At baseline and every 1 to 2 weeks
          c. At baseline and every 1 to 2 days

          8. What is a “K-hole?”
          a. A networking experience
          b. A near-death experience
          c. An extraterrestrial experience

          9. What is a limitation of using ketamine in MDD?
          a. Depressive symptoms improve slowly
          b. Requires an 8-week trial period first
          c. Effects last only a few days to weeks

          10. A police officer asks you to discuss ketamine and asks why you refer to similar drugs as “kissing cousins.” How would you explain it?
          a. They all have similar potency and antagonize NMDA receptor
          b. They are used in similar doses and act as a NMDA receptor agonist
          c. They are structurally similar and antagonize NMDA receptor

          Pharmacy Technician Post Test (for viewing only)

          Technician Post-Test
          Objectives:
          1. Identify patient populations in which ketamine use is justified based on its FDA approved indications and for off-labeled use where it has been sufficiently studied
          2. Compare the different formulations of ketamine and its “kissing cousins”
          3. Describe potential risks associated with ketamine use

          1. In which patient should prescribers avoid using ketamine?
          a. patient with serious peptic ulcer
          b. patient older than 3 months old
          c. patient with uncontrolled hypertension

          2. What ketamine dose results in dissociation?
          a. 0.1 to 0.5 mg/kg
          b. 0.5 to 2 mg/kg
          c. 2 to 3.5 mg/kg

          3. What is a risk associated with using ketamine in RSII?
          a. adrenal suppression
          b. increase ARDS incidence
          c. emergent reactions

          4. What ketamine formulation is currently available by prescription?
          a. sublingual tablet
          b. injectable solution
          c. 24-hour patch

          5. What risk is associated with ketamine use?
          a. exacerbates underlying schizophrenia
          b. lowers focal seizure threshold
          c. increases incidence of ARDS

          6. What is a key difference between PCP and ketamine?
          a. PCP has a shorter duration of action than ketamine
          b. PCP is 10 time more potent than ketamine
          c. PCP has less severe psychiatric effects than ketamine

          7. What is a benefit of using ketamine for agitation in comparison to haloperidol?
          a. faster onset
          b. more redosing
          c. fewer side effects

          8. What is ketamine’s FDA-approved indication?
          a. agitation
          b. analgesia
          c. anesthesia

          9. What can be expected when people use oral ketamine?
          a. high bioavailability
          b. high rate of adverse effects
          c. low plasma peak concentrations

          10. What is ketamine’s role in RSII?
          a. premedication
          b. sedative
          c. paralytic

          References

          Full List of References

          References

             
            1. Li L, Vlisides PE. Ketamine: 50 Years of modulating the mind. Front Hum Neurosci. 2016;10:612. Published 2016 Nov 29. doi:10.3389/fnhum.2016.00612

            2. Ketalar. Prescribing information. Par Pharmaceutical; 2022. Accessed July 25, 2022. https://www.parpharm.com/pdfs/catalog/sterile/Ketalar_PI_20220613.pdf

            3. Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary. Washington (DC): National Academies Press (US); 2011.

            4. Aleksandrova LR, Phillips AG, Wang YT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. Journal of Psychiatry Neuroscience. 2017;42(4):222-229. DOI: 10.1503/jpn.160175.

            5. Vyklicky V, Korinek M, Smejkalova T, et al. Structure, function, and pharmacology of NMDA receptor channels. Physiol Res. 2014;63(Suppl 1):S191-S203. doi:10.33549/physiolres.932678

            6. Godwin SA, Burton JH, Gerardo CJ, et al. American College of Emergency Physicians. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med. 2014;63(2):247-258.e18. doi:10.1016/j.annemergmed.2013.10.015[PubMed 24438649]

            7. Ellingson A, Haram K, Sagen N, Solheim E. Transplacental passage of ketamine after intravenous administration. Acta Anaesthesiol Scand. 1977;21(1):41-44.[PubMed 842268]

            8. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006;60(7):341-348. doi:10.1016/j.biopha.2006.06.021

            9. Zhu X, Kohan LR, Goldstein RB. substantial elevation of liver enzymes during ketamine infusion: a case report. A Pract. 2020;14(8):e01239. doi:10.1213/XAA.0000000000001239

            10. Wilkinson ST, Sanacora G. Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders. JAMA. 2017;318(9):793-794. doi:10.1001/jama.2017.10697

            11. Ho JH, Dargan PI. Arylcyclohexamines (Ketamine, Phencyclidine, and Analogues). In: Critical Care Toxicology. Brent J, Burkhart K, Dargan P, Hatten B, Megarbane B, Palmer R, eds. Springer; 2016. https://doi.org/10.1007/978-3-319-20790-2_124-1

            12. Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacology. 2015;172(17):4254-4276. doi:10.1111/bph.13222

            13. Study of Wafermine™ for post-bunionectomy or abdominoplasty pain. ClinicalTrials.gov identifier: NCT03246971. Updated July 23, 2018. Accessed Jul 25, 2022. https://clinicaltrials.gov/ct2/show/study/NCT03246971

            14. Treating major depressive disorder: a quick reference guide. American Psychiatric Association. Published October 2010. Accessed July 25, 2022. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd-guide.pdf

            15. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006;60(7):341-348. doi:10.1016/j.biopha.2006.06.021

            16. Lankenau SE, Clatts MC. Patterns of polydrug use among ketamine injectors in New York City. Subst Use Misuse. 2005;40(9-10):1381-1397. doi:10.1081/JA-200066936

            17. Drug Fact Sheet: Ketamine. Department of Justice and Drug Enforcement Administration. Published April 2020. Accessed July 25, 2022. https://www.dea.gov/sites/default/files/2020-06/Ketamine-2020.pdf

            18. Lankenau SE, Sanders B, Bloom JJ, et al. First injection of ketamine among young injection drug users (IDUs) in three U.S. cities. Drug Alcohol Depend. 2007;87(2-3):183-193. doi:10.1016/j.drugalcdep.2006.08.015

            19. Average Cost of Illicit Street Drugs. AddictionResource.net. Updated June 21, 2021. Accessed July 25, 2022. https://www.addictionresource.net/cost-of-drugs/illicit/

            20. Świądro M, Stelmaszczyk P, Lenart I, Wietecha-Posłuszny R. The Double Face of Ketamine-The Possibility of Its Identification in Blood and Beverages. Molecules. 2021;26(4):813. Published 2021 Feb 4. doi:10.3390/molecules26040813

            21. Morris, H. Hamilton’s Pharmacopeia Ketamine: Realms and Realities. [Video]. Vice TV. December 26, 2017. Accessed July 25, 2022. https://www.vicetv.com/en_us/video/hamiltons-pharmacopeia-ketamine-realms-and-realities/59cd5d0b7752d1ac3e90aacf

            22. Kurdi MS, Theerth KA, Deva RS. Ketamine: Current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8(3):283-290. doi:10.4103/0259-1162.143110

            23. Scarponcini TR, Edwards CJ, Rudis MI, Jasiak KD, Hays DP. The role of the emergency pharmacist in trauma resuscitation. J Pharm Pract. 2011;24(2):146-159. doi:10.1177/0897190011400550

            24. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161.

            25. Johnstone-Petty, M. Ketamine use for complex pain in the palliative care population. J Hosp Palliat Nurs. 2018;20(6):561-567. doi: 10.1097/NJH.0000000000000488.

            26. Mercadante S, Caruselli A., Casuccio A. The use of ketamine in a palliative-supportive care unit: a retrospective analysis. Ann Palliat Med. 2018;7(2): 205-210. doi: 10.21037/apm.2018.01.01

            27. Bell RF, Kalso EA. Ketamine for pain management. Pain Rep. 2018;3(5):e674. Published 2018 Aug 9. doi:10.1097/PR9.0000000000000674

            28. Lalanne L, Nicot C, Lang JP, et al. Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report. BMC Psychiatry. 2016;16(1):395. doi:10.1186/s12888-016-1112-2

            29. Blonk MI, Koder BG, Van Den Bemt PMLA, Huygen FJPM. Use of oral ketamine in chronic pain management: a review. Eur J Pain. 2012;14(5): 466-472. https://doi-org.ezproxy.lib.uconn.edu/10.1016/j.ejpain.2009.09.005

            30. Linder LM, Ross CA, Weant KA. Ketamine for the acute management of excited delirium and agitation in the prehospital setting. Pharmacotherapy. 2018;38(1):139-151. doi:10.1002/phar.2060

            31. Lulla AA, Singh M. The Art of the ED Takedown. emDOCs.net - Emergency Medicine Education. Published March 4, 2015. Accessed July 25, 2022. http://www.emdocs.net/the-art-of-the-ed-takedown/

            32. Young R, McMahon S. Some States Allow Authorities to Use Ketamine to Subdue Suspects in The Field. But Is It Safe? Some States Allow Authorities to Use Ketamine to Subdue Suspects in The Field. But Is It Safe? | Here & Now. Published September 8, 2020. Accessed July 25, 2022. https://www.wbur.org/hereandnow/2020/09/08/ketamine-police-safety-elijah-mcclain

            33. Ketamine. In: Lexi-Drugs. Lexi-Comp, Inc. Updated July 20, 2022. Accessed July 25, 2022. http://usj-ezproxy.usj.edu:2099/lco/action/doc/retrieve/docid/patch_f/7135?cesid=a8n33eDrj1M&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dketamine%26t%3Dname%26acs%3Dfalse%26acq%3Dketamine#rfs

            34. Montgomery-Asperg Depression Rating Scale. Accessed July 27, 2022. https://www.mdcalc.com/calc/4058/montgomery-asberg-depression-rating-scale-madrs

            35. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616-630. doi:10.1093/ijnp/pyz039

            36. Spravato. Prescribing information. Janssen Pharmaceutical Companies; 2019. Accessed July 25, 2022. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf

            37. Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019;22(10):616-630. doi:10.1093/ijnp/pyz039

            Arthur E. Schwarting Symposium LIVE Event: Friday, April 17, 2026 REGISTRATION IS OPEN!

            Arthur E. Schwarting was an internationally recognized leader in the transformation of pharmacognosy from a plant-based discipline to a science based on the chemistry of natural products. He also was the preeminent pharmacognosist in the U.S. to engage in the study of medicinal agents from microorganisms, and he was a pioneer in the use of radio isotopes to elaborate the biochemical pathways by which plants and microorganisms make medicinally active products. The Arthur E. Schwarting Symposium is now an educational conference focused on pharmacy practice for pharmacists in many settings.

            Measure Twice, Cut Once: A Carpentry Approach to Pharmacy

            Five hours of live streaming CE including Law, Patient Safety, and Immunization

            2026 AGENDA

            11:00am-12:00 pm 

            Load-Bearing Walls: Getting Cardiovascular Therapy Right the First Time
            Katelyn Galli, PharmD, BCCP, UConn School of Pharmacy, Storrs, CT
            Type of Activity: Application
            ACPE UAN 0009-0000-26-009-L01-P
            Learning Objectives: At the end of this presentation the learner will:

            • Identify high-risk cardiovascular medications that are most commonly associated with preventable adverse drug events amid transitions of care
            • Describe evidence-based principles for precise cardiovascular medication dosing, including clinically relevant pharmacokinetic considerations that influence drug and dose selection
            • Explain the benefits and limitations of clinical decision support tools in cardiovascular pharmacotherapy
            • Recognize common system-level and cognitive factors contributing to cardiovascular medication near misses and adverse effects

             

            12:05-1:05 pm 

            LAW: The Legal Blueprint: Designing Error-Proof Pharmacy Policies
            Dylan DeCandia, PharmD, RPh, Franklyn’s Pharmacy in Ho-Ho-Kus, New Jersey
            Type of Activity: Application
            ACPE UAN 0009-0000-26-010-L03-P
            Learning Objectives: At the end of this presentation the learner will:

            • Describe the roles and responsibilities of each pharmacy staff member
            • Articulate when a pharmacist should seek legal clarification
            • Identify common pharmacy mistakes that may leave pharmacists liable
            • Construct policies and procedures that prevent future pharmacy errors

             

            1:10-2:10 pm 

            Patient Safety: Blueprints Before Builds: Patient Assessment in Clinical Decision-Making
            Devra Dang, PharmD, CDCES, FNAP, Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT  
            Type of Activity: Application
            ACPE UAN 0009-0000-26-013-L05-P
            Learning Objectives:

            • Explain the Pharmacists’ Patient Care Process and strategies to optimize the “Collect” and “Assess” steps to improve assessment and clinical decision-making
            • Identify common pitfalls that affect optimal patient assessment across healthcare settings
            • List strategies to incorporate patient-centered approaches into patient assessment and clinical decision-making

             

            2:15-3:15 pm 

            Immunization: The Right Tool for the Job: Precision and Preparation in Immunization Practice
            Thomas E. Buckley, RPh, MPH, FNAP; Associate Clinical Professor Emeritus, UConn School of Pharmacy, Storrs, CT
            Type of Activity: Application
            ACPE UAN 0009-0000-26-011-L06-P
            Learning Objectives: At the end of this presentation the learner will:

            • Analyze contraindications as the “measurement” step
            • Determine the correct vaccine, dose, route, and needle length
            • Document and report finishing work
            • Detect administration errors and adverse events
            • Illustrate reliable vaccine information

             

            3:20-4:20 pm 

            Right Fit, Tight Seal: Building Better Cancer Care
            Thomas M Levay, PharmD, CSP, Yale New Haven Health, New Haven, CT
            Type of Activity: Application
            ACPE UAN 0009-0000-26-012-L01-P
            Learning Objectives: At the end of this presentation the learner will:

            • Recognize ways that general education and consultation contributes to better care
            • Identify crucial elements of a patient’s non-clinical care for patients with cancer
            • Demonstrate different ways to help patients at each phase of care

             

            Handouts will be posted 72 hours prior to the event  in 2 slides per page and 6 slides per page below:

             

            ACPE Logo“The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.”

            Continuing Education Units

            The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations. Pharmacists can earn up to 5 contact hours (0.50 CEU) one of which is a law credit, one is an Immunization Credit, and one is a Patient Safety Credit.

            Please Note: Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (before February 1, 2026).  Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with Heather.Kleven@uconn.edu to resolve a discrepancy in a timely manner. PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to ensure that your credits have been properly uploaded.  Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.

            Registration Fees: 50% discount for UConn faculty/preceptors

            Long-Acting Injectable Medication Products

            About this Course

            Pharmacists possess the training and skills necessary to administer certain long-acting injectable (LAI) medications used in the management of mental illnesses and substance use disorders. Through collaborative practice agreements, pharmacists can administer Long Acting Injectables in almost every state. In some states, including the state of Connecticut, this occurs via collaborative agreements, and necessary injection and disease state training.  Administration of these medications by pharmacists can increase accessibility of care for patients.

            UConn has developed web-based continuing pharmacy education activity to enhance pharmacists’ skills and help them make sound clinical decisions about long acting injectables administration. This course includes eight hours of CPE (or eight hours of credit), required by the State of Connecticut.  Successful completion of these eight hours (with four activities consisting of three hours online pre-requisite work and five hours of LIVE CE) will earn the pharmacist a Certificate in Long-Acting Injectables of Psychotropic Medication.

            The three activities below are available separately for $17/hour each, or as pre-requisites for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program at $299 which includes both the prerequisites and the full day of LIVE training.

            Target Audience

            Pharmacists who are interested in administering long acting injectable psychotropic medications to their patients.

            This activity is NOT accredited for technicians.

            Pharmacist Learning Objectives

            At the end of this application-based continuing education activity, the learner will be able to:

            Compare and contrast among different long-acting injectable (LAI) medications currently available for the

            treatment of schizophrenia, bipolar disorder and substance use disorders including:

            ·        Dosing

            ·        Generic and brand names

            ·        Adverse effects

            ·        Administration schedule

            ·        Overlap with oral medications

            ·        FDA-approved indications

            Release Date

            Released:  11/15/2023
            Expires:  11/15/2026

            Course Fee

            $17

            ACPE UAN

            0009-0000-23-052-H01-P

            Accreditation Hours

            1.0 hours of CE

            Session Code

            23LA52-WXT36

            Bundle Options

            If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

            or for the individual activities.   The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

            You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

            You must register for ALL 4 activities to receive the bundled pricing of $299.00

            Accreditation Statement

            ACPE logo

            The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit 1.0 hours (or 0.1 CEUS) for the online activity ACPE #0009-0000-23-052-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

            Grant Funding

            There is no grant funding for this activity.

            Requirements for Successful Completion

            To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

            Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

            Faculty

            Kristin Waters, PharmD, BCPS, BCPP,
            Assistant Clinical Professor
            UConn School of Pharmacy
            Storrs, CT

            Faculty Disclosure

            In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

            Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

            Disclaimer

            This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

            Program Content

            Program Handouts

            Post Test Evaluation

            View Questions for Long-Acting Injectable Medication Products

            Additional Courses Available for Long Acting Injectable Training

             

            Mental Illness and Substance Use Disorders: Background - 1 hour

            Guideline-Driven Treatment for Mental Illnesses and Substance Abuse Disorders– 1 hour

             

            Guideline-Driven Treatment for Mental Illnesses and Substance Abuse Disorders

            About this Course

            Pharmacists possess the training and skills necessary to administer certain long-acting injectable (LAI) medications used in the management of mental illnesses and substance use disorders. Through collaborative practice agreements, pharmacists can administer Long Acting Injectables in almost every state. In some states, including the state of Connecticut, this occurs via collaborative agreements, and necessary injection and disease state training.  Administration of these medications by pharmacists can increase accessibility of care for patients.

            UConn has developed web-based continuing pharmacy education activity to enhance pharmacists’ skills and help them make sound clinical decisions about long acting injectables administration. This course includes eight hours of CPE (or eight hours of credit), required by the State of Connecticut.  Successful completion of these eight hours (with four activities consisting of three hours online pre-requisite work and five hours of LIVE CE) will earn the pharmacist a Certificate in Long-Acting Injectables of Psychotropic Medication.

            The three activities below are available separately for $17/hour each, or as pre-requisites for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program at $299 which includes both the prerequisites and the full day of LIVE training.

            Target Audience

            Pharmacists who are interested in administering long acting injectable psychotropic medications to their patients.

            This activity is NOT accredited for technicians.

            Pharmacist Learning Objectives

            At the end of this application-based continuing education activity, the learner will be able to:

            Describe first- and second-line treatment options for the following disease states:

            ·        Schizophrenia

            ·        Bipolar disorder

            ·        Alcohol use disorder

            ·        Opioid use disorder

             

            Identify where long-acting injectable medications fit into treatment guidelines for each disorder

             

            Apply clinical treatment guidelines to select optimal pharmacologic treatment for a patient diagnosed with these disorders

            Release Date

            Released:  11/15/2023
            Expires:  11/15/2026

            Course Fee

            $17

            ACPE UAN

            0009-0000-23-051-H01-P

            Accreditation Hours

            1.0 hours of CE

            Session Code

            23LA51-VXT88

            Bundle Options

            If desired, pharmacists can register for the entire Long-Acting Injectable Psychotropic Medication Pharmacist Certificate Training Program

            or for the individual activities.   The Certificate consists of three activities in our online selection, and a 5 hour LIVE activity.

            You may register for individual topics at $17/CE Credit Hour, or for the Entire LAIA Certificate at $299.00 which includes 5 hours of LIVE CE and the 3 online pre-requisites listed below.

            You must register for ALL 4 activities to receive the bundled pricing of $299.00

            Accreditation Statement

            ACPE logo

            The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Statements of credit 1.0 hours (or 0.1 CEUS) for the online activity ACPE #0009-0000-23-051-H01-P will be awarded when the post test and evaluation have been completed and passed with a 70% or better. Your CE credits will be uploaded to your CPE monitor profile within 2 weeks of completion of the program.

            Grant Funding

            There is no grant funding for this activity.

            Requirements for Successful Completion

            To receive CE Credit go to Blue Button labeled "take Test/Evaluation" at the top of the page.

            Type in your NABP ID, DOB and the session code for the activity.  You were sent the session code in your confirmation email.

            Faculty

            Kristin Waters, PharmD, BCPS, BCPP,
            Assistant Clinical Professor
            UConn School of Pharmacy
            Storrs, CT

            Faculty Disclosure

            In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

            Dr. Waters is a consultant with Janssen Pharmaceuticals. She will discuss all drugs without bias. All financial interests with ineligible companies (as noted) have been mitigated.

            Disclaimer

            This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

            Program Content

            Program Handouts

            Post Test Evaluation

            View Questions for Mental Illness and Substance Use Disorders: Background

            Additional Courses Available for Long Acting Injectable Training

             

            Mental Illness and Substance Use Disorders: Background - 1 hour

            Long-Acting Injectable Medication Products– 1 hour